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Abstract 
 
 
Actinobacteria, primarily the genus Streptomyces, have led to the development of a number of 
antibiotics, which result from their secondary metabolites or modified derivatives. Secondary 
metabolite production can result from competition with neighboring microbes in an effort to 
disrupt growth, aiding in the competition for vital nutrients in impoverished conditions. Such 
secondary metabolites have the potential to affect a plethora of cellular functions in target cells, 
including, cell wall development, protein synthesis, protein function and fatty acid 
synthesis/metabolism. Due to the pandemic spread of antibiotic resistant bacteria, it is 
imperative to continue the search for new therapeutic agents targeting these deadly organisms. 
As such, our group explored soil and marine samples from Tampa Bay’s surrounding farmlands 
and waterways for secondary metabolite producing microbes using culture methods specific to 
Actinobacteria. Through these efforts we isolated over 750 bacterial species, of which almost 
half are confirmed Actinobacteria. In an attempt to derive new and novel chemistry from these 
organisms, we used our novel collection, and developed techniques for epigenetic modification 
to un-silence dormant and cryptic metabolic pathways. Our work reveals that a number of these 
Actinobacteria produce secondary metabolites that are effective against the ESKAPE 
pathogens, some at very low concentrations. Although the bioactivity from secondary 
metabolites is a well-known source for antibiotic drug discovery, our epigenetic methods 
suggest a potential to isolate previously overlooked compounds that have a very real possibility 
for use as antibacterial therapeutics. 
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Introduction 
 
Antibiotics: Costs and Resistance.  
Some of the greatest advances in healthcare have been the advent of antimicrobial agents that 
are safe and effective. This therapeutic option has been associated with winning wars or 
prolonging life and is an essential part of modern medicine. Through the development of 
antibiotics human kind has had the benefit of increased food production in the form of 
preventing large-scale infections that wipe out entire populations of livestock. Anti-infective 
agents have also allowed for the advancement of surgeries including invasive procedures that 
may not have been available for fear of disease. There is however, a rather large caveat, which 
is antibiotic resistance. This issue is not limited to third world countries, it occurs on a global 
scale, in fact there were over two million antibiotic resistance infections and roughly 23,000 
antibiotic resistance related deaths in the United States in 2013 (1). Antibiotics can be described 
as a double-edged sword being that using them is what drives resistance. While we constantly 
struggle to identify novel therapeutics, bacteria have inadvertently found numerous mechanisms 
for escaping the threat of antimicrobials. Bacteria have not only developed resistance to one 
antibiotic, but have acquired resistance to numerous antibiotics simultaneously, thus bringing 
about multi-drug resistance and even pan-resistance as seen in Acinetobacter baumannii 
isolates (2). Antimicrobial resistance does not only affect fitness of humans and microbes, but it 
also creates an extreme economic burden for humanity. Estimates suggest direct healthcare 
costs as high as $20 billion and lost productivity costs as high as $35 billion annually (3). 
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There are numerous arguments for how humanity may have misused antibiotics including 
overuse, inappropriate prescriptions, and use in agriculture. One of the biggest issues with 
regards to antibiotic resistance is the extensive overuse of these drugs (1). As mentioned 
earlier, resistance is acquired through the use of antibiotics, however it seems as though this 
occurrence could have been delayed if antibiotics were not issued unnecessarily. Antibiotic 
resistance could also be delayed if there were less of a need for antibiotics, this could easily be 
achieved if humanity were proactive with regards to infection prevention. Inappropriate 
prescriptions play a gargantuan role in antibiotic resistance as research has estimated that 
antibiotics are either misused or unwarranted 50% of the time (1). Failure to provide accurate 
prescriptions by doctors may not even provide relief for the patient, and is causing an extreme 
level of detriment for the future of humanity. In a 2015 Food and Drug Administration report, 
71% of antibiotics sold in the United States were for use in food animals as an aid for production 
or production/therapeutics while the remaining 29% was used for as a therapeutic only (4). This 
staggering statistic is known to play a role in antibiotic resistance in many forms including 
emerging antibiotic resistant organisms and organisms that have acquired much higher 
tolerances to current antibiotics (5). It is impossible to know what could have been if humanity 
had used antibiotics appropriately, however in the generation leading up to a potential post-
antibiotic era, we may yet rectify some of these deleterious effects. 
 
ESKAPE Pathogens 
Since the discovery of penicillin by Alexander Fleming, humanity has entered a non-stop 
struggle against the constant flow of evolution and genetic transfer that microbes rapidly 
undergo. This genomic flexibility seen in bacteria has led to an increase of antibiotic-resistance, 
which has resulted in the need for new bioactive therapeutic compounds (6). The increase in 
resistance is associated with the overuse of antibiotics, negligent patients and a 
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misunderstanding of how microbes play an important role governing our homeostasis (7). A 
group of bacteria, commonly associated with human infection that have developed the ability to 
escape the antimicrobial effects of modern antibiotics, have been termed the ESKAPE 
(Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter 
baumannii, Pseudomonas aeruginosa and Enterobacter species) pathogens by the Infectious 
Disease Society of America (IDSA) (7). These ESKAPE pathogens comprise the majority of 
nosocomial-acquired infections in the United States (8). 
 
Enterococcus faecium is a Gram-positive, facultative anaerobe and opportunistic pathogen, 
which reside within the digestive tract of animals. It is a non-spore forming member of the 
Firmicutes, which are characterized by their low G+C content (9). Prior to 1984, this bacterium 
was known as Streptococcus faecium (10). E. faecium infections can result in pelvic and urinary 
tract infections as well as endocarditis (11). Enterococci are well equipped with intrinsic 
resistance to a number of antibiotics such as aminoglycosides, and are able to mutate or 
acquire genes in order to deal with other antibiotics, such as β-lactams (12, 13). Prior to the mid 
1980s vancomycin resistant E. faecium was unheard of, but as of 2007 more than 80% of E. 
faecium isolates possessed vancomycin resistance (14). E. faecium doesn’t possess the level of 
pathogenic potential as other organisms such as Staphylococcus aureus, however, it is proving 
to be quite problematic as it has demonstrated resistance to almost every antibiotic used for 
enterococcal infections (12, 14). 
 
Staphylococcus aureus is a Gram-positive, facultative anaerobe and opportunistic pathogen, 
which can reside on the skin, or within the anterior nares and throat of humans and also a wide 
range of animals (15). It is a non-spore forming member of the Firmicutes (9). S. aureus has 
been a major public health concern for a long while and is the leading cause of foodborne 
illness worldwide (16, 17). Staphylococci are also well known for their ability to acquire 
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resistance to harsh antibiotics such as methicillin or vancomycin as well as the speed with which 
they acquire such resistance. There are numerous mechanisms with which S. aureus is capable 
acquiring resistance, such as hydrolytically cleaving a compound as seen in β-lactam antibiotic 
resistance, or alteration of their architecture in order to prevent binding of compounds as seen 
with glycoside antibiotic resistance (18). Some of the components that make S. aureus such a 
threat are the variety of virulence factors, toxins as well as the ability to survive host immune 
responses (19). 
 
Klebsiella pneumoniae is a Gram-negative, facultative anaerobe and opportunistic pathogen, 
which can reside in the mouth, intestines and other mucosal surfaces of healthy humans (20). 
K. pneumoniae can also naturally reside within the soil (21). It is a non-spore forming member of 
the Proteobacteria, specifically the Gammaproteobacteria, which includes numerous medically 
relevant groups of bacteria (22). Majority of K. pneumoniae isolates possess a capsule which 
helps the bacterium evade the immune system (23). Colistin has been a last resort antibiotic for 
K. pneumoniae infections, but with the rise in carbapenum resistance, colistin became a 
necessary treatment option for carbapenum-resistant K. pneumoniae (24). As a result of the 
continued use of colistin, we are now seeing colistin resistance amongst this bacterium, which 
will eventually leave humanity vulnerable again (24). 
 
Acinetobacter baumannii is a Gram-negative, facultative anaerobe and opportunistic pathogen, 
which resides almost exclusively on humans, unlike other Acinetobacter species, which reside 
within soil, water and animals (25). It is a non-spore forming member of the Proteobacteria, 
specifically the Gammaproteobacteria (22). A. baumannii can cause numerous infections 
including skin and soft tissue infections, wound infections, urinary tract infections and also has 
been implicated in pneumonia as well as septicemia (26, 27). Resistance to a broad spectrum of 
therapeutics has been seen in A. baumannii including beta-lactam, quinolone and 
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aminoglycoside antibiotics (28). These antibiotics are dealt with in a number of ways, including 
enzyme degradation, as seen in beta-lactam antibiotics, mutations and highly active efflux 
pumps, as seen with quinolone resistance, or enzyme modification, as seen in aminoglycoside 
resistance (28). 
 
Pseudomonas aeruginosa is a Gram-negative, facultative anaerobe and opportunistic pathogen, 
which can reside in almost any environment including soil, water, animals, humans, and plants 
(29). It is a non-spore forming member of the Proteobacteria, specifically the 
Gammaproteobacteria (22). One of the biggest concerns for this bacterium is the low nutrient 
requirements as well as its uncanny ability to escape antibiotic effects (30). Of the mechanisms 
for antibiotic resistance, over active efflux pumps play a significant role in preventing drugs from 
reaching their targets (31). Other mechanisms for antibiotic resistance include modification of 
drugs or drug targets (31). 
 
Enterobacter cloacae is a Gram-negative, facultative anaerobe and opportunistic pathogen, 
which can reside in the gastrointestinal tract of humans as well as throughout the environment 
(32). It is a non-spore forming member of the Proteobacteria, specifically Gammaproteobacteria 
(22). E. cloacae was originally thought to occur as a nosocomial agent from the environment or 
hospital staff, however it was later concluded to be a result of the patients own microflora (33). It 
has been demonstrated that E. cloacae possesses resistance to ampicillin and a number of 
cephalosporin antibiotics, and has the potential to mutate in order to acquire alternative 
antibiotic resistance (32). 
 
There are many ongoing debates as to which acquisition of infection type is worse, community 
acquired, or hospital acquired. Some suggest that hospital acquired infectious agents possess 
less virulence, but are more robust and difficult to treat and therefore impossible to completely 
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eradicate from the host (34). Others pose that community acquired infectious agents have had 
limited exposure to antibiotics and are more virulent suggesting that disease onset is much 
more rapid (34). Original thoughts were that hospitals provided the optimal environment for 
infection as residents were often ill or had some form of immune deficiency (35). This is no 
longer the case as number of community acquired infectious agents is on the rise and one 
mathematical model suggests community acquired methicillin-resistant S. aureus will 
outcompete hospital acquired strains (36). Many reports from hospitals suggest that community 
acquired strains include the ESKAPE pathogens among others (37, 38). A study of methicillin-
resistant S. aureus diagnoses in 2013 from California hospitals reported that 1 in 100 inpatient 
stays possessed a primary or secondary diagnosis (39). 
 
Antibiotic Resistance Mechanisms 
There are many methods by which bacteria confer antibiotic resistance. Methods that are 
utilized by many different bacteria include reduced uptake of antibiotic, antibiotic target 
modification by mutation or chemical modification, antibiotic modification, overproduction of 
antibiotic target, enzymatic degradation or efflux of antibiotic (Figure 1). Even with this torrent of 
antibiotic resistance mechanisms, we still have numerous classes of therapeutics that maintain 
some level of potency today. The antibiotic class that includes sulphonamides, which are still 
synthetically derived today, need perpetual alterations, as microorganisms continuously acquire 
resistance, furthermore, a large portion of the human population have allergies to sulpha drugs 
(40). Sulphonamides are typically used today for treatment of urinary tract infections, as they 
are broad spectrum and target folate synthesis. Other antibiotic classes used in medicine today 
include β-lactams (penicillins, cephalosporins, carbapenums etc.), which have undergone 
numerous structural evolutions through the years, target the bacterial cell wall (41, 42).  
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Figure 1. Antibacterial Resistance Mechanisms  
Resistance to antibacterial compounds can e achieved in a number of ways. Drugs are not able 
to permeate through the membrane (a); drug target is modified or mutated (b); drug is modified 
(c); drug target is overproduced (d); drug is enzymatically degraded (e); effluxed immediately 
after entry (f).  
Antibiotic
a.
f.
e.
b. c.
Impaired Influx
EffluxTarget Modification/Mutation
Drug Degradation
Drug
Modification d.
Overproduction
of target
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Amendments to β-lactam antibiotics primarily involve prevention of enzymatic degradation via β-
lactamase, by addition of substituents that “shield” the β-lactam ring structure (41). 
 
Reducing the uptake of a harmful compound ensures it will never reach its designated target. All 
antibiotics, regardless of their mechanism of action require some form of uptake into the cell; 
therefore permeability plays an important role in antibiotic efficiency. Gram-negatives possess a 
secondary membrane, which provides an extra layer of protection from permeable and semi-
permeable compounds. Reducing permeability in Gram-negatives outer membrane proteins 
also limits antibiotic entry (43). In Enterobacteriaceae, it was seen that there was a reduction in 
carbapenemase expression, the enzyme responsible for enzymatic degradation of carbapenem, 
yet the bacteria were still exhibiting resistance to the antibiotic (44). It was determined that there 
was selective pressure by carbapenum that caused a mutation in porin expression genes (45, 
46) (Figure 1a). 
 
Antibiotics are target specific in that they bind with extreme prejudice to specific sites thereby 
inhibiting or reducing normal function. Subtle changes to the target site and still allowing for 
normal function can provide partial or complete resistance to the antibiotic. In an infection, there 
are many different subpopulations within the overall population. If a single point mutation were 
to occur in the gene of an antibiotic target, this could be the difference between surviving or 
succumbing to the onslaught. This has been demonstrated with linezolid resistance in S. 
aureus. Single nucleotide mutations in S. aureus’ genes encoding the 23S rRNA ribosomal 
subunit prevents binding of linezolid, but does not inhibit function and thereby conferring 
antibiotic resistance (47, 48). Modifications that result in resistance do not always occur by 
mutations, they can also occur via transformation, or uptake of foreign DNA from the 
environment that results in “mosaic” genes. An example of such a phenomenon occurred in 
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Streptococcus pneumoniae with regard to penicillin resistance. S. pneumoniae acquired genes 
which encode penicillin binding proteins that possessed a reduced affinity towards penicillin 
(49). Another example occurred in methicillin resistant Staphylococcus aureus in which the 
bacterium acquired a staphylococcal cassette chromosome mec element, which allowed S. 
aureus to produce β-lactam insensitive penicillin binding protein (50). Acquisition of this 
insensitive penicillin binding protein allowed for cell wall synthesis to continue as indigenous 
penicillin binding proteins were inactivated by present antibiotics (50) (Figure 1b). 
 
Modification of antibiotic target using the addition of a small chemical group can be just as 
beneficial to bacteria as mutations or acquisition of modified target genetic material. One 
method that bacteria have established in the war against antibiotics is methylation of the target 
site. An example was observed with regard to erythromycin resistance whereby the 
erythromycin ribosome methylase (erm) family of genes would methylate the 16S rRNA 
ribosomal subunit (51, 52). Another instance where methylation conferred resistance has been 
observed in chloramphenicol resistance which involves the chloramphenicol-florfenicol 
resistance (cfr) methyltransferase enzyme transferring a methyl group to the 23S rRNA 
subunit’s active site to prevent drug binding not only for chloramphenicol, but to a number of 
drugs that rely on this site for inhibition (53-55). Modification of drug targets is not limited to 
methylation, but can also occur with proteins that bind with higher affinity than the drug or bind 
to facilitate release of the drug. With regard to quinolone resistance, qnr genes encode 
pentapeptide repeat proteins that can bind to the topoisomerase-quinolone complex and result 
in the release of the antibiotic (56) (Figure 1c). 
 
Bacteria have not only unlocked methods modify self to prevent antibiotic binding, but they have 
also ascertained approaches to modify the antibiotic compound itself. Addition of chemical 
groups to an antibiotic can result in resistance to the drug. Bacteria modify antibiotics with 
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proteins called “resistance enzymes,” which transfer chemical groups to the drug. Group 
transfer can include acetylation, phosphorylation thiol transfer among others. Acetylation as a 
drug modification system has been seen with aminoglycosides, which prevents the drug from 
binding to the ribosome (56). Due to their nature, aminoglycosides possess many substituents 
that can be modified in different ways including phosphorylation, which also prevents the drug 
from binding to the ribosome (57). Phosphorylation modifications can occur on other antibiotics 
as well; macrolides such as erythromycin are also susceptible to this modification, which 
prevents interaction with the 23S rRNA ribosomal subunit (58-60). Thiol transfer inactivation of a 
drug has been seen in fosfomycin resistance, through which the bacteria can resume 
peptidoglycan biosynthesis (61). It has been found that a number of these resistance enzymes 
are plasmid encoded and perhaps originated in the bacterium that produced the antibiotic (61). 
 
A technique used by bacteria to overcome the barrage from antibiotics includes an 
overproduction of the drug target. Additional production, higher than standard levels, can result 
in antibiotic resistance as seen with trimethoprim resistance. Typically overproduction of the 
drug target seems to be pure circumstance. Random mutations in the promoter region of the 
gene can lead to more efficient binding of the RNA polymerase, which results in higher levels of 
transcription of the gene. Alternatively, random mutations to the ribosomal binding site can yield 
the same outcome as more of the mRNA is then translated. In the case of trimethoprim 
resistance in Escherichia coli, both of these events occurred which resulted in an 
overproduction of dihydrofolate reductase, which is used for tetrahydrofolate production, an 
important cofactor in amino acid and nucleotide biosynthesis (62). This overproduction allowed 
for trimethoprim sequestration as well as cellular functions to continue normally (Figure 1d). 
 
Since resistance to antibiotics cannot always be obtained through modifications or mutations, 
bacteria have also demonstrated numerous methods for the destruction of the drugs. Enzymatic 
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destruction has occurred in bacteria since the introduction of penicillin in 1943 by Alexander 
Fleming (5). There are a wide variety of β-lactamases, which are able to hydrolyze most of the 
β-lactam antibiotics such as penicillins, cephalosporins, and carbapenums (41, 42). Attempts 
have been made to modify β-lactam antibiotics to provide more rigid structures that are less 
prone to degradation, however bacteria have still demonstrated resistance. An example of such 
a modification is seen with oxyimino-aminothiazolyl cephalosporins where the β-lactam ring is 
typically sheltered from hydrolysis, however β-lactamases found in K. pneumoniae have 
demonstrated hydrolytic capabilities (41, 63) (Figure 1e). 
 
Another proficient method of escaping the effects of antibiotics is to remove the drug from the 
cell before it has a chance to reach its target. Efflux pumps are transporters that provide such 
an act. Many times antibiotics that have bacteria specific targets only affect Gram-positives due 
to the effectiveness of efflux pumps found in Gram-negatives. Overexpression of efflux pump 
related genes can provide a significant advantage and ensure high levels of resistance (64) 
(Figure 1f). 
 
Actinobacteria 
The name Actinomycetes was first proposed in 1916 as a way to categorize bacteria (65). 
Originally known as the “thread” bacteria, which possess a filamentous form and share very 
similar characteristics to filamentous fungi, Actinobacteria have had many changes with regards 
to taxonomy overtime (65). This phylum exhibits great diversity with regard to varying 
morphologies, physiologies, and metabolism. As one of the largest phyla it contains six classes, 
which are composed of 22 orders. The largest class, Actinobacteria, possesses 15 of the orders 
and is made up by 43 families (66). Actinobacteria are Gram-positive filamentous bacteria that 
typically possess high G+C genomic content (66). Actinobacteria can be spore and non-spore 
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forming and occupy almost all ecological niches including terrestrial, aquatic, and plant or 
animal associated as either pathogens or commensals (67, 68) Many organisms within this 
phylum have very diverse secondary metabolism, which has been and continues to be exploited 
by humans for use in biotechnology, medicine and agriculture. By appearance, many closely 
resemble filamentous fungi as majority of the Actinobacteria develop mycelia and reproduce via 
sporulation. The varying morphologies of Actinobacteria can include coccoid, short-rod, or 
branched filaments and can possess substrate mycelia, aerial hyphae, both or neither. Spore 
formers can produce in spore chains containing as many as two through 100’s of spores, or as 
singular spores (69). 
 
Actinobacteria life cycle varies greatly between the classes, however many that include 
sporulation in their lifecycle such as Streptomyces, begin as a free spore. Spore germination 
occurs and leads to vegetative growth and development of substrate mycelium. As nutrient 
levels begin to dwindle, aerial hyphae begin to form and finally spore formation occurs, however 
spore formation can occur without the presence of aerial hyphae (69). Streptomycetes and other 
Actinobacteria do not divide via elongation of the lateral wall as seen in other rod shaped 
bacteria such as Escherichia coli or Bacillus subtilis, instead they replicate via tip extension (70-
72). Cell wall synthesis occurs at the tip of the growing bacteria due to DivIVA accumulation (70, 
71). These tip extensions are segregated into compartments which results in multi-chromosomal 
filaments which penetrate the substrate known as substrate mycelium (72, 73). 
 
Actinobacteria are characterized via the 16S rRNA gene, which can organize isolates into their 
respective genera, it is difficult to discern between closely related genera or species. Genome 
sizes can vary from as small as 0.93 mega base pairs seen in Tropheryma whipplei to 12.7 
mega base pairs seen in Streptomyces rapamycinicus (74, 75). Small genome size is thought to 
be a result of genome compaction as the bacteria adapt to a host, which provides a relatively 
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unchanging environment (74). Conversely it is theorized that strains that remain the open 
environment such as soil maintain their large genome size in order to acclimate to constant 
change and potential threats (74). 
 
The secondary metabolism of Actinobacteria is remarkably diverse and has provided roughly 
two-thirds of all antibiotics as either native natural products or as natural product derivatives 
(76). Secondary metabolites are not only classified as antibiotics, they play an immense role in 
the survival of Actinobacteria. Aside from killing or inhibition of other microorganisms, they can 
aid in metal acquisition, and even have toxic affects against plants and animals (77). It is 
thought that the number of secondary metabolites being produced by specific bacterium is a 
mere fraction of the biosynthetic potential of these bugs (78). Gene clusters within the genome 
that are not expressed under normal growth conditions and cannot be isolated are typically 
referred to as cryptic or silent. Actinobacteria in the environment come into contact with an 
enormous variety of organisms, including insects, plants, bacteriophages, fungi, and of course 
other bacteria. Interactions with any of these organisms, or their respective metabolites, could 
initiate a cascade of transcriptional machinery for cryptic or silenced biosynthetic pathways. It 
was found that within Streptomyces coelicolor alone actinorhodin, streptorubin B, geosmin, 2-
methylisoborneol, albaflavenone, calcium-dependent antibiotic 2a, desferrioxamine E, 
coelimycin P1, methylenomycin A, germicidin A, coelichelin, Streptomyces coelicolor 
butyrolactone 1, methylenomycin furan 1, TW95a, flaviolin dimer, 
aminotrihydroxybacteriohopane, and isorenieratine could be produced, each of these belonging 
different classes of secondary metabolite (78-80). In a study of the whole genome of one of the 
best-characterized Actinobacteria, Streptomyces coelicolor, Bentley et al. described almost 20 
theorized secondary metabolite biosynthetic pathways (78). The biggest complication lies within 
identifying appropriate conditions necessary for transcription of said biosynthetic pathways (78). 
Large strides have been made in a global effort for the search of novel chemistry from 
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Actinobacteria including methods such as co-cultivation, genome mining and chemical or small 
molecule induction (81). Co-cultivation is thought to better mimic environmental interactions of 
the Actinobacteria. One study demonstrated N-acetylglucosamine, a cell wall component of 
bacteria, could induce more production of actinorhodin in S. coelicolor (82). Genome mining 
involves scouring the entire genome of one bacterium in search for homologous genes to those 
that have already been annotated for use in secondary metabolite biosynthesis. Bentley et al. 
utilized this method in unearthing the 20 theorized secondary metabolite biosynthetic pathways 
(78). Chemical or small molecule induction practices suggest that introduction of a chemical 
agent can alter the secondary metabolite production of a bacteria. Varying concentrations of 
dimethyl sulfoxide were used on three different Streptomyces strains and demonstrated 
increased compound production (83). 
 
Natural Products 
The field of natural products chemistry encompasses any chemical substances produced by a 
living organism, however it is notoriously associated with chemical substances that have a 
pharmacological effect. Before modern medicine, natural products were applied in the form of 
crude pastes or teas, such as willow bark, which contains salicylic acid, better known as aspirin 
(84, 85). With the discovery of penicillin in 1928 and its introduction in the early 1940s, natural 
products chemistry morphed into what we now know as the field of antibiotics (86). Shortly after 
the introduction of penicillin, Actinobacteria entered the scene with the discovery of actinomycin 
in 1940 by Selman Waksman from a soil organism, Actinomyces sp. (87, 88). Waksman spent 
many years looking at soil content and resident organisms as far back as 1916 in search of 
whether soil organisms grew the same way in their natural environment as in the laboratory 
(89).  The early years of natural product drug discovery focused on industrial scale culturing of 
microorganisms in the search for potential therapeutics (90). The time between the 1940s and 
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1960s are regarded as the “golden age” of antibiotics, where many of the classes of antibiotics 
we know today were discovered (91). This fleeting moment of history was over all too soon; as 
humanity entered the 1970s changes were being made in science, medicine and the economy. 
Antibiotics were becoming increasingly expensive to pursue and too often were they re-
discovered (76). We have since left the golden age of antibiotics and entered into a state with 
which a post-antibiotic era is a potential and terrifying scenario (7). While natural products are 
still providing as a prolific source of antibiotics, the rigor required for FDA approval combined 
with the rate of antimicrobial resistance is proving a herculean task (5). Antimicrobial resistance 
in a few cases has even been identified prior to the introduction of an antibiotic, such as 
penicillin resistance, which was observed in 1940 and the drug released three years later (5). 
Current drug pipelines involve the process of screening for products, finding an extract that 
possesses some form of biological activity, purifying the compound and elucidating the 
structure, followed by rigorous testing to ensure it maintains activity in its purified state, all of this 
before the compound is even considered for medicinal chemistry (Figure 2). After all of the 
preliminary data is acquired, compounds can eventually make their way to clinical trials, which 
could take roughly 15 years, if the drug passes all three phases (92). Aside from the timeline, 
the average cost of introducing a drug in modern medicine averages almost $2.6 billion (92). As 
a result of the financial burden and the life span, a number of pharmaceutical companies 
downsized their natural product divisions and changed focus to synthetic chemistry and the 
introduction of combinatorial chemistry (90). However there are still many programs that exist 
today that focus on natural products, which is due to nature’s imagination acting better than any 
synthetic chemist. The field has evolved through the years to include modern techniques such 
as high-pressure liquid chromatography (HPLC) and mass spectrometry (93). 
 
An enormous challenge with natural products drug discovery involves the timeline; in order to 
find a potential therapeutic, it must first be produced by nature. Alternative approaches 
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mentioned earlier describe current techniques used to modify organisms in an attempt to 
produce alternative chemistry including chemical, biological or genomic elicitation (78, 82, 83). 
Another issue lies within the screening of natural product extracts, which usually contain an 
amalgam of compounds, some which may present issues later in the purification process (90). 
 
Regardless of the daunting reputation of natural products chemistry, it has still provided 
antibiotics such as penicillin, streptomycin, polymyxin and many more, which are used in the 
treatment of infectious disease. The alarming rate of resistance developing continually 
challenges humanity to develop new therapeutics. Of the ~500,000 natural product derived 
compounds discovered up until 2012, 20% are animal derived, 70% are plant derived, and 10% 
are microbial derived (76). Although natural products can be isolated from animals and plants, 
bioactivity is seen from only three and seven-percent, respectively, while 47% of microbial 
derived natural products maintain bioactivity (76). Roughly 37% of all microbial derived bioactive 
metabolites are identified from bacteria of the order Actinomycetales (76). 
 
DNA Methyltransferase 
Of the many regulatory mechanisms possessed by bacteria, methylation is extremely fast as 
well as efficient. Methylation of DNA provides numerous benefits including control of DNA 
replication and regulation of cell cycle; indication and administration of mismatch repair, as well 
as distinguishing self from foreign DNA (such as bacteriophage) (94-96). DNA methylation 
occurs via enzymes known as DNA methyltransferase. DNA methyltransferases are ubiquitous 
in nature and occur in all domains of life. There are three primary targets of DNA 
methyltransferases, which leave behind methylated base pairs. C5 methyl-cytosine possesses a 
methyl group on the on the fifth carbon position; this is seen most commonly in Eukaryotes, but 
can occur in bacteria, however not very often (97). N6 methyl-adenine possesses a methyl 
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Figure 2. Traditional Pipeline for Drug Discovery 
The natural product is extracted from a biological source and tested for bioactivity then purified. 
The structure is determined and a mechanism of action is established. Novel compounds are 
scaled or tested to determine if synthetic derivatives can be produced. Once a feasible method 
for scaled production is determined, the compound proceeds to additional optimization and 
eventually medicinal chemistry.
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group on the sixth nitrogen position; this is seen most commonly in Prokaryotes and lower 
eukaryotes, but not in vertebrates (97). N4 methyl-cytosine possesses a methyl group on the 
fourth nitrogen position; this method of methylation has only been seen in bacteria thus far (97). 
All DNA methyltransferases utilize S-adenosine-L-methionine (SAM) as the methyl donor. In the 
case of C5 methyl-cytosine the transfer of a methyl group begins with a nucleophilic attack by a 
thiol group (found within the protein complex) on the sixth carbon on a cytosine base, which will 
result in the transfer of a methyl group from SAM (found within the protein complex), after this 
transfer a β-elimination reaction will release the DNA methyltransferase from the DNA leaving 
behind a methylated cytosine base (Figure 3A) (98). 
 
Epigenetic Modification 
Since Actinobacteria have historically been such a prevalent source of bioactive compounds, 
scientists have exploited many novel techniques for exploring their genomes with the hopes of 
finding novel secondary metabolites (91). Techniques, such as whole genome sequencing, 
have changed the way we look at organisms, such that we can now analyze an organism’s 
chromosome and determine homologous genes. This phenomenon was observed with S. 
coelicolor, when Bentley et al. scoured the chromosome for any biosynthesis genes that may be 
to known bioactive secondary metabolite biosynthesis associated genes and found over 20 
gene clusters that were known or hypothesized to code for secondary metabolites (78). One of 
the difficulties with such findings; it raises the question “how can the organism be modified to 
ensure these cryptic biosynthetic pathway genes are expressed?” The task of ensuring genetic 
expression sounds daunting enough, but then the transcribed genes also need to exercise their 
intended function. There are two very generalized approaches to such a challenge 1) pick a 
specific organism and a target within that organism then begin modifications or 2) prepare a 
universal technique that can be performed in a high throughput fashion. Both approaches are 
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Figure 3. Mechanisms of DNA Methyltransferase 
DNA methyltransferase enzymes possess a thiol group, which allows for a nucleophilic attack 
on the carbon in the sixth position of a cytosine base and through multiple steps of electron 
transfer a methyl group is transferred from SAM to a carbon in the fifth position of the cytosine 
base, finally a β-elimination releases the enzyme (A). Using a DNA methyltransferase inhibitor 
which resembles a cytosine base, the same nucleophilic attack from the thiol group to the 
carbon in the sixth position and through multiple steps of electron transfer a methyl group is 
transferred from SAM to a nitrogen in the fifth position, finally there are no further reactions that 
can take place and the enzyme is unable to be released resulting in its degradation (B).  
H
H
A) Standard Cytosine Methylation
B) DNMTi Methylation
DNA methyltransferase 
release
DNA methyltransferase 
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utilized throughout the world today; however there have been a number of successes identifying 
novel compounds from well-characterized organisms using epigenetic modification (99, 100). 
 
Epigenetic modification, looking at differences in an organism due to changes in gene 
expression, involves the addition of a chemical agent designed to inhibit genetic modifiers such 
as methyltransferase or histone deacetylase, in order to prevent proper gene regulation (99, 
101). Proper gene regulation is disrupted when an epigenetic modifier, such as a DNA 
methyltransferase inhibitor, prevents methylation of specific regions near or within gene 
promoter regions. This lack of methylation has the potential to increase the affinity with which 
transcription machinery binds to the promoter regions (102). Substances such as 5-azacytidine 
can be used as a DNA methyltransferase inhibitor (DNMTi). 5-azacytidine will be converted 
upon entrance to 5-azacytosine, a molecule analogous to the DNA base pair, cytosine. The 
difference between the two is in the fifth carbon position of cytosine, which has been replaced 
with nitrogen. This subtle change in the molecule still allows for methyl transfer, however 
prevents the DNA methyltransferase enzyme from dissociating, which results in degradation as 
well as eliminating the enzyme from the cellular environment (97) (Figure 3B). Literature 
searches suggest that epigenetically modifying organisms for elicitation of secondary 
metabolites has been limited primarily to fungi (100, 103-106). Under a variety of laboratory 
growth conditions Aspergillus niger will suppress transcription of more than 70% of the gene 
clusters dedicated to secondary metabolite biosynthesis (106). Using a histone deacetylase 
inhibitor, Henrikson et al. were able to demonstrate variation of A. niger’s secondary 
metabolome with the identification of a novel secondary metabolite, nygerone A (106). 
 
These methods for fungal epigenetic modification have utilized primarily DNA methyltransferase 
inhibitors and histone deacetylase inhibitors. Bacteria do not possess histones; instead they 
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possess DNA-binding histone-like proteins such as HU or H-NS found in E. coli. There have 
been examinations of the effects of histone deacetylase inhibitors on prokaryotes, which have 
exhibited variations in gene expression levels, although the mechanism by which this occurs is 
not fully understood, and therefore we focused our efforts on the DNA methylation (107). 
Although the literature primarily describes fungal epigenetic modification, bacterial epigenetic 
modification literature is also available. Kumar et al. found that epigenetically modified S. 
coelicolor possessed an additional major protein band when compared to the unmodified control 
(108). There were also differences within the HPLC chromatogram as the crude extract from the 
modified bacterium demonstrated 12 compounds and unmodified only displayed five (108). 
Another group looked at antibiotic production in bacteria using kinase inhibitors and cell 
transport regulators as a form of epigenetic modification and found that one of the kinase 
inhibitors actually increased production (109). 
 
Using a DNA methyltransferase inhibitor, we believe a collection of Actinobacteria can be 
modified and extracted in a high throughput screen. We anticipate that by altering the epigenetic 
regulatory enzymes, the well-characterized strains will be unable to properly regulate previously 
unidentified and highly sought after genetic pathways, yielding new bioactive secondary 
metabolites (Figure 4). 
 
Anthracyclines 
The first anthracycline was isolated from Streptomyces peucetius and titled daunomycin or 
rubidomycin, however quickly changed to daunorubicin (110-112). Farmitalia Research 
Laboratories of Milan, Italy and the French firm of Rhóne Poulenc of Paris, France founded 
daunorubicin. The compound received its name for Daunii, a pre-Roman tribe where to soil  
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Figure 4. Potential Outcome of Demethylation 
Control possesses methyl groups along DNA, which prevents transcription of potential 
secondary metabolite biosynthesis pathways or their products. Using a DNMTi effectively 
prevents methylation of DNA, which allows transcription of potential secondary metabolite 
biosynthesis pathways or their products. Presence or absence of methyl groups on DNA can 
either induce or repress transcription.
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sample was collected, and rubis, the French word for ruby (113). Since the introduction of 
anthracyclines in the 1960’s, many more have been discovered and synthesized including 
analogs such as doxorubicin (Adriamycin), epirubicin, or idarubicin. Many anthracyclines have 
been approved for use throughout the world, however doxorubicin was the first to be approved 
by the Food and Drug Administration in the United States. The only difference between 
daunorubicin and doxorubicin is a single hydroxyl group (Figure 5). This subtle change seems 
insignificant, however both compounds display different anti-tumor activity (111). Since this 
subtle change in structure resulted in changes in anti-tumor activity, chemists have synthesized 
anthracycline analogs with numerous variations on the original structure. 
 
Anthracyclines are characterized as intercalating agents that possess anti-tumor activity as well 
as mild Gram-positive antibacterial activity (110). This class of antibiotic has been ranked as 
one of the most effective anti-cancer drugs ever developed and the most utilized worldwide 
being doxorubicin (113). A major drawback of anthracycline compounds is the inevitable 
cardiotoxicity. The search and creation of new anthracyclines is held to the standard of 
doxorubicin, whereby the anti-tumor activity is assessed, followed by the cardiotoxicity. 
Compounds that exhibit any combination of anti-tumor activity or cardiotoxicity that would be 
more severe for a patient are dismissed. 
 
A number of methods by which anthracyclines are effective have been proposed, including 
prevention of topoisomerase II from binding to DNA due to anthracycline intercalating ability, 
inhibition of religation of DNA after a double strand or single strand break from topoisomerase 
(114), induction of apoptosis, or free radical generation (115). It is thought that anthracyclines 
inhibit growth of bacteria using similar mechanisms to those seen in humans (116). Inhibition of  
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Figure 5. Comparing Two Anthracyclines 
Daunorubicin possesses a basic acetyl substituent on the D ring while Doxorubicin is identical 
except for the hydroxyl substituent attached to the acetyl residue. This subtle change provides 
significantly higher anti-tumor bioactivity.
Daunorubicin Doxorubicin
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growth in bacteria is limited to the Gram-positive organisms, and studies have shown sensitivity 
to anthracyclines in Gram-negative bacteria lacking efflux systems (117). 
 
Project Aim 
One of the major issues humanity faces is the potential of a post-antibiotic era, where currently 
effective drugs, will no longer be useful and diseases that have been maintained for over 75 
years will once again wreak havoc. Natural products have provided many potential therapeutic 
options throughout the years as well as scaffolds for natural product derivatives. We know that 
Actinobacteria have historically provided many of these natural product compounds, but the 
difficulty lies within coaxing the bacteria to produce. Genomic studies have found that numerous 
well-characterized Actinobacteria still have cryptic secondary metabolite biosynthesis pathways 
that are not expressed. Using our DNA methyltransferase inhibitor, we plan to disrupt gene 
regulation of our Actinobacteria strain collection one by one and compare the secondary 
metabolite crude extract of the modified and unmodified organisms. This comparison will allow 
us to determine if cryptic secondary metabolite biosynthesis pathways have been unlocked, or 
remain dormant. 
 
We will first establish isolation protocols for growth of Actinobacteria from environmental 
samples as well as identification techniques. After establishing an Actinobacteria strain 
collection we will optimize methods of secondary metabolite extraction. Epigenetic modification 
techniques will be optimized as well, which will determine the best parameters for inhibition of 
DNA methylation including concentration of inhibitors, length of time for fermentation and what 
media should be used. In order to determine if any of these secondary metabolites are effective 
inhibitory agents, they will be screened against the multidrug resistant ESKAPE pathogens. 
When a crude extract displays bioactivity above a specific threshold, it becomes viable for large-
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scale fermentation and purification. Using techniques such as high-pressure liquid 
chromatography (HPLC), liquid chromatography coupled mass spectrometry (LC/MS), H1, C13, 
COSY, and HSQC NMR we can elucidate the structure of a bioactive compound. We hope to 
identify novel secondary metabolites that possess inhibitory activity against one or more of the 
ESKAPE pathogens. It is possible a secondary metabolite of this nature could lead to 
identification of a novel therapeutic that would aid in the war against multidrug resistant 
pathogens. 
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Materials and Methods 
 
Initial Soil Collection and Processing Optimization 
Two soil samples were collected from a farm in Ft. Meyers in May of 2015. The samples were 
collected in sterile 50mL conical tubes from a depth of at least 15 cm. All future soil samples 
were collected in the same fashion. 
 
Media 
All media were prepared by using deionized water supplemented with 36 g L-1 Instant Ocean® 
and autoclaved for sterility. Media used for isolation and cultivation of Actinobacteria were 
supplemented with antibiotics designated for inhibition of fungal cultures. The antibiotics were 
added at the following concentrations: 50 µg mL-1 nystatin and 50 µg mL-1 cycloheximide. 
 
Arginine-Glycerol-Salt Medium (AGS) (118) 
0.1% Arginine monochloride     1 g L-1 
1.25% Glycerol      12.5 g L-1 
0.1% Dibasic potassium phosphate    1 g L-1 
1.5% Agar       15 g L-1 
 
Starch Casein Agar (SCA) (119) 
0.1% Casein       1 g L-1 
1.0% Soluble starch      10 g L-1 
0.2% Potassium nitrate (KNO3)    2 g L-1 
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1.5% Agar       15 g L-1 
 
Salt-water Yeast Extract Agar (SYE)(120) 
0.025% Yeast extract     0.25 g L-1 
0.05% Dibasic potassium phosphate (K2HPO4)  0.5 g L-1 
1.8% Agar       18 g L-1 
 
International Streptomyces Project Medium – 2 (ISP-2)(120) 
1.0% Malt extract      10 g L-1 
0.4% Glucose      4 g L-1 
0.4% Yeast extract      4 g L-1 
1.5% Agar       15 g L-1 
 
Tryptic Soy Broth (TSB) 
3.0% Tryptic soy      30 g L-1 
 
Inoculation Techniques 
Method 1 (dilute/heat). One gram of soil samples was added to 5 mL of sterile seawater and 
shaken vigorously until homogenized. Dilutions of the suspension were made to 10-3. The 
dilution was heated to 55 °C for six minutes, then 100 µl were inoculated onto a sterile agar 
plate and spread via autoclave sterilized glass beads (121). 
 
Method 2 (dry/stamp). One gram of soil samples was added to a petri dish and allowed to dry 
overnight in a laminar flow hood. Using a 2cm foam stamp, sample was stamped six to eight 
times around the inside perimeter of the plate to simulate serial dilutions (121). 
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Method 3 (dilute/spread). One gram of soil samples was added to 5 mL of sterile seawater and 
shaken vigorously until homogenized. The homogenized mixture was then centrifuged 10 
minutes at 2900 × g. Dilutions of the supernatant were made to 10-3. 100 µl were inoculated 
onto a sterile agar plate and spread via autoclave sterilized glass beads (121). 
 
Method 4 (dry/spread). One gram of soil samples was added to a petri dish and allowed to dry 
overnight in a laminar flow hood. Dry sample was aseptically transferred directly to the agar 
plate. The plate was flooded with 100 microliters of sterile seawater and spread via autoclave 
sterilized glass beads (121). 
 
Isolation and Purification of species 
Plates were allowed to grow for 2-8 weeks and monitored weekly for growth. After plates 
demonstrated growth, individual colonies were transferred to petri dishes containing ISP-2 for 
isolation. Bacteria on plates of ISP-2 were streaked for isolation no fewer than three times to 
ensure growth was identical to previous growth and isolation had been achieved. 
 
DNA Extraction – Isolated colonies were grown in six mL of tryptic soy broth (TSB) for 3-7 days 
at 28 °C in a shaking incubator until adequate growth was present to perform a DNA extraction 
following manufacturer instructions (DNeasy Blood & tissue kit, Qiagen). 
 
PCR Amplification – The 16S rRNA gene was then PCR amplified using the universal 16S rRNA 
primer pair OL2629 (5’-CCA TCT CAT CCC TGC GTG TCT CCG ACT CAG TCT AAC GGA 
CGA TAG AGT TTG ATC CTG GCT CAG-3’) (forward) and OL399 (5’-GGA CTA CCA GGG 
TAT CTA ATC CTG TT-3’) (reverse) (122) and the products were purified using QIAquick PCR 
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purification Kit (Qiagen) following the manufacturer instructions. Sanger sequencing based upon 
OL2629 was performed and sequences generated were aligned and related to sequences 
obtained from a NCBI Nucleotide BLAST (BLASTN) search in order to determine identity to at 
least a genus level or if possible, a species level. 
 
Current Actinobacteria Culture Techniques 
Modified ISP-2 (120, 123, 124) 
1.0% Malt extract      10 g L-1 
0.4% Glucose      4 g L-1 
0.4% Yeast extract      4 g L-1 
1.5% Agar       15 g L-1 
0.038% Tyrosine      0.38 g L-1 
 
Isolate Identification 
Inoculated agar plates were allowed to incubate for 2-8 weeks at room temperature to allow 
slow-growing bacteria to form adequate sized colonies. Plates were monitored on a weekly 
basis and adequate growth was monitored visually. Actinobacteria were removed from the low 
nutrient media after no longer than 8 weeks of incubation based upon colony morphology, visual 
confirmation of aerial mycelia or substrate hyphae, visual confirmation of spore formation, 
pigment formation, or the presence of diffusible pigments.  Colonies were separated and plated 
on ISP-2 followed by serial streaking until isolation was achieved. ISP-2 supplemented with 
tyrosine aided in further characterizing Actinobacteria, as there are numerous genera that are 
able to produce the soluble pigment melanin. Isolates were then Gram-stained, in an effort to 
eliminate the possibility of further characterization of Gram-negatives. Isolates were then DNA 
extracted, the 16S rRNA gene was amplified via PCR for Sanger sequencing, followed by 
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comparison of the generated sequences to known 16S rRNA genes using BLASTN. Isolates 
that identified as Actinobacteria were added to the Shaw lab strain collection and frozen glycerol 
stocks were prepared. 
 
Isolates Used for Optimization Techniques 
Cultures selected for epigenetic modification optimization were chosen for their phenotypic traits 
as well as their unique metabolism and metabolites. Isolate 11 (Gordonia namibiensis) colonies 
were slimy, smooth, orange in the center and white on the rim, and pinpoint. Isolate 11 was 
chosen because Gordonia species have been found to possess unique metabolism, which 
allows them to play a role in biodegradation of rubber materials, utilization of hydrocarbons, as 
well as break down other natural products that are not easily degraded in the environment (125-
127). Isolate 39 (Streptomyces griseorubens) colonies were leathery, smooth, yellow, and 
pinpoint that produced the soluble pigment melanin when plated on tyrosine containing media. 
Isolate 39 was chosen because Streptomycetes are well known producers of bioactive 
secondary metabolites and Streptomyces griseorubens has been noted for its ability to utilize 
lignocellulose as its sole carbon source (128). Isolate 40 (Streptomyces fradiae) colonies were 
leathery, smooth, white to yellow, pinpoint to large, and irregular. Isolate 40 was chosen also 
because of Streptomycetes well known nature to produce bioactive secondary metabolites as 
well as the bacterium’s ability to produce a number of well characterized compounds such as 
neomycin, tylosin and urdamycins A-F (129-131). All three isolates were grown for 21 days in 
ISP-2 broth (liquid media recipes omitted agar from preparation) prior to commencement of the 
extraction methods below and performed in triplicate. 
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Secondary Metabolite Extraction Optimization 
Method A (partition/extract). Whole bacterial cultures were transferred from 50 mL bio-reactor 
conical tubes to 120 mL glass French square bottles and partitioned using 25 mL of EtOAc. 
Culture and organic layer were homogenized followed by transfer of the organic layer to pre-
weighed 20 mL scintillation vials. Organic layer was dried under constant airflow. The addition of 
EtOAc and transfer of the organic layer was repeated three times in order to obtain as much 
product as possible. 
 
Method B (freeze dry/extract). Whole bacterial cultures were frozen at -80°C and then 
lyophilized. Dried material was then extracted using 25 mL of EtOAc. Whole extract was filtered 
such that only EtOAc-soluble material could be transferred to pre-weighed 20 mL scintillation 
vials. EtOAc was dried under constant airflow. The addition of EtOAc and whole extract filtration 
was performed three times in order to obtain as much product as possible. 
 
Method C (centrifuge/extract supernatant). Whole bacterial cultures were centrifuged and the 
supernatant transferred to 120 mL glass French square bottles and partitioned using 25 mL of 
EtOAc. Supernatant and organic layer were homogenized followed by transfer of the organic 
layer to pre-weighed 20 mL scintillation vials. Organic layer was dried under constant airflow. 
The addition of EtOAc and transfer of the organic layer was repeated three times in order to 
obtain as much product as possible. 
 
Method D (centrifuge/extract pellet). Whole bacteria cultures were centrifuged and the removed. 
The pellet was frozen at -80°C and then lyophilized. Dried material was then extracted using 25 
mL of EtOAc. Whole extract was then filtered such that only EtOAc-soluble material could be 
transferred to pre-weighed 20 mL scintillation vials. EtOAc was dried under constant airflow. 
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The addition of EtOAc and whole extract filtration was repeated three times in order to obtain as 
much product as possible. 
 
Epigenetic Modification Optimization 
DNMTi Concentration Optimization - Cultures of isolates 11, 39 and 40 were grown on ISP-2 
media for three days in order to obtain a working stock. Each isolate was inoculated into 50 mL 
bio-reactor conical tubes containing 35 mL of liquid media. The liquid media used for this 
optimization was ISP-2 broth. 5-azacytidine was added to each of the flasks at the following 
concentrations: 0 µM, 1 µM, 10 µM, 50 µM, 100 µM, and 500 µM. Tubes were allowed to 
incubate for 21 days and were monitored for growth and color changes daily. A second round of 
DNMTi concentration optimization was performed in conjunction with time optimization. 
 
Time Optimization - Cultures of isolates 11, 39 and 40 were grown on ISP-2 media for three 
days in order to obtain a working stock. Each isolate was inoculated into 50 mL bio-reactor 
conical tubes containing 35 mL of ISP-2 broth. 5-azacytidine was added to each of the 50 mL 
bio-reactor conical tubes at the following concentrations: 0 µM, 1 µM, 5 µM, and 10 µM. Tubes 
were allowed to incubate for 7, 14, and 21 days. 
 
Media Optimization - Cultures of isolates 11, 39 and 40 were grown on ISP-2 media for three 
days in order to obtain a working stock. Each isolate was inoculated into 50 mL bio-reactor 
conical tubes containing 35 mL of SCA broth, SYE broth or ISP-2 broth. 5-azacytidine was 
added to each of the 50 mL bio-reactor conical tubes at the following concentrations: 0 µM, 1 
µM, and 5 µM. Tubes were allowed to incubate for 21 days. 
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Screening Extracts Against the ESKAPE Pathogens 
20 mL scintillation vials containing crude extract from the various extraction methods were re-
suspended in DMSO to a concentration of 5 mg mL-1. The extracts were assessed for the ability 
to inhibit growth against the ESKAPE pathogens. ESKAPE pathogen strains were grown 
overnight in TSB at 37 °C in a shaking incubator then diluted (10-3) into fresh media. The MIC 
was determined through a tiered approach beginning with 200 µg mL-1 and continually halving 
the inhibitory concentration until inhibition was no longer seen. Sterile 96-well microtiter plates 
were loaded with culture and solvated compounds were added such that the total volume was 
200 µl. 
 
Small-Scale Growth 
Slow growing Actinobacteria were grown at 28 °C in 35 mL of SCA broth in 50 mL bio-reaction 
conical tubes (Cell-Treat) in a shaking incubator under constant agitation for 21 days, in the 
presence and absence of one µM of our DNMTi (5-azacytidine). Rapidly growing Actinobacteria 
were also grown at 28 °C in 35 mL of ISP-2 broth in 50 mL bio-reaction conical tubes (Cell-
Treat) in a shaking incubator under constant agitation for 21 days, in the presence and absence 
of one µM of 5-azacytidine. The bio-reaction conical tubes were monitored for color changes 
and secreted pigments throughout the incubation period. 
 
Secondary Metabolite Extraction – after 21 days of growth, actinobacterial cultures were 
transferred to 120 mL glass French square bottles and 25 mL of ethyl acetate (EtOAc) were 
added to the glass bottles, the culture/EtOAc mixture was homogenized and filtered. The 
resulting mixture was allowed to settle for 24 hours and layers were formed, after which the top 
organic layer was decanted into a pre-weighed 20 mL scintillation vial. Care was taken to 
ensure only the EtOAc layer was removed and not the aqueous layer containing the media and 
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bacterial cultures. This process was repeated three times in order to remove as much material 
potentially containing secondary metabolites as possible. Between removals of the organic 
layers, the previously removed EtOAc was dried; secondary and tertiary removals of EtOAc 
were added to the same corresponding scintillation vials. Scintillation vials were weighed after 
drying to determine total yield of crude extract. Crude extracts weighing >= 1 mg were solvated 
to 5 mg mL-1 in 100% dimethyl sulfoxide (100% DMSO), 0.5 – 0.99 mg were solvated to 2.5 mg 
mL-1 in 100% DMSO, and <0.5 mg were solvated to 1 mg mL-1 in 100% DMSO. Aliquots of 
extracts were transferred into 96-well plates, with stock solutions archived. 
 
ESKAPE Bioactivity Screening – in order to assess the antimicrobial activity of the crude 
extracts we used the ESKAPE pathogens, which are an excellent representation for multidrug 
resistant pathogens. All of the ESKAPE strains were grown overnight in TSB at 37 °C in a 
shaking incubator, and then diluted (10-3) into fresh media. The minimum inhibitory 
concentration (MIC) was determined through a tiered approach beginning with 200 µg mL-1 and 
continually halving the inhibitory concentration until inhibition was no longer seen. Sterile 96-well 
microtiter plates were loaded with culture, and solvated compounds were added to equal a total 
volume of 200 µl. Care was taken not to add more than 5% of the total volume of the compound 
to any of the wells and a control well was included with 5% total volume being 100% DMSO. 
Plates were then incubated at 37°C for 24 hours and MICs were determined via visual 
inspection, inhibition was apparent by a lack of turbidity in the wells. 
 
Large-Scale Growth 
Actinobacteria were grown in 1000 mL of SCA broth at 28 °C in a two liter Erlenmeyer flask in a 
shaking incubator under constant agitation for 28 days. The flasks were monitored for color 
changes and secreted pigments throughout the incubation period. After 28 days of growth 500 
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mL of EtOAc were added to the flask and the culture/EtOAc mixture was homogenized by 
shaking incubator for 24 hours. The resulting mixture was filtered and allowed to settle for 24 
hours before decanting the organic layer. This process was repeated twice more using only 250 
mL of EtOAc in order to remove as much material potentially containing secondary metabolites 
as possible. Between removals of the organic layers, the previously removed EtOAc was dried; 
secondary and tertiary removals of EtOAc were added to the same corresponding glass bottle. 
Five milligrams of crude extract was removed and placed in a 20 mL scintillation vial and kept 
for storage. 
 
Partition – The whole crude extract was suspended in EtOAc and transferred to a separatory 
funnel and partitioned using double distilled H2O. Three partitions were collected in separate 
20mL scintillation vials, the liquid layer (H2O), the middle layer (insoluble material) and the 
organic layer (EtOAc). These partitions were dried under air and weighed, then five milligrams 
of each were removed and placed in separate 20 mL scintillation vials and kept for storage. 
Following the partition, whole crude extract, as well as each of the partitions were subjected to 
bioassay to ensure activity of the large-scale extract and partitions were similar to that of the 
small-scale crude extract as well as determine the active partition for further characterization 
and testing. 
 
HPLC Purification and Bioassay Guided Fractionation 
The bioactive crude extract was subjected to normal-phase high-pressure liquid 
chromatography (HPLC) purification with two silica columns in tandem as the stationary phase. 
The mobile phase used a five minute 100% hexanes run, followed by a 35-minute continuous 
gradient until 100% EtOAc, then a 15-minute 100% EtOAc run, and finally a 10-minute 100% 
50:50 EtOAc:IPA wash. An evaporative light scattering (ELS) as well as an ultraviolet (UV) 
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detector monitored HPLC analysis in order to identify a variety of potential fractions. Fractions 
were submitted to bioassay to determine which possessed the activity seen in the crude extract. 
 
Modified HPLC Purification and Bioassay Guided Fractionation 
Partitioned crude extracts were used as an initial modification of this purification process. The 
bioactive partition was subjected to normal-phase HPLC purification with a silica stationary 
phase. The mobile phase used a five minute 100% hexanes run, followed by a 35-minute 
continuous gradient until 100% 50:50 EtOAc:IPA, then a 15 minute 100% 50:50 EtOAc:IPA run. 
An evaporative light scattering (ELS) as well as an ultraviolet (UV) detector monitored HPLC 
analysis in order to identify a variety of potential fractions. Fractions were submitted to bioassay 
to determine which possessed the activity seen in the active partition. 
 
Bioactive fractions were subjected to reverse-phase HPLC purification with a C8 column, using 
a five minute 90% H2O: 10% 1:4 THF:ACN run, followed by a 35 minute continuous gradient 
until 99% 1:4 THF:ACN, then a 15 minute 1% H2O 99% 1:4 THF:ACN run. and this process will 
be repeated until a single bioactive compound has been identified. Purified bioactive fractions 
will be analyzed by liquid chromatography coupled mass spectrometry (LCMS) in order to 
identify a molecular weight and potential chemical formula.
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Results 
 
Investigating Cultivation Strategies Necessary for Actinobacteria Growth 
Historically, Actinobacteria have been an ample source of antibiotics and bioactive secondary 
metabolites, the difficulty lying within the recovery rate of isolates from environmental samples. 
Initially, using the two soil samples from the farm in Ft. Meyers, we attempted to isolate and 
identify Actinobacteria. Using SCA, SYE, and AGS coupled with methods 1-4 and performing 
each combination in triplicate, we generated 36 plates per sample. After eight weeks of growth, 
we began serially streaking isolates onto ISP-2 agar plates to ensure isolation. A total of 432 
isolates were obtained from the investigation of cultivation strategies (Table 1). We selected 36 
isolates that possessed at least one of the Actinobacteria-like characteristics including rough or 
leathery colonies, aerial hyphae, substrate mycelia, presence of pigments, presence of spores, 
or diffusible pigments to perform Sanger sequencing. Media or methods that were considered 
optimal and use continued resulted in Actinobacteria identification for at least 80% of the 
sequenced isolates from their respective media or method (Table 2). The various identified 
isolates were from both samples, Soil 1 and Soil 2, and both samples possessed identified 
Actinobacteria. Isolates identified as Actinobacteria included species from the genera 
Rhodococcus, Streptomyces, Gordonia, Nocardia, Arthrobacter, Aeromicrobium, and 
Mycobacterium (Table 3). These preliminary results demonstrate the omnipresence of 
Actinobacteria. Using this preliminary data, we were able to determine that SCA and SYE in 
conjunction with methods one and three were optimal for growth and isolation of Actinobacteria 
and were used moving forward with future soil samples. 
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Table 1. Number of Isolates Obtained Using Various Media and Methods 
Method Media Number of Isolates from Soil 1 Number of Isolates from Soil 2 
1 
AGS 23 41 
SYE 29 63 
SCA 25 37 
2 
AGS 5 13 
SYE 13 10 
SCA 4 15 
3 
AGS 14 28 
SYE 18 16 
SCA 19 11 
4 
AGS 4 16 
SYE 8 6 
SCA 7 7 
  Total isolates 169 263 
* Listed are the total yields from each media and method combination from environmental 
samples Soil 1 and Soil 2. Media used includes: AGS – arginine-glycerol-salt; SYE – salt-water 
yeast-extract; SCA – starch casein agar. 
 
 
 
 
 
 
 
Table 2. Prevalence of Actinobacteria 
Media Percent Actinobacteria Method Percent Actinobacteria 
AGS 22% 1 84% 
SCA 95% 2 43% 
SYE 80% 3 80% 
    4 0% 
 
* Listed are the percentages associated with the number of Actinobacteria identified that were 
cultivated under each media type or method. Media used includes: AGS – arginine-glycerol-salt; 
SYE – salt-water yeast-extract; SCA – starch casein agar 
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Table 3. Identity and Acquisition Method 
Strain Number Identity Media Method Sample 
1 Rhodococcus rhodochrous SCA 3 Soil 2 
2 Staphylococcus gallinarum SYE 3 Soil 2 
3 Staphylococcus cohnii AGS 3 Soil 2 
4 Bacillus aryabhattai AGS 2 Soil 2 
5 Rhodococcus rhodochrous SCA 1 Soil 2 
6 Streptomyces violarus SCA 3 Soil 1 
7 Streptomyces sp. SCA 1 Soil 2 
8 Streptomyces beijiangensis AGS 1 Soil 2 
9 Halomonas venusta AGS 1 Soil 2 
10 Streptomyces coelicoflavus SCA 1 Soil 2 
11 Gordonia namibiensis SCA 1 Soil 2 
12 Rhodococcus rhodochrous SCA 1 Soil 2 
13 Nocardia vermiculata SCA 1 Soil 2 
14 Streptomyces platensis SCA 1 Soil 1 
15 Streptomyces violarus SCA 1 Soil 2 
16 Streptomyces albiflavescens SCA 1 Soil 2 
17 Streptomyces corchorusii SCA 1 Soil 2 
18 Arthrobacter protophormiae SYE 1 Soil 2 
19 Gordonia namibiensis SCA 3 Soil 1 
20 Aeromicrobium tamlense SCA 2 Soil 2 
21 Rhodococcus phenolicus SCA 2 Soil 2 
22 Gordonia terrae SCA 3 Soil 1 
23 Bacillus sp. AGS 2 Soil 2 
24 Bacillus sp. AGS 2 Soil 2 
25 Rhodococcus rhodochrous SCA 2 Soil 2 
26 Streptomyces chromofuscus SCA 1 Soil 2 
27 Streptomyces acrimycini SCA 1 Soil 2 
28 Bacillus aryabhattai AGS 2 Soil 2 
29 Mycobacterium parafortuitum SCA 3 Soil 2 
30 Streptomyces macrosporeus SCA 3 Soil 2 
31 Streptomyces antibioticus SYE 3 Soil 1 
32 Streptomyces gardneri SCA 3 Soil 1 
33 Streptomyces tumescens AGS 1 Soil 1 
34 Nocardia asteroides AGS 1 Soil 1 
35 Streptomyces minoensis SYE 1 Soil 1 
36 Streptomyces aurantiogriseus SYE 1 Soil 2 
* Listed are the strain numbers used as an identifier for each addition to the Actinobacteria 
strain collection as well as the respective isolate identity, media, method, and environmental 
sample used for cultivation. Media used includes: AGS – arginine-glycerol-salt; SYE – salt-water 
yeast-extract; SCA – starch casein agar. 
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Using SCA and SYE with methods one and three, and plating in triplicate, a total of 12 plates 
were generated per sample in order to accurately cultivate potential microbes harbored within 
the environmental samples. Environmental samples were acquired from a variety of sources 
including farmland, deserts, aquatic environments, as well as high altitudes (Table 4). 
 
Model for Rapid Identification of Actinobacterial Cultures and Strain Collection 
Development 
Typically, the identification of an unknown bacterium can be determined using 16S rRNA gene 
sequencing, which can be compared to previously sequenced genes, to provide an identity to a 
genus and sometimes species level. A common issue within the phylum is the similarity of the 
16S rRNA gene sequence, which raises difficulties when organizing isolates at a species level. 
This common issue has limited our identification to at least a genus level, and in some cases a 
species level identification was achieved when comparable genetic sequences were available. 
A number of modifications were made when transitioning between investigating cultivation 
strategies and current cultivation strategies, which include added steps to rapidly detect 
Actinobacteria, thereby reducing costs associated with identification via Sanger sequencing. 
Recognizing that a number of bacteria possess tyrosinases, which can be used in the formation 
of pigments such as melanin, was a crucial step in the rapid identification of Actinobacteria 
(124). As one of the Actinobacteria-like indicators was pigment production, the addition of 
tyrosine to our ISP-2 media aided immensely. The production of melanin was added to the list of 
Actinobacteria-like indicators. Many of the colonies cultivated from environmental samples 
possessed at least one of the Actinobacteria-like indicators, such that upon visual inspection, a 
colony could be identified as Actinobacteria-like or not. This visual identification made it possible 
to remove the need for Sanger sequencing of each isolate. 16S rRNA gene sequencing was still 
of use for isolates that did not possess at least one of the Actinobacteria-like indicators. 
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Table 4. List of Environmental Samples 
Sample 
Number Location Description 
Type of 
Sample 
Number of 
Isolates 
-3 Soil 1 Farm (field) Ft. Myers Soil 32  
-2 Soil 2 Farm (horse) Ft. Myers Soil  119 
-1 Sed 8 Florida Keys Sediment  N/A 
0 Sed 10 Florida Keys Sediment  N/A 
1 TSF Oak hickory heavy shade Soil  36 
2 TSF Cow loading area, empty for years Soil  30 
3 TSF Cow pasture, under hay (feeding area) Soil  48 
4 TSF Pond 1 edge Soil  32 
5 TSF Pond 1 edge further out Soil  16 
6 TSF Pond 2 edge Soil  13 
7 TSF Arid cow pasture Soil  29 
8 TSF Organic soil, heavy trees Soil  1 
9 TSF low lands (wet cow pasture) Soil  31 
10 TSF Organic soil, cedar trees Soil  69 
11 TSF Gopher hole Soil  8 
12 TSF Forest Floor Soil  14 
13 TSF Deep in the forest Soil  5 
14 TSF Deeper in the forest Soil  10 
15 TSF Cave floor Soil  17 
16 TSF Clay near house Soil  1 
17 SHH Deep under sprinkler Soil  10 
18 SHH Front Garden Soil  60 
19 SIS Ding Darling Island Soil  66 
20 SIS Beach Dunes Soil  84 
21 SIS Low tide beach Soil   N/A 
22 SHH Back garden Soil   N/A 
23 CWR 14 Sponge 1  
24 CWR 15-16 Sponge  N/A 
25 CWR 15-18 Sponge   N/A 
26 CWR 15-19 Sponge   N/A 
27 CWR 15-20 Sponge 1  
28 CWR 15-21 Sponge   N/A 
29 CWR 15-22 Sponge   N/A 
30 CWR 15-23 Sponge   N/A 
31 CWR 15-SED1 Sediment 1  
32 CWR 15-SED2 Sediment   N/A 
33 CWR 15-SED3 Sediment   N/A 
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34 BB 15-6 Soil   N/A 
35 BB 15-3 Soil 8  
36 MFG15 Sed 1 Sediment   N/A 
37 MFG15 Sed 2 Sediment   N/A 
38 MFG15 Sed 3 Sediment   N/A 
39 MFG15 Sed 4 Sediment   N/A 
40 MFG15 Sed 5 Sediment   N/A 
41 MFG15 Sed 6 Sediment   N/A 
42 MFG15 Sed 7 Sediment   N/A 
43 MFG15 Sed 8 Sediment   N/A 
44 MFG15 Sed 9 Sediment   N/A 
45 MFG15 Sed 10 Sediment   N/A 
46 MFG15 Sed 11 Sediment   N/A 
47 MFG15 Sed 12 Sediment   N/A 
48 MFG15 Sed 13 Sediment   N/A 
49 MFG15 Sed 14 Sediment   N/A 
50 MFG15 Sed 15 Sediment   N/A 
51 MFG15 Sed 16 Sediment   N/A 
52 MFG15 Sed 17 Sediment   N/A 
53 MFG15 Sed 18 Sediment   N/A 
54 MFG15 6a Sponge   N/A 
55 MFG15 6b Sponge   N/A 
56 MFG15 8 Sponge   N/A 
57 MFG15 10 Sponge   N/A 
58 MFG15 12 Sponge   N/A 
59 MFG15 14 Sponge   N/A 
60 MFG15 16a Sponge   N/A 
61 MFG15 16b Sponge   N/A 
62 MFG15 18 Sponge   N/A 
63 MFG15 20 Sponge   N/A 
64 MFG15 22 Sponge   N/A 
65 MFG15 24 Sponge   N/A 
66 MFG15 26 Sponge   N/A 
67 MFG15 30 Sponge   N/A 
68 MFG15 32 Sponge   N/A 
69 MFG15 38 Sponge   N/A 
70 MFG15 40 Sponge   N/A 
71 MFG15 42 Sponge   N/A 
 
Table 4. (Continued) 
 
44 
 
 
 
72 MFG15 52 Sponge   N/A 
73 MFG15 54 Sponge   N/A 
74 MFG15 56 Sponge   N/A 
75 MFG15 60 Sponge   N/A 
76 EG 15 Sand 1 Sand 10 
77 EG 15 Sand 2 Sand 9  
78 EG 15 Sahel shemally Sediment  N/A 
79 HRT Memphis, TN Soil 3  
80 HRT Newalla, OK Soil   N/A 
81 HRT Muldrow, OK Soil   N/A 
82 HRT South Rim Grand Canyon, AZ Sand   N/A 
83 HRT Hatch, UT Soil   N/A 
84 HRT Death Valley Lakebed Sand   N/A 
85 HRT Amarillo, TX Soil   N/A 
86 HRT Fulton, MS Soil   N/A 
87 HRT Brinkley, AR Soil   N/A 
88 HRT Moriarty, NM Soil   N/A 
89 HRT Chambers, AZ Soil   N/A 
90 HRT Lone Pine, CA Soil   N/A 
91 HRT Valley of Fire, NV Soil   N/A 
92 TN16 Tri-cities, TN beside boulder Soil   N/A 
93 TN16 Tri-cities, TN rattlesnake trail Soil   N/A 
94 TN16 Tri-cities, TN tree roots Soil   N/A 
95 TN16 Tri-cities, TN under tree Soil   N/A 
96 TN16 Tri-cities, TN on Embankment Soil   N/A 
97 TN16 Church Hill, TN (1509 ft.) Soil   N/A 
98 TN16 Church Hill, TN (1445 ft.) Soil   N/A 
99 TN16 Johnson City, TN (1481 ft.)(soil in root) Soil   N/A 
100 TN16 Church Hill, TN (1466 ft.) Soil   N/A 
101 TN16 Church Hill, TN (1394 ft.) (bottom layer) Soil   N/A 
102 TN16 Johnson City, TN (1481 ft.)(under wagon) Soil   N/A 
103 TN16 Church Hill, TN (1396 ft.) (top layer) Soil   N/A 
104 TN16 
Johnson City, TN (1481 ft.) (soil below 
root) Soil   N/A 
105 RC16 Shamrock Soil Soil   N/A 
106 AS16 Forrest in Newton, PA (#1) Soil   N/A 
107 AS16 Forrest in Newton, PA (#2) Soil   N/A 
108 AS16 Forrest in Newton, PA (#3) Soil   N/A 
109 AS16 Forrest in Newton, PA (#4) Soil   N/A 
Table 4. (Continued) 
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110 WR16 11,753 ft., Estes Park, CO Soil   N/A 
111 WR16 12,193 ft., Estes Park, CO Soil   N/A 
112 WR16 9,247 ft., Estes Park, CO Soil   N/A 
113 WR16 9,444 ft., Estes Park, CO Soil   N/A 
114 WR16 10,057 ft., Estes Park, CO Soil   N/A 
115 NV16 Nashville, TN 795 ft. Soil   N/A 
116 NV16 Nashville, TN Valve House Trail Soil   N/A 
117 PH16 USF campus, FL Soil   N/A 
118 PH16 Tampa, FL Soil   N/A 
119 PH16 Tampa, FL Soil   N/A 
120 PH16 Tampa, FL Soil   N/A 
121 PH16 Tampa, FL Soil   N/A 
122 PH16 Tampa, FL Soil   N/A 
* Listed are the environmental samples acquired throughout this study as well as the associated 
number of Actinobacteria identified. Location identifiers are: TSF – Te Strake farm; SHH – 
Shaw House; SIS – Sanibel Island soil; CWR – Clearwater reef; BB – Bill Baker; MFG15 – 
Florida middle grounds 2015; EG 15 – Egypt 2015; HRT – Hailey road trip; TN16 – Tennessee 
2016; RC16 – Ronan Carroll 2016; AS16 – Arielle Sharp 2016; WR16 – Wind river 2016; NV16 
– Nashville, Tennessee 2016; PH16 – Phage biology class 2016.  
* N/A indicates samples have not yet been processed. 
Table 4. (Continued) 
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Over 750 isolates displaying Actinobacteria-like indicators have been added to the Shaw lab 
Actinobacteria strain collection, of which over 200 have a confirmed genus based upon BLASTN 
confirmation of the 16S rRNA gene (Appendix I). The over 200 Actinobacteria are represented 
a variety of genera, including, Aeromicrobium, Agromyces, Arthrobacter, Brevibacterium, 
Gordonia, Isoptericola, Leifsonia, Microbacterium, Micrococcus, Mycobacterium, 
Micromonospora, Nocardia, Nocardioides, Promicromonospora, Pseudonocardia, 
Rhodococcus, Streptomyces, and Williamsia (Table 5). The most abundant of the genera, 
Streptomyces, which comprises more than half of the identified isolates, originated from all 
sample sites screened for Actinobacteria. This finding is concurrent with the literature that 
suggests that majority of the Actinobacteria found within the soil are of the genus Streptomyces 
(68). A circular cladogram was constructed with the over 200-actinobacterial-16S rRNA genes 
that displays the vast diversity of our collection as well as separates the genera into their 
respective families and orders (Figure 6). All Sanger sequenced isolates belong to the same 
class, Actinobacteria. 
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Table 5. Order, Family and Genus of Identified Isolates 
No. of isolates Genus Family Order 
1 Aeromicrobium Nocardioidaceae Proprionibacteriales 
2 Agromyces Microbacteriaceae Micrococcales 
2 Arthrobacter Micrococcaceae Micrococcales 
1 Brevibacterium Brevibacteriaceae Micrococcales 
6 Gordonia Nocardiaceae Corynebacteriales 
1 Isoptericola Promicromonosporaceae Micrococcales 
3 Leifsonia Microbacteriaceae Micrococcales 
3 Microbacterium Microbacteriaceae Micrococcales 
2 Micrococcus Micrococcaceae Micrococcales 
20 Mycobacterium Mycobacteriaceae Corynebacteriales 
1 Micromonospora Micromonosporaceae Micromonosporales 
9 Nocardia Nocardiaceae Corynebacteriales 
2 Nocardioides Nocardioidaceae Proprionibacteriales 
1 Promicromonospora Promicromonosporaceae Micrococcales 
1 Pseudonocardia Pseudonocardiaceae Pseudonocardiales 
20 Rhodococcus Nocardiaceae Corynebacteriales 
163 Streptomyces Streptomycetaceae Streptomycetales 
1 Williamsia Nocardiaceae Corynebacteriales 
* Listed are the different genera identified throughout this study as well as their respective 
family, order, and the number of isolates obtained that belongs to each genus. 
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Figure 6. Circular Cladogram of Identified Actinobacteria 
Cladogram was assembled using the 16S rRNA gene from identified Actinobacteria within our 
strain collection. Colors surrounding the cladogram identify bacteria as displaying specific traits 
or production of known compounds.
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Secondary Metabolite Extraction Optimization 
Secondary metabolite extraction results in a crude extract that may contain thousands of 
compounds, some of which may polar, non-polar, insoluble, temperature sensitive, pH sensitive, 
or even sensitive to the type of solvent used. As a consequence of the number of variables we 
strove to identify a method for secondary metabolite extraction that would afford suitable 
weights with which to work in a high throughput fashion. All three isolates (11, 39 and 40) were 
grown in triplicate for a period of 21 days and each were extracted following each of the 
methods above (A-D). The crude extract weights were recorded and used to determine which of 
the extraction methods would work best in a high throughput manner (Table 6). It was 
determined based upon average weights of all three isolates for each of the extraction methods 
that extraction method B would work optimally. 
 
Epigenetic Modification Optimization 
DNMTi Concentration Optimization – It was not yet known how 5-azacytidine would interact with 
our three isolates or the necessary concentration to use that would confer a change. Based 
upon existing literature for epigenetically modified fungi, we decided it would be best to optimize 
this method to ensure appropriate concentrations were being tested. Initial concentrations of 5-
azacytidine included: 0 µM, 1 µM, 10 µM, 50 µM, 100 µM, and 500 µM. Eighteen 50 mL 
bioreactor conical tubes were used to determine the maximum threshold for unaltered growth of 
each of the Actinobacteria. All three isolates had no visually noticeable growth defects at 0 µM 
and 1 µM concentrations. All three isolates showed some visually noticeable growth defects at 
the 10 µM concentration. None of the isolates matured passed inoculation in any of the 
concentrations greater than 10 µM (Table 7).  
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Table 7. Growth Based Upon Concentration of DNMTi 
[DNMTi] Isolate 11 Isolate 39 Isolate 40 
0 µM Growth Growth Growth 
1 µM Growth Growth Growth 
10 µM Growth Defect Growth Defect Growth Defect 
50 µM No Growth No Growth No Growth 
100 µM No Growth No Growth No Growth 
500 µM No Growth No Growth No Growth 
* Listed are the DNA methyltransferase inhibitor (DNMTi) concentrations used. Cultures were 
assessed based upon growth or no growth. A culture was labeled with growth defect if the 
culture did not achieve growth comparable to that of the control culture.
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Basing this initial optimization solely on visual inspection, it was determined that another round 
of DNMTi concentration optimization would be performed following a more narrow scope of 
concentrations. 
 
Time Optimization – Majority of Actinobacteria possess doubling times significantly longer than 
other bacteria, such as Staphylococcus aureus, which can have doubling times as low as 24 
minutes under laboratory conditions (132). As such, we needed to optimize a length of time that 
would suit majority of the Actinobacteria collection in a high throughput fashion. Cultures of 
isolates 11, 39, and 40 represent varying growth rates, which can provide a length of time that 
suits all isolates. In conjunction with time optimization, we also further specified the 
concentration of our DNMTi. Each of the isolates were challenged with the following 
concentrations of 5-azacytidine: 0 µM, 1 µM, 5 µM, and 10 µM. These tubes were allowed to 
incubate for 7, 14, or 21 days in triplicate. At each of the time points, a tube with each of the 
combinations of isolates and concentrations of 5-azacytidine were extracted with method B 
mentioned above. The crude extract weights were measured at each of time points and 
averaged (Table 8). All samples yielded, regardless of concentration of 5-azacytidine, the 
highest mass after 21 days of incubation. While samples that were inoculated with 10 µM of 5-
azacytidine for 21 days averaged the highest mass overall, it was clear that majority of the 
extracted mass was unusable and contained significant levels of cell material. These results 
provided an optimal length of time for incubation of 21 days, but still did not provide an optimal 
concentration of 5-azacytidine that would allow for continuous growth of the isolates. Therefore 
yet another round of DNMTi concentration optimization would be performed following an even 
more narrow scope of concentrations. 
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Media Optimization – Numerous studies have been performed in the hopes of determining 
optimal media for the production of antibiotics. A study by Cortes et al. found that in 
Streptomyces too much glucose could inhibit antibiotic production as it signals to the bacteria 
that there is an abundance of nutrients (133). Therefore it was essential to determine which of 
the media (SYE broth, SCA broth or ISP-2 broth) would be optimal for growth and production of 
secondary metabolites. In conjunction with media optimization, we further explored the optimal 
concentration of 5-azacytidine to include the following concentrations: 0 µM, 1 µM, and 5 µM in 
triplicate. With all three media options, a tube with each of the combinations of isolates and 
concentrations of 5-azacytidine were extracted with method B after 21 days of growth. Averages 
of the crude extract weights were taken for each of combinations and averaged (Table 9). All of 
the sample’s averages yielded the highest crude extract mass in either the SCA and ISP-2 
broths. The samples in all instances except one resulted in the highest crude extract mass in 
either the unmodified or 1 µM concentration of 5-azacytidine. These results provided both the 
optimal media for the production of secondary metabolites as well as the optimal concentration 
of 5-azacytidine for modification of Actinobacteria isolates. 
 
Before commencement of analysis of secondary metabolite production from our Actinobacteria 
strain collection, we needed to optimize a number of factors. These results aided in identifying 
the optimal parameters for the growth of these bacteria including two different media (SCA and 
ISP-2), a time frame with which to grow each batch (21 days) and the appropriate concentration 
of 5-azacytidine to use in conjunction with an unmodified control (1 µM).
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Quantitative Analysis of Secondary Metabolite Production of Actinobacteria Strain 
Collection 
Bacteria utilize DNA methylation as a method to rapidly activate or inactivate gene transcription, 
which allows them to acclimate to their environment more efficiently (95). As such, using 5-
azacytidine to prevent DNA methylation has the potential to disrupt bacterial gene expression 
including, but not limited to secondary metabolite biosynthesis pathways. 
 
Secondary metabolites have the potential to affect a plethora of cellular functions including cell 
wall development, protein synthesis, protein function and fatty acid synthesis/metabolism (77). 
Therefore, using purified bacterial isolates from soil and sediment samples, a total of 148 
bacterial isolates have been screened for the presence of bioactive secondary metabolites. 
After 21 days of incubation in the presence and absence of 1 µM of 5-azacytidine, it was seen 
that all of the Actinobacteria were able to produce some level of crude extract (Table 10). The 
masses of crude extract from each of the bacterial isolates varied greatly, however, there were 
40 of the 148 (27%) isolates that had >= +/- 1.0 mg difference between the challenged and 
unchallenged samples. The remaining 108 (73%) varied between challenged and unchallenged 
less than +/- 1.0 mg or there were no changes. The changes in crude extract mass observed in 
the 40 isolates with >= +/- 1.0 mg indicates there may be a difference in regulation between the 
two. The differences seen in crude extract weight may provide insight into how much material is 
being produced, however there is no indication as to what is being produced and whether or not 
bioactive secondary metabolite regulation is being disrupted. 
 
Evaluating the Effects of Crude Secondary Metabolites Against the ESKAPE Pathogens 
A major problem with the discovery of bioactive secondary metabolites lies within determination 
of how to assess such activity and where to focus our efforts. A majority of compounds  
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Table 10. Comparison of Crude Extract Mass 
Strain 
Number Identity 
Unchallenged 
(milligrams) 
Challenged 
(milligrams) 
Change 
(milligrams) 
1 Rhodococcus rhodochrous 2.6 3.5 0.9 
5 Rhodococcus rhodochrous 3.0 3.1 0.1 
6 Streptomyces violarus 1.7 1.4 -0.3 
7 Streptomyces sp. 1.6 1.9 0.3 
8 Streptomyces beijiangjensis 1.2 0.9 -0.3 
10 Streptomyces coelicoflavus 2.2 1.6 -0.6 
11 Gordonia namibiensis 6.4 6.2 -0.2 
12 Rhodococcus rhodochrous 9.3 6.4 -2.9 
13 Nocardia vermiculata 4.6 3.5 -1.1 
14 Streptomyces platensis 9.3 4.7 -4.6 
15 Streptomyces violarus 3.4 3.0 -0.4 
16 Streptomyces antibioticus 14.7 13.9 -0.8 
17 Streptomyces corchorusii 1.8 2.2 0.4 
18 Arthrobacter protophormiae 4.2 2.2 -2.0 
19 Gordonia namibiensis 3.1 4.4 1.3 
20 Aeromicrobium tamlense 16.3 13.3 -3.0 
21 Rhodococcus phenolicus 13.8 14.8 1.0 
22 Gordonia terrae 6.5 6.4 -0.1 
25 Rhodococcus rhodochrous 3.0 2.3 -0.7 
26 Streptomyces chromofuscus 3.2 8.5 5.3 
27 Streptomyces acrimycini 6.7 4.3 -2.4 
29 Mycobacterium parafortuitum 2.0 2.4 0.4 
30 Streptomyces macrosporeus 6.2 22.5 16.3 
31 Streptomyces antibioticus 12.0 16.9 4.9 
32 Streptomyces gardneri 1.6 2.3 0.7 
33 Streptomyces tumescens 4.0 3.1 -0.9 
34 Nocardia asteroides 4.1 3.3 -0.8 
35 Streptomyces minoensis 2.1 2.2 0.1 
36 Streptomyces aurantiogriseus 3.0 3.1 0.1 
37 Streptomyces matensis 2.6 3.1 0.5 
39 Streptomyces griseorubens 4.7 6.8 2.1 
40 Streptomyces fradiae 2.7 3.0 0.3 
41 Streptomyces violascens 3.6 4.2 0.6 
42 Streptomyces zaomyceticus 2.0 2.2 0.2 
43 Streptomyces viridochromogenes 7.6 6.8 -0.8 
44 Streptomyces beijiangensis 3.4 4.2 0.8 
45 Streptomyces intermedius 4.8 4.6 -0.2 
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46	 Streptomyces	intermedius	 5.1	 4.2	 -0.9	
47	 Streptomyces	albidoflavus	 3.2	 3.1	 -0.1	
48	 Streptomyces	matensis	 2.4	 1.5	 -0.9	
49	 Streptomyces	griseoplanus	 11.5	 10.8	 -0.7	
50	 Streptomyces	drozdowiczii	 1.2	 2.4	 1.2	
51	 Streptomyces	drozdowiczii	 1.8	 2.6	 0.8	
52	 Streptomyces	coelicoflavus	 2.1	 1.4	 -0.7	
54	 Streptomyces	intermedius	 1.4	 1.6	 0.2	
56	 Streptomyces	intermedius	 3.3	 2.5	 -0.8	
57	 Streptomyces	sampsonii	 2.3	 2.5	 0.2	
58	 Nocardia	asteroides	 3.0	 5.6	 2.6	
59	 Nocardia	asteroides	 3.4	 3.2	 -0.2	
60	 Streptomyces	glebosus	 4.8	 1.3	 -3.5	
61	 Streptomyces	hawaiiensis	 2.4	 4.9	 2.5	
62	 Streptomyces	variabilis	 2.1	 2.0	 -0.1	
64	 Streptomyces	drozdowiczii	 4.5	 3.7	 -0.8	
65	 Streptomyces	drozdowiczii	 3.5	 3.1	 -0.4	
66	 Streptomyces	griseoaurantiacus	 2.6	 3.3	 0.7	
67	 Streptomyces	intermedius	 2.5	 2.6	 0.1	
68	 Streptomyces	thermocarboxydus	 2.5	 3.1	 0.6	
69	 Streptomyces	viridobrunneus	 1.8	 3.2	 1.4	
70	 Streptomyces	intermedius	 2.4	 1.9	 -0.5	
71	 Brevibacterium	epidermidis	 2.3	 2.5	 0.2	
72	 Streptomyces	intermedius	 4.5	 3.8	 -0.7	
73	 Microbacterium	ginsengterrae	 4.0	 5.2	 1.2	
74	 Streptomyces	coelicoflavus	 1.6	 1.2	 -0.4	
75	 Streptomyces	gardneri	 1.7	 1.1	 -0.6	
76	 Streptomyces	intermedius	 2.5	 2.4	 -0.1	
77	 Streptomyces	malachitospinus	 1.6	 1.0	 -0.6	
78	 Streptomyces	intermedius	 2.9	 2.4	 -0.5	
79	 Streptomyces	aurantiacus	 3.2	 2.5	 -0.7	
80	 Streptomyces	malachitospinus	 1.1	 1.2	 0.1	
81	 Streptomyces	tendae	 0.4	 0.5	 0.1	
82	 Streptomyces	drozdowiczii	 1.2	 0.7	 -0.5	
84	 Streptomyces	tendae	 0.8	 1.1	 0.3	
85	 Streptomyces	tendae	 0.4	 0.9	 0.5	
86	 Streptomyces	gardneri	 0.3	 0.5	 0.2	
87	 Streptomyces	praecox	 4.6	 3.1	 -1.5	
88	 Streptomyces	turgidiscabies	 0.3	 0.5	 0.2	
Table 10. (Continued) 
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89	 Streptomyces	drozdowiczii	 12.6	 11.1	 -1.5	
90	 Streptomyces	drozdowiczii	 5.3	 9.4	 4.1	
91	 Streptomyces	zaomceticus	 18.1	 11.1	 -7.0	
92	 Gordonia	namibiensis	 16.7	 14.6	 -2.1	
93	 Rhodococcus	opacus	 5.5	 4.0	 -1.5	
95	 Micrococcus	yunnanensis	 15.5	 10.4	 -5.1	
96	 Streptomyces	griseorubens	 7.6	 11.2	 3.6	
97	 Streptomyces	lividans	 8.7	 6.3	 -2.4	
98	 Nocardia	caverna	 0.7	 0.6	 -0.1	
99	 Streptomyces	violascens	 2.4	 1.8	 -0.6	
100	 Streptomyces	drozdowiczii	 1.8	 1.0	 -0.8	
101	 Streptomyces	griseus	 1.1	 1.3	 0.2	
104	 Streptomyces	coelicoflavus	 1.6	 0.7	 -0.9	
105	 Streptomyces	malachitospinus	 1.7	 1.6	 -0.1	
106	 Streptomyces	libani	 1.7	 1.8	 0.1	
107	 Nocardia	asteroides	 1.2	 1.2	 0.0	
108	 Streptomyces	spongiae	 1.6	 0.8	 -0.8	
109	 Streptomyces	parvulus	 1.1	 1.9	 0.8	
110	 Streptomyces	olivoverticillatus	 1.5	 1.1	 -0.4	
111	 Streptomyces	chartreusis	 1.4	 2.1	 0.7	
112	 N/A	 0.9	 0.8	 -0.1	
113	 Streptomyces	hawaiiensis	 0.9	 0.6	 -0.3	
114	 Streptomyces	cinereospinus	 1.1	 1.5	 0.4	
115	 Streptomyces	intermedius	 3.6	 3.5	 -0.1	
116	 Streptomyces	chartreusis	 3.2	 1.4	 -1.8	
117	 Streptomyces	chartreusis	 1.2	 1.6	 0.4	
118	 Streptomyces	griseocarneus	 0.1	 0.1	 0.0	
121	 Streptomyces	cyanoalbus	 0.5	 0.3	 -0.2	
122	 Rhodococcus	erythropolis	 2.7	 4.3	 1.6	
123	 Streptomyces	atratus	 2.3	 1.6	 -0.7	
124	 Streptomyces	chartreusis	 0.9	 0.9	 0.0	
125	 Streptomyces	cinereorectus	 1.0	 1.5	 0.5	
126	 Streptomyces	diastatochromogenes	 0.8	 1.2	 0.4	
127	 Streptomyces	chartreusis	 4.0	 2.4	 -1.6	
128	 Streptomyces	drozdowiczii	 2.3	 1.3	 -1.0	
129	 Streptomyces	platensis	 0.8	 0.9	 0.1	
130	 Rhodococcus	opacus	 1.0	 3.8	 2.8	
131	 Rhodococcus	opacus	 5.7	 5.6	 -0.1	
132	 Streptomyces	rishiriensis	 0.6	 0.9	 0.3	
Table 10. (Continued) 
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133	 Streptomyces	drozdowiczii	 2.3	 9.3	 7.0	
134	 Rhodococcus	opacus	 4.2	 5.1	 0.9	
135	 Streptomyces	angustmyceticus	 1.1	 0.8	 -0.3	
136	 Streptomyces	drozdowiczii	 1.7	 1.7	 0.0	
137	 Streptomyces	purpurescens	 1.4	 1.3	 -0.1	
138	 Streptomyces	exfoliatus	 5.5	 1.6	 -3.9	
139	 Streptomyces	septatus	 1.3	 19.9	 18.6	
140	 Streptomyces	rochei	 1.1	 1.1	 0.0	
141	 Streptomyces	angustmyceticus	 0.9	 0.8	 -0.1	
142	 Streptomyces	olivoverticillatus	 1.5	 1.3	 -0.2	
143	 Streptomyces	hirsutus	 1.3	 4.9	 3.6	
144	 Streptomyces	angustmyceticus	 1.1	 1.3	 0.2	
145	 Streptomyces	olivochromogenes	 1.0	 1.2	 0.2	
146	 Agromyces	lapidis	 2.0	 1.7	 -0.3	
147	 Rhodococcus	opacus	 2.3	 3.2	 0.9	
149	 Arthrobacter	kerguelensis	 1.3	 1.1	 -0.2	
150	 Streptomyces	exfoliatus	 1.0	 1.2	 0.2	
152	 Streptomyces	tendae	 1.4	 1.1	 -0.3	
153	 Streptomyces	lavendulae	 2.2	 1.7	 -0.5	
154	 Mycobacterium	parafortuitum	 3.1	 2.6	 -0.5	
155	 Streptomyces	malachitospinus	 1.4	 1.7	 0.3	
156	 Streptomyces	pactum	 2.4	 1.3	 -1.1	
157	 Streptomyces	olivaceus	 2.2	 1.1	 -1.1	
158	 Streptomyces	malachitospinus	 2.7	 1.3	 -1.4	
159	 Streptomyces	olivaceus	 2.7	 2.0	 -0.7	
160	 Streptomyces	praecox	 1.8	 0.5	 -1.3	
161	 Streptomyces	malachitospinus	 0.7	 0.7	 0.0	
162	 Streptomyces	griseoaurantiacus	 0.2	 0.5	 0.3	
163	 Streptomyces	griseoplanus	 0.1	 0.1	 0.0	
164	 Streptomyces	malachitospinus	 0.4	 1.0	 0.6	
165	 Streptomyces	malachitospinus	 1.1	 1.1	 0.0	
166	 Streptomyces	malachitospinus	 0.1	 0.6	 0.5	
713	 Micrococcus	sp.	 1.0	 1.1	 0.1	
* Listed are the strain numbers associated with each of the isolate identities along with the 
crude extract mass yield from both modified and unmodified cultures as well as the comparison 
between the two. Positive change indicates the modified culture’s crude extract possessed more 
mass and negative change indicates the unmodified culture’s crude extract possessed more 
mass.
Table 10. (Continued) 
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discovered from Actinobacteria confer some form of bioactivity against other bacteria, and the 
antibiotic resistance seen in pathogenic bacteria is proving to be a worldwide issue. Therefore 
we decided that in order to properly assess the presence of antibacterial bioactive secondary 
metabolites, we needed to a panel of bacteria that could be used to do so. We wanted to ensure 
if any bioactivity were identified, it was novel; therefore we utilized clinical isolates in the 
screening process. The clinical isolates were comprised of the ESKAPE pathogens, which are 
responsible for majority of hospital-acquired infections in the United States and well 
characterized as possessing resistance to antibiotics (8). The 296 crude extracts, when solvated 
in DMSO to a concentration of 5 mg mL-1, were screened for antimicrobial activity against all of 
the ESKAPE pathogens using a MIC assay. A heat map was constructed to represent the 
bioactivity of only the active extracts against the ESKAPE pathogens individually, the combined 
activity for the Gram-positives, the combined activity for the Gram-negatives and collective 
activity for all six (Figure 7). Of the 296 crude extracts, 78 (~26%) possessed bioactivity against 
one or more of the ESKAPE pathogens (Appendix 2). The genera responsible for the activity 
seen in these 78 crude extracts are Streptomyces, Nocardia, and Mycobacterium. As suggested 
earlier, we looked at differences in crude extract mass of each of the Actinobacteria, which 
provided little insight, but may have alluded to differences in gene regulation with a number of 
the isolates. However, as we established bioactivity, we could further this insight and illustrate 
actual biochemical differences between modified and unmodified isolates. As such, we looked 
at changes in ESKAPE bioactivity between only the active extracts (Figure 8). Differences seen 
between modified and unmodified isolate crude extract bioactivities occurred with almost every 
sample. A few noteworthy crude extracts demonstrated higher levels of bioactivity against the 
same pathogen when compared to their counterpart and a number showed bioactivity against 
different pathogens compared to their counterpart. These differences indicate there are changes  
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Figure 7. Heat Map of Crude Extract Bioactivity 
All crude extracts were screened against the ESKAPE pathogens and the crude extracts with 
any level of bioactivity were assembled in this heat map. Heat map demonstrates level of 
activity to each of the individual ESKAPE pathogens, the Gram-positives, the Gram negatives, 
followed by the compiled activity against all ESKAPE pathogens as a whole. 
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Figure 8. Comparison of Activity Between Modified and Unmodified Crude Extracts 
All crude extracts that possessed bioactivity were assembled and compared to their modified or 
unmodified counterpart. Any portion of the bar graph that falls within the positive spectrum of 
this graph indicates the unmodified crude extract possessed higher bioactivity than the modified. 
Any portion of the bar graph that falls within the negative spectrum of this graph indicates the 
modified crude extract possessed higher bioactivity than the unmodified
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being made to the regulation of these isolates, whether it is transcriptional, translational, or post-
translational, further characterization is required. 
 
These efforts to disrupt gene regulation via inhibition of DNA methylation have resulted in 
numerous changes thus far. We have observed differences in crude extract mass as well as 
changes in bioactivity against the ESKAPE pathogens, however in order to bottleneck the 
number of isolates we are working with, we needed to identify an approach to do so. We 
needed to establish a minimum scaled score to ensure the crude extracts we were excavating 
would provide adequate bioactivity upon purification. Therefore we determined any crude 
extract possessing a combined scaled score of >= 8 would be a priority for purification and 
characterization, while the remainder were archived. Of the 78 bioactive crude extracts, 17 
(~22%) possessed a combined scaled score >= 8 (Figure 9). The genera responsible for these 
higher scaled scores belonged to Streptomyces and Nocardia, 15 of which were crude extracts 
from Streptomyces (Figure 10). These 17 offered a location with which to begin scaling up 
growth of our collection for higher yields of crude extract in order to further purify and 
characterize each of the extracts. 
 
From the initial ranking data, we decided to move forward with sample 6 (Streptomyces 
violarus) as this crude extract possessed a vibrant ruby color and diffusible pigments can be an 
indicator of bioactive secondary metabolites (134). Aside from the coloration of the crude 
extract, sample 6 control was able to effectively inhibit A. baumannii at 50 µg/mL and S. aureus 
at 4 µg/mL and sample 6 DNMTi effectively inhibited E. faecium at 50 µg/mL and S. aureus at 
10 µg/mL. Therefore we scaled up production and grew sample six in the presence and 
absence of 1 µM 5-azacytidine in two liter Erlenmeyer flasks containing 1000 mL of SCA broth. 
These flasks were kept at 28 °C in a shaking incubator under constant agitation for 28 days.  
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Figure 9. Crude Extracts with High Levels of Bioactivity 
Crude extracts were organized based upon level of bioactivity in order to determine a prioritized 
system for future characterization.
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The initial elements to analyze were to determine if there were a correlation between the crude 
extract mass and bioactivities of the small scale and large scale. The difference in volume of 
media was almost a 30-fold increase, while the fold change in crude mass extracted for the 
unchallenged and challenged were 32-fold and 42-fold, respectively (Figure 11A). The 
bioactivities of both of the large-scale crude extracts were almost 2-fold, with regards to S. 
aureus bioactivity, of the small-scale (Figure 11B). E. faecium bioactivity remained the same 
between small-scale and large-scale when challenged with 5-azacytidine, but bioactivity seen 
with A. baumannii in the unmodified small-scale crude extract was now replaced with bioactivity 
against E. faecium in the unmodified large-scale crude extract. We weren’t as concerned with 
the level of activity as both the modified and unmodified demonstrated the same trend with the 
primary difference being a 2-fold increase in bioactivity. Therefore we proceeded to purification 
of the crude extract. 
 
Initial High Performance Liquid Chromatography Coupled with Bioassay Guided 
Fractionation 
High performance (pressure) liquid chromatography is a very beneficial form of column 
chromatography used by a number of fields for the purpose of separating complex mixtures. 
The system involves pumping your mixture through a column (stationary phase) in a solvent 
(mobile phase), mixture of solvents, or solvent-solvent gradient. The chromatogram displays the 
retention times of the separated compounds. Each of the compounds within the mixture 
interacts with the column and solvents differently; this interplay is what causes separation. 
There are numerous detectors used with HPLC analysis, however we focused on ultraviolet 
(UV) and electronic light scattering (ELS) detectors. We used two semi-preparatory silica 
columns in tandem as our stationary phase. Our mobile phase used 100% hexanes for 5 
minutes, followed by a 35 minute gradient from 0-100% EtOAc, after which 15 minutes of 100%  
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Sample Small-Scale (milligrams) 
Large-Scale 
(milligrams) 
Fold change 
(Media) 
Fold Change 
(Crude mass) 
Sample 6 
(Control) 1.7 55 ~29 ~32 
Sample 6 
(DNMTi) 1.4 59.3 ~29 ~42 
 
 
 
 
Figure 11. Small-Scale and Large-Scale Variations 
Large-scale unmodified and modified crude extract masses were 32 and 42 fold higher than 
small-scale masses, respectively (A). Large-scale unmodified and modified crude extract level 
of bioactivity against the ESKAPE pathogens were both ~2-fold higher than small-scale 
bioactivity (B). 
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EtOAc, and concluded with 15 minutes of 1:1 EtOAc:IPA. This method yielded 10 fractions for 
the modified crude extract and 11 fractions for the unmodified crude extract (Figure 12A-D). 
After separating the two crude extracts into 21 separate fractions, we needed to determine 
which portion possessed the bioactivity seen in previous bioassays. The screen was performed 
against all of the ESKAPE pathogens in the same fashion as above and resulted with bioactivity 
in two fractions from sample 6 control, F and baseline (Figure 13). Bioactivity was only 
observed against S. aureus and was significantly reduced from bioactivity seen in prior 
screenings, and the bioactivity that was originally observed against E. faecium was lost 
completely. After performing bioassay with all of the fractions, we only possessed ~2.0 mg of 
the bioactive fraction J, which we attempted to purify further with reverse phase HPLC, however 
the mass acquired simply was not enough for further purification. 
 
We learned a few important key factors with regard to our initial HPLC purification screening, 
one of which was that we required much more crude extract mass in order to obtain higher 
masses of purified fractions. Another important lesson learned was that a method needed to be 
optimized for purification of the crude extract, as there were a number of issues with regards to 
mobile phase optimization, stationary phase optimization and collecting of the fractions. 
High Performance Liquid Chromatography Coupled with Bioassay Guided Fractionation 
With initial large-scale purification we learned a number of valuable lessons, which we intended 
to improve upon with further attempts at HPLC purification. Our first amendment involved 
drastically increasing the crude extract mass, whereby we grew two liters of culture every 28 
days, and three liters on the final 28 days, to a total of 13 liters for extraction. Each two-liter 
interval was considered the same and crude extracts were combined, as such we concluded 
with six individual crude extracts (Table 11). Our second amendment involved an extra 
purification step for each of the samples in an attempt to ensure uniform solubility for our  
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Figure 13. Bioactivity of HPLC Fractions 
All fractions from HPLC purification of modified and unmodified sample 6 were screened against 
the ESKAPE pathogens to determine which of these possessed bioactivity. None of the 
fractions except for fraction J and the baseline fraction from unmodified sample 6 possessed 
bioactivity and only against S. aureus.
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Table 11. Two-Liter Fermentation cycles and Partitioned Masses 
Partition First (mg) Second (mg) Third (mg) Fourth (mg) Fifth (mg) Sixth (mg) 
Crude 212.0 180.2 135.6 240.3 210.6 330.7 
EtOAc 65.2 111.6 56 151.6 110.3 160  
Insoluble 25.6 9.6 7.8 20.6 12.3  75.6 
H2O 100.5 40.9 58.1 55.6 66.9  59.6 
* Listed above are the mass yields for each of the two-liter fermentation cycles including crude 
mass as well as the mass for each of the partitions. Slight overall losses can be attributed to 
residual crude extract within the original collection vials.
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complex mixture of compounds. This involved re-suspending each of our crude extracts in 
EtOAc followed by partitioning with an equal volume of double distilled H2O in a separatory 
funnel, and collecting each of the layers (EtOAc soluble, insoluble, and H2O soluble) into 
separate pre-weighed 20 mL scintillation vials, this was repeated three times to ensure 
complete separation. The collections were dried under constant flow of air and weighed. After 
an initial weigh in, a small mass of each partition was collected for bioassay (Table 12). Each of 
the partitions were screened against the ESKAPE pathogens to ensure bioactivity towards E. 
faecium and S. aureus were still present amongst each extraction as well as to identify which 
partition possessed bioactivity. For the purpose of identifying whether or not activity was 
present, MICs were not performed; instead all partitions were screened at a test concentration 
of 25 µg mL-1. At this concentration, all of the crude extracts, as well as the EtOAc and insoluble 
partitions possessed bioactivity towards the two pathogens, while the H2O layer only possessed 
activity in a few of the extractions. This circumstantial activity alluded to a number of 
possibilities, the first being we were unable to completely remove all bioactive compounds from 
the H2O partition in all of the extractions, a second being multiple compounds possessing 
bioactivity and varying polarities are present in our complex mixture and therefore our partitions. 
Our most likely scenario is the former, as a result of bioactivity being seen in only a few of the 
H2O partitions and not all. 
 
The increased number of fermentations alongside partitioning provided ~650 mg of the EtOAc 
partitioned crude extract to be purified via HPLC. This mass was suspended in 4:6 hexanes: 
EtOAc to a final concentration of 75 mg mL-1 for normal-phase HPLC using one semi-
preparatory silica column as the stationary phase. Our mobile phase used 100% hexanes for 5 
minutes, followed by a 35 minute gradient from 0-100% 1:1 EtOAc:IPA, and concluded with 15 
minutes of 100% 1:1 EtOAc:IPA. This method is slightly modified from our former method, which  
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Table 12. Total Mass for Each Two-Liter Fermentation Cycle 
Partition 
First 
Extraction 
(mg) 
Second 
Extraction 
(mg) 
Third 
Extraction 
(mg) 
Fourth 
Extraction 
(mg) 
Fifth 
Extraction 
(mg) 
Sixth 
Extraction 
(mg) 
Crude mass 
removed for 
bioassay 
5.0 5.0 3.3 7.8 4.9 6.0 
Crude mass 
remaining 8.7 5.2 7.1 2.3 12.7 5.2 
EtOAc mass 
removed for 
bioassay 
5.0 4.3 5.0 6.6 7.4 5.0 
EtOAc mass 
remaining 60.2 107.3 51.0 145.0 102.9 155.0 
Insoluble mass 
removed for 
bioassay 
5.0 2.7 1.3 4.5 5.0 6.9 
Insoluble mass 
remaining 20.6 6.9 5.5 16.1 7.3 68.7 
H2O mass 
removed for 
bioassay 
2.5 4.3 5.3 7.8 8.3 8.1 
H2O mass 
remaining 98.0 36.6 52.8 47.8 58.6 51.1 
Sum 205.0 172.3 131.3 237.9 207.1 306.4 
Overall 
Percent lost 3.3% 4.4% 2.4% 1.0% 1.7% 7.3% 
 
* Listed above are the total masses from the partitions from each of the two-liter fermentation 
cycles. This includes all of the masses removed for bioassay as well as the remaining mass and 
finally the total mass to determine the amount lost from each partition.
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used a mobile phase of EtOAc followed by a 1:1 EtOAc:IPA wash and a single silica column as 
opposed to two in tandem for our stationary phase. These minor modifications provided 
significantly better separation of the compounds present in the mixture and yielded 18 fractions 
(Figure 14A-B, B not present yet). In order to determine which of these fractions possessed 
the bioactivity seen in previous screenings, they were challenged against the ESKAPE 
pathogens. Fractions N and O retained activity against both E. faecium and S. aureus, which 
therefore required even further HPLC purification. We were unconcerned with the MIC of these 
fractions due to the limited masses we acquired, and therefore only analyzed each of the 
fractions as bioactive or inactive. The retention times for both fractions N and O indicated that 
the compounds present were more polar as they did not elute until majority of the mobile phase 
was 1:1 EtOAc:IPA. Further purification via HPLC utilized the system in reverse phase, which 
involves a hydrophobic stationary phase. 
 
We began by suspending fractions N and O in a 20% solution of tetrahydrofuran (THF) in 
acetonitrile (ACN) and used an analytical C8 column as our stationary phase. Our mobile phase 
used 9:1 H2O:20%THF:ACN for five minutes, followed by a 35 minute gradient from 10-99% of 
20%THF:ACN, and concluded with 15 minutes of 99% of 20%THF:ACN. This method was used 
for both fractions for purification and yielded seven sub-fractions each (Figure 14C, 
Chromatogram needs to be obtained). Once again we needed to determine which of these 
sub-fractions possessed the bioactivity seen in previous screenings, as such, they were all 
challenged against the ESKAPE pathogens. Fractions 2ND and 2OD retained bioactivity against 
both E. faecium and S. aureus, while fraction 2OC displayed a hint of bioactivity as there was a 
severe growth defect with both E. faecium and S. aureus. As we now had even more limited 
masses than prior ESKAPE screenings, we once again limited our analysis to determine if the 
fractions were bioactive or inactive. This clear indication of which fractions possess bioactivity 
  76 
has allowed for further characterization of our compound using mass spectrometry, H1 NMR and 
C13 NMR.  
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Discussion 
 
It has long been known that Actinobacteria in the soil can provide a plethora of bioactive 
secondary metabolites, but have we just scratched the surface? We know that many species 
within the phylum Actinobacteria possess very diverse secondary metabolism, which can aid in 
their survival (77). Although some of the best described and most helpful for humanity have 
been antibiotics, which inhibit enzymes and cellular processes, Actinobacteria can also 
manufacture siderophores, for iron acquisition (135), spore pigments, which have been shown 
to provide some level of UV protection (136), as well as enzymes specialized for degradation, 
such as chitin binding proteins, which can aid in chitin degradation as a carbon and nitrogen 
source (137). The multitude of secondary metabolic potentials arise when Actinobacteria are 
stressed in the form of threats by other micro- or macroorganisms, nutrient depletion, and 
environmental stressors such as temperature and pH. These secondary metabolite products 
provide the structures and scaffolds we need to identify novel therapeutics and encouraging 
these organisms to produce them is only the first step. 
 
Actinobacteria Diversity 
Actinobacteria as a phylum have undergone numerous taxonomical classification events, only to 
be adjusted as technology advances. Originally classified as thread bacteria that closely 
resemble filamentous fungi, their organization has been adapted to include cell wall 
composition, morphological features, biochemical analysis, 16S rRNA gene sequencing, and 
nowadays we fall to whole genome sequencing (65, 138, 139). The constant evolution of 
Actinobacteria taxonomy is a result due to the remarkable diversity within this phylum. As each 
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new method of classification arises, we find outliers that do not match the necessary 
descriptions that fall within certain classes, genera, or species. An issue seen with cell wall 
composition as a mode of classification is that bacteria are typically classified as Gram-positive 
or –negative. This is based upon a Gram’s stain, which will either indicate a thick peptidoglycan 
layer and single membrane (Gram-positive) or a thin peptidoglycan layer and two membranes 
(Gram-negative) (140). However the issue that arises is when bacteria don’t match either of 
these descriptions and are considered Gram-variable, this can include Actinobacteria such as 
Actinomyces, Corynebacterium, and Arthrobacter (141). Biochemical analysis for classification 
saw similar issues as seen with cell wall composition taxonomy. Between the species there 
were a number of isolates that demonstrated similar cell-wall characteristics, and while the 
biochemical analyses could differentiate between a few, overlap was still observed, as seen with 
Mycobacterium spp. (142). Along with the advent of gene sequencing, the 16S rRNA gene 
became the method by which prokaryotes would be organized (143). As there are conserved 
regions of the 16S rRNA gene within a genus, there are also regions of variability that can be 
species specific, which is what gives this technique such remarkable cataloguing potential. As 
with all methods thus far, problems have arisen and while it is well known that bacteria possess 
16S rRNA genes in numerous locations scattered throughout their chromosome, it was found 
that bacteria can also possess 16S rRNA genes that vary from one another as seen in 
Thermomonospora chromogena, which also happens to be a member of Actinobacteria (144). 
With whole genome sequencing becoming increasingly affordable, 16S rRNA gene 
classification may eventually lose its place, however it can still organize prokaryotes based upon 
their phylum, class, order, family and in a majority of instances, genus (66). 
 
Within our unique collection of Actinobacteria we utilized 16S rRNA gene sequencing in order to 
identify the strains. With the objective of identifying a high throughput technique for isolating 
Actinobacteria we began by using 16S rRNA gene sequencing as an initial method for 
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identifying the bacteria we were working with. Using this technique, we were able to become 
familiar with Actinobacteria characteristics, which aided in rapid detection thereby eliminating 
the need for 16s rRNA gene sequencing. As we were isolating these bacteria with the intention 
of modifying already characterized isolates to unlock dormant or overlooked metabolism, we 
only resorted to 16S rRNA gene sequencing only when isolates possessed characteristics 
unlike those of Actinobacteria. In such cases we first ensured they were Gram-positives or 
repeatedly demonstrated a Gram-variable phenotype. Concurrent with literature, we have found 
that majority of our isolates for which we have identified belong to the genus Streptomyces. The 
majority of the isolates within the strain collection possess some level of semblance to the 
identified Streptomycetes therefore these bacteria which share a likeness were added to the 
collection (68). Regardless of the dominance of Streptomycetes in our environmental samples, 
we have still managed to isolate and identify a variety Actinobacteria, which provides alternative 
secondary metabolite potential in our search. We believe the diversity in our Actinobacteria 
collection is due to the variety of locations our environmental samples were obtained. Thus far 
we have primarily focused on terrestrial samples, however we have scavenged a few 
Actinobacteria in our collection from other areas including aquatic and arid environments. As we 
continue to isolate and identify Actinobacteria, we anticipate that the diversity will continue and 
grow as we move to more unique environments such as deep-sea sediments, sponges, and 
high-altitude soils. 
 
Many researchers in the Actinobacteria world focus their efforts on locating novel genera and 
species from exotic locations in an effort to discover new chemistry that allows the bacteria to 
survive in these unique environments. We however are combining this common approach while 
simultaneously focusing on cultivation of as many isolates as possible from environmental 
samples. We have looked at a variety of locations for Actinobacteria including in our back yard 
or a farm, which has the potential to provide immense diversity. For numerous soils it is 
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estimated that the population density is ~ 1 billion bacteria per gram, while the variety of species 
can be between 4,000 and 50,000 (145, 146). Actinobacteria are only thought to account for 
between 2 – 9% of the overall population, this would suggest a large range of potential 
actinobacterial isolates (80-4,500 Actinobacteria g-1) (145). Most of our samples yielded a 
number of isolates that falls within this range perfectly, as shown with our Soil 1 environmental 
sample from a Ft. Meyers farm. Soil 1 was able to provide 32 Actinobacteria that we were able 
to identify into our strain collection. Taking into consideration the dilution series undergone and 
volume plated, we see that the estimated number present in the original sample was ~1,600 
Actinobacteria g-1. This number only represents the Actinobacteria we were able to culture 
within the laboratory, which suggests we may be missing potential additions to our collection. 
One study proposed that the use of many different media types would increase the chance of 
identifying novel members of the phylum, their results suggest that the number of isolates 
acquired was higher when more media types were used (147). We attempted to use a greater 
variety of media and methods initially, however it did not seem a feasible option with the number 
of environmental samples we possess. Although the exact media composition for optimal 
growth of Actinobacteria is unknown, our two low-nutrient media provide an excellent basis for 
high throughput isolation. 
 
Drug Discovery 
With the introduction of penicillin by Alexander Fleming in 1928 and its subsequent release to 
the public in the 1940s, so began the era of natural products drug discovery (86). The field 
delved further with the introduction of actinomycin and streptomycin by Selman Waksman 
shortly after (87, 88). Antimicrobial resistance spurred drug discovery into a never-ending 
endeavor to prevent infection and soon it seemed all pharmaceutical companies and drug 
discovery researchers were growing microorganisms in the search for antibiotics. This search 
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for anti-infective agents did not come without a price tag or regulations, which were becoming 
more and more stringent. In the 1970s, many pharmaceutical companies were realizing that 
natural product drug discovery branches were becoming a financial burden as the proverbial 
“low hanging fruit” was now out of reach (148). As the 1990s came about, we were looking at a 
revolution within the drug discovery world and that was combinatorial chemistry, a method by 
which tens of thousands of chemical structures can be tested at once as potential therapeutics 
(90). One of the issues with combinatorial chemistry is that the synthetic capabilities of chemists 
cannot compete with that of nature, and therefore natural products chemistry has produced 
scaffolds and compounds that cannot be mimicked in the laboratory. As seen with 
Actinobacteria classification, new technologies provided alternative approaches to searching for 
novel bioactive compounds. Technological advancements have led to resurgence in natural 
product drug discovery. Liquid chromatography advancements now allow for accurate and 
replicative separating of soluble compounds and mass spectrometry has provided analysis of 
crude extracts, which can detect trace amounts of individual compounds. Novel cultivation 
techniques cater the isolation of previously unattainable microbes to be grown in lab conditions 
and whole genome sequencing has allowed for genome mining in the search for genes 
homologous to those found in known biosynthetic pathways. All of these coupled to one another 
have thrust natural product drug discovery in new directions previously unexplored.  
 
Today, drug discovery looks very different than before as novel techniques are used in 
numerous applications. Bioactive secondary metabolites have been found in unorthodox 
locations such as a Colorado iron-rich freshwater spring by a group from Oklahoma (149). Six 
new compounds were identified from fungi found within a microbial mat and the group was able 
to characterize clearanols A-E and disulochrin (149). Of these six natural products disulochrin 
demonstrated bioactivity against methicillin-resistant Staphylococcus aureus and clearanol C 
showed weak bioactivity against Candida albicans biofilm formation (149). Identifying microbes 
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from unique locations can lead to remarkable chemistry as these organisms have developed 
methods for thriving in such environments. An alternative habitat that has been explored to yield 
new secondary metabolites is sea life. Former explorations of marine life such as tunicates 
suggested that compounds found within were synthesized by the Ascidians (150). While they 
are a prolific source of natural products, it was later found that these compounds were actually 
produced by the endophytic bacteria. This was elucidated using genome sequencing where it 
was found that the Prochloron didemni did not possess the necessary genes for synthesis of the 
antitumor polyketides known as patellazoles (151). The combination of new habitats and whole 
genome sequencing allowed natural products to identify the specific producer of the 
compounds.  
 
In the constant struggle of imitating the natural environment within the lab there have been 
numerous attempts at replicating such conditions. In order to mirror nutrient fluctuations seen in 
the environment, groups in Germany have devised a clever way including continuous culture of 
Aspergillus nidulans, one of the model organisms used to study fungal genetics. This 
continuous culture could be modified to mimic nitrogen, phosphorous and carbon limiting 
conditions that could occur in the environment (152). Under nitrogen and phosphorous 
limitations silent polyketide synthase genes were differentially expressed when compared to 
standard growth conditions (152). A search that yielded novel secondary metabolites utilized a 
novel growth technique that allowed bacteria to grow in their natural environment. Using a multi-
channel device known as an isolation chip or iChip, the group was able to isolate previously 
unculturable microbes (153). This iChip consists of hundreds of diffusion chambers made up of 
through holes with semi-permeable membranes on either side (153). The process involves 
loading each of the wells with a sample of soil that has been diluted to roughly one cell per 20 
microliters of molten agar, assembling the remainder of the iChip, and then burying it where the 
original soil sample was obtained (153). This method was used by Ling et al. to isolate and 
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identify the novel cell wall inhibitor, teixobactin from the new species Eleftheria terrae (154). 
Prior to identification of this compound, this group of Gram-negatives were not known to 
produce any antibiotics, which exposes how little is known about bacteria in their natural 
environment (154). 
 
Although bacteria possess seemingly limitless diversity when it comes to secondary 
metabolites, a struggle commonly seen is the abundance with which they are synthesized. 
Advancements in instrumentation used for detection and analysis of metabolite production has 
given rise to the term “metabolome.” The metabolome is in reference to the overall metabolite 
production by an organism, much the same, as the genome and the associated genes or the 
proteome and proteins produced. Improvements to mass spectrometry have allowed for 
detection of trace loads of a compound in a mixture. Using HPLC and mass spectrometry in 
tandem grants separation as well as mass detection of crude mixtures resulting in a metabolic 
profile. After further purification, even the insignificant portions of the amalgam of compounds 
could be identified. Many metabalomic profiles exist from bacteria today; they can be used to 
determine effect of nutrient starvation, mutation, temperature or pH stressors on metabolite 
production. A group at the University of Wisconsin – Madison were able to discover analogs of a 
known compound using liquid chromatography coupled mass spectrometry (LCMS) (155). This 
analog, bottromycin D possessed slightly lower levels of bioactivity than the original bottromycin 
A2, however identifying the compound cements LCMS as a promising technique for future 
analysis of metabolites (155). 
 
Our research has utilized a number of these methods listed above, which could be what drives 
the immense diversity of our collection. We have not only obtained samples from diverse 
locations, but we also are using HPLC coupled with mass spectrometry as well as NMR 
techniques to elucidate the structure of a compound. Our environmental samples include soil 
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from numerous locations including farms (higher nitrogen levels), high altitudes (lower oxygen 
levels) and forests (higher organic content). Not only does our environmental sample collection 
have a variety of soils, but we also possess numerous sponges, sand from arid and high 
temperature regions, as well as shallow and deep-sea sediments. This variety of conditions can 
play a significant role in the behavior and lifestyle of the native microbes and by using such a 
wide variety environmental samples we have been able to demonstrate similarities to literature 
in acquiring a diverse collection of Actinobacteria. Interestingly, some of our environmental 
samples that have provide the most numerous isolates of Actinobacteria have been locations 
that have had ample traffic by grazing animals. Our biggest contributor with regards to the 
Actinobacteria collection was from a soil sample procured from horse stables, however this has 
been only an observation thus far. A hypothesis that could provide insight to this observation is 
that grazing animals leave in their wake a myriad of particulate organic matter, which is readily 
colonized by Actinobacteria, as they possess the necessary metabolism to decompose such 
substances. Of the 13 different Actinobacteria that possessed high levels of bioactivity against 
the ESKAPE pathogens, all were from soil samples that had interaction with grazing animals. 
This suggests the bacteria within the soil samples may have had interactions with mammalian 
associated bacteria, therefore requiring them to mount defensive strategies that persisted 
throughout lab cultivation. An alternative theory suggests the soil may have been supplemented 
with lime, which is commonly used as a remedy for low soil pH and help plants and fields 
flourish, and has also been shown to enhanced presence of Streptomycetes (156, 157). 
Furthermore majority of the crude extracts that possessed high levels of bioactivity were from 
the genus Streptomyces, which has historically been a primary source of antibiotics. Majority of 
our bioactivity is towards our Gram-positive organisms E. faecium and S. aureus, which seems 
fairly common with drug discovery campaigns. Within the literature it seems that bioactive 
compounds trend towards the Gram-positives for a number of reasons including two attributes 
of the Gram-negatives, an outer cell membrane and efflux pumps (158). It has been 
  86 
demonstrated that antibiotics with intracellular targets possessed by both Gram-positives and 
negatives can affect only the Gram-positives and efflux deficient Gram-negatives (117).  
 
Although we have successfully extracted bioactive secondary metabolites from our cultured 
Actinobacteria, there are numerous improvements that could provide better yields. One such 
improvement could be to increase aeration within our flasks. It is suggested that for cultivation of 
Streptomycetes, there should be 4-10 fold volumes of air compared to that of the liquid medium. 
Currently in our methods we are using a 1:1 ratio of liquid media to air, which may not be 
enough for the bacteria to properly thrive. We have also noticed significant clumping of our 
bacteria in liquid cultures, primarily the Streptomycetes. This is a common issue that can be 
dealt with in numerous ways including addition of sucrose, polyethylene glycol, or using baffled 
flasks (159). As such we will be optimizing a method to prevent clumping and perhaps 
optimizing even further the necessary volumes for increased production of bioactive secondary 
metabolites. Additional to our potentially sub-optimal aeration, our extraction methodology 
focuses solely on secondary metabolites, which are soluble in EtOAc. This could be rectified 
with modifications to procedure that involve drying the entire growth culture prior to extraction. 
 
Epigenetics 
Many efforts have been devoted to discovering new methods of unlocking silent metabolic 
pathways in Actinobacteria and other natural product-producing organisms. Of these methods 
there have been attempts of small molecule or chemical, co-cultivation, or genome mining 
elicitation of these cryptic genes. Much of the literature regarding co-cultivation suggests that 
quorum sensing molecules or presence of a nutrient competitor elicits the production of 
secondary metabolites (160). Genome mining has also proved a potential for novel metabolites, 
as shown with S. coelicolor, which displayed over 20 theorized secondary metabolite 
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biosynthetic pathways (78). However, our search for silent metabolic pathways involves 
epigenetic modification of Actinobacteria using small molecules. This has only been performed 
a handful of times, however for fungal elicitation it has been very successful with identification of 
novel metabolites. A study performed in 1995 by Fernandez et al. and Novella and Sanchez 
discussed the differences in production of rhodomycin from S. antibioticus (161, 162). It was 
noticed that the cultures with 5-azacytidine began producing the anthracycline after only six 
hours of growth, while the control didn’t display any signs of production even after four days of 
growth (161). The study by Fernandez et al. attributed the changes in anthracycline production 
to low levels of methyltransferase in the 5-azacytidine challenged culture stating that 
methyltransferase activity was as low as 50% of that seen in the control (161). Fernandez et al. 
were looking for effects of DNA methyltransferase inhibitors on the overall growth and 
development of Streptomyces, which was not limited to secondary metabolite production, but 
other characteristics as well. In the subsequent study by Novella and Sanchez, it was 
demonstrated that neither DNA, RNA or protein synthesis in S. antibioticus were inhibited by 5-
azacytidine, yet this study confirmed the low level of activity from methyltransferases (162). 
Another study that used 5-azacytidine as a small molecule elicitor of secondary metabolite 
biosynthesis was performed at Banaras Hindu University in Varanasi, India. This study by 
Kumar et al. involved exposing S. coelicolor to varying concentrations of 5-azacytidine to 
compare crude extracts bioactivity to untreated cultures. Kumar et al. tested crude extracts from 
each of the S. coelicolor cultures at the varying concentrations against five human pathogenic 
bacteria (108). Using a combination of Kirby-Bauer disk diffusion and MTT assays, they 
determined that a concentration of 25 µM was sufficient to induce antibacterial activity (108). 
The group continued to HPLC and MALDI-TOF/mass spectrometry analysis of the crude 
extracts to derive differences between the 25 µM and untreated growth cultures. Their 
conclusion alludes to antibacterial activation after epigenetic modification as their control culture 
produced only five compounds, while their modified produced 12 (108). Although the study 
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provided compelling evidence to suggest epigenetically modifying S. coelicolor induced 
inhibitory agents after a threshold concentration was achieved, there was no mention of the 
inhibitory action of 5-azacytidine against the human pathogens at the concentrations mentioned. 
In our study we overcame this obstacle by ensuring 5-azacytidine concentrations used would 
not affect growth of our pathogens. We also ensured the concentration of 5-azacytidine would 
not inhibit growth of our Actinobacteria as we optimized the concentration used rigorously. In 
our studies of epigenetic modification of Actinobacteria we have attempted to ensure each of 
our processes are optimal for a high throughput screening campaign. By identifying optimal the 
optimal cultivation period, media, concentration of epigenetic modifier, and catering to multiple 
growth types present in Actinobacteria, we believe this high throughput endeavor will 
successfully unlock cryptic metabolic pathways. 
 
As a result of our rigor, we have successfully observed differences in production and 
antibacterial activity of our crude extracts from modified and unmodified Actinobacteria. As 
mentioned previously, the masses associated with our crude extracts vary greatly, however the 
differences in mass between modified and unmodified cultures demonstrates the level of 
change each of the Actinobacteria are undergoing. These changes in mass primarily indicate 
that the proportions of product are different, which we believe is a direct effect of our epigenetic 
modifier. We have also established diversity in the level of antibacterial bioactivity between 
modified and unmodified cultures indicating different compound production between the two. It 
has been demonstrated that mutations in gene promoters and changes in methylation patterns 
can alter expression of the subsequent genes (45, 46, 95). Therefore we hypothesize that the 
variations in crude extract mass and bioactivity against the ESKAPE pathogens could be a 
result of augmented regulation due to gene promoter de-methylation. This of course suggests 
three outcomes for secondary metabolite biosynthesis gene promoters; they can be expressed 
more frequently, less frequently, or can be unaffected. This interpretation would provide 
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adequate rationale for our modified crude extracts yielding higher, lower or equal mass and 
bioactivity compared to the unmodified crude extracts.  
 
As we near the potential of a post-antibiotic era, we require new therapeutics that can combat 
the rise of resistance. Actinobacteria have historically contributed to majority of the antibiotics 
we possess today, and continue to provide natural products and natural product derivatives. Our 
results demonstrate the abundance of compounds yet to be identified in both new organisms as 
well as the well established. The identification of our lead compound has and will remain our top 
priority as it has demonstrated such inhibitory potential of S. aureus and E. faecium. Thus far we 
have successfully purified our crude extract from the large-scale fermentation of S. violarus via 
HPLC and have moved to structure elucidation. The structure of our compound thus far, when 
comparing the NMR and mass spectrometry data, seems to possess characteristics often 
associated with anthracyclines. The phenotype of our compound also suggests anthracycline as 
it retains the same ruby pigmentation often associated with this class of drug. Anthracyclines 
are characterized as possessing anti-tumor capabilities as well as have been observed to inhibit 
Gram-positives, although we have not yet performed cytotoxic screening of our compound, we 
have noticed inhibition of only Gram-positives thus far. Although the exact mechanism of action 
of anthracyclines is perpetually debated, it has been shown resistance in Gram-negatives may 
be due to efflux pumps (117).  
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Future Directions 
 
Preliminary results suggest the bioactivity of our extract is due to an anthracycline compound 
based upon the ruby pigment, the Gram-positive specific bioactivity, and initial NMR data. In 
order to properly elucidate the structure of our lead compound, it would be beneficial to obtain 
significantly more crude extract for purification. We have performed numerous purifications via 
HPLC in order to obtain as much pure compound as possible, yet we seem to be left with 
minuscule amounts. Regrettably the long cultivation period and low extraction yield results in 
providing only preliminary data that suggests subtle hints of the structure of our lead compound. 
Therefore significantly more crude extract is needed in order to purify higher more. Alternatively, 
we could also optimize our growth period and determine at what point S. violarus is producing 
the highest yield of our bioactive compound. This can be done in a few ways including a 
bioactivity based approach or a mass spectrometry approach, either would provide insight into 
the abundance at different growth stages. Alternatively, it would also be worthwhile performing 
whole genome sequencing on the isolate to determine the gene clusters responsible for our 
compound. This information would potentially allow us to identify biosynthesis and regulatory 
pathways, which would allow for optimized growth and production. Genome mining could also 
help identify otherwise unknown alternative secondary metabolite biosynthesis pathways, which 
could harbor previously unseen chemistry. After establishing the structure of our lead compound 
we will focus on further characterizing the bioactivity seen including whether the compound is 
bacteriostatic or bactericidal in nature, cytotoxicity of the compound and whether this compound 
has the ability to affect bacteria within a biofilm. 
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We also plan to continue growing and modifying the Actinobacteria strain collection followed by 
determining antibacterial activity against the ESKAPE pathogens. Thus far we have successfully 
grown and extracted a large number of isolates, however, as the collection continues to grow, 
so must the extractions. We possess a number of environmental samples we have been unable 
to cultivate organisms from, however, this requires further optimization that we will achieve. We 
have identified a number of high activity crude extracts, which have provided a number of 
avenues with which to pursue in further large-scale culturing followed by purification and 
characterization. In an attempt to further identify the impact of our DNMTi, we would also like to 
establish a metabolome profile for our unmodified and modified organisms. This of course could 
not be performed on all organisms we cultivate; however it would be interesting to analyze our 
crude extracts that possess high levels of bioactivity against the ESKAPE pathogens and 
demonstrate differences between the modified and unmodified samples. 
  92 
 
References 
 
 
1. Centers for Disease Control and Prevention, Office of Infectious Disease. Antibiotic 
resistance threats in the United States, 2013. April 2013. Available at: 
http://www.cdc.gov/drugresistance/ threat-report-2013. Accessed March 30, 2016. . 
2. Wang SH, Sheng WH, Chang YY, Wang LH, Lin HC, Chen ML, Pan HJ, Ko WJ, Chang 
SC, Lin FY. Healthcare-associated outbreak due to pan-drug resistant Acinetobacter baumannii 
in a surgical intensive care unit. J Hosp Infect. 2003;53(2):97-102. PubMed PMID: 12586567. 
3. Roberts RR, Hota B, Ahmad I, Scott RD, 2nd, Foster SD, Abbasi F, Schabowski S, 
Kampe LM, Ciavarella GG, Supino M, Naples J, Cordell R, Levy SB, Weinstein RA. Hospital 
and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: 
implications for antibiotic stewardship. Clin Infect Dis. 2009;49(8):1175-84. doi: 10.1086/605630. 
PubMed PMID: 19739972. 
4. US Food and Drug Administration. 2015 summary report on antimicrobials sold or 
distributed for use in food producing animals, 2016. Available at: 
http://www.fda.gov/downloads/ForIndustry/UserFees/AnimalDrugUserFeeActADUFA/UCM5342
43.pdf. Accessed 7 February 2017. 
5. Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. P T. 
2015;40(4):277-83. PubMed PMID: 25859123; PMCID: PMC4378521. 
6. Duncan KR, Haltli B, Gill KA, Correa H, Berrue F, Kerr RG. Exploring the diversity and 
metabolic potential of actinomycetes from temperate marine sediments from Newfoundland, 
Canada. J Ind Microbiol Biotechnol. 2015;42(1):57-72. doi: 10.1007/s10295-014-1529-x. 
PubMed PMID: 25371290. 
7. Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial 
pathogens: no ESKAPE. J Infect Dis. 2008;197(8):1079-81. doi: 10.1086/533452. PubMed 
PMID: 18419525. 
8. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, 
Spellberg B, Bartlett J. Bad bugs, no drugs: no ESKAPE! An update from the Infectious 
Diseases Society of America. Clin Infect Dis. 2009;48(1):1-12. doi: 10.1086/595011. PubMed 
PMID: 19035777. 
  93 
9. Wolf M, Muller T, Dandekar T, Pollack JD. Phylogeny of Firmicutes with special 
reference to Mycoplasma (Mollicutes) as inferred from phosphoglycerate kinase amino acid 
sequence data. Int J Syst Evol Microbiol. 2004;54(Pt 3):871-5. doi: 10.1099/ijs.0.02868-0. 
PubMed PMID: 15143038. 
10. Schleifer KH, Kilpper-Bälz R. Transfer of Streptococcus faecalis and Streptococcus 
faecium to the Genus Enterococcus nom. rev. as Enterococcus faecalis comb. nov. and 
Enterococcus faecium comb. nov. International Journal of Systematic and Evolutionary 
Microbiology. 1984;34(1):31-4. doi: doi:10.1099/00207713-34-1-31. 
11. Maccallum WG, Hastings TW. A Case of Acute Endocarditis Caused by Micrococcus 
Zymogenes (Nov. Spec.), with a Description of the Microorganism. J Exp Med. 1899;4(5-6):521-
34. PubMed PMID: 19866921; PMCID: PMC2118017. 
12. Arias CA, Murray BE. The rise of the Enterococcus: beyond vancomycin resistance. Nat 
Rev Microbiol. 2012;10(4):266-78. doi: 10.1038/nrmicro2761. PubMed PMID: 22421879; 
PMCID: PMC3621121. 
13. Chow JW. Aminoglycoside resistance in enterococci. Clin Infect Dis. 2000;31(2):586-9. 
doi: 10.1086/313949. PubMed PMID: 10987725. 
14. Arias CA, Murray BE. Emergence and management of drug-resistant enterococcal 
infections. Expert Rev Anti Infect Ther. 2008;6(5):637-55. doi: 10.1586/14787210.6.5.637. 
PubMed PMID: 18847403. 
15. Sivaraman K, Venkataraman N, Cole AM. Staphylococcus aureus nasal carriage and its 
contributing factors. Future Microbiol. 2009;4(8):999-1008. doi: 10.2217/fmb.09.79. PubMed 
PMID: 19824791; PMCID: PMC2908500. 
16. Ortega E, Abriouel H, Lucas R, Galvez A. Multiple roles of Staphylococcus aureus 
enterotoxins: pathogenicity, superantigenic activity, and correlation to antibiotic resistance. 
Toxins (Basel). 2010;2(8):2117-31. doi: 10.3390/toxins2082117. PubMed PMID: 22069676; 
PMCID: PMC3153285. 
17. Genigeorgis CA. Present state of knowledge on staphylococcal intoxication. Int J Food 
Microbiol. 1989;9(4):327-60. PubMed PMID: 2701861. 
18. McCallum N, Berger-Bachi B, Senn MM. Regulation of antibiotic resistance in 
Staphylococcus aureus. Int J Med Microbiol. 2010;300(2-3):118-29. doi: 
10.1016/j.ijmm.2009.08.015. PubMed PMID: 19800843. 
  94 
19. Kong C, Neoh HM, Nathan S. Targeting Staphylococcus aureus Toxins: A Potential form 
of Anti-Virulence Therapy. Toxins (Basel). 2016;8(3). doi: 10.3390/toxins8030072. PubMed 
PMID: 26999200; PMCID: PMC4810217. 
20. Ryan KJ, Ray CG, Sherris JC. Sherris medical microbiology : an introduction to 
infectious diseases. 4th ed. New York: McGraw-Hill; 2004. xiii, 979 p. p. 
21. Postgate JR. Nitrogen fixation. 3rd ed. Cambridge, U.K. ; New York, NY, USA: 
Cambridge University Press; 1998. vi, 112 p. p. 
22. Williams KP, Gillespie JJ, Sobral BW, Nordberg EK, Snyder EE, Shallom JM, Dickerman 
AW. Phylogeny of gammaproteobacteria. J Bacteriol. 2010;192(9):2305-14. doi: 
10.1128/JB.01480-09. PubMed PMID: 20207755; PMCID: PMC2863478. 
23. Podschun R, Ullmann U. Klebsiella spp. as nosocomial pathogens: epidemiology, 
taxonomy, typing methods, and pathogenicity factors. Clin Microbiol Rev. 1998;11(4):589-603. 
PubMed PMID: 9767057; PMCID: PMC88898. 
24. Ah YM, Kim AJ, Lee JY. Colistin resistance in Klebsiella pneumoniae. Int J Antimicrob 
Agents. 2014;44(1):8-15. doi: 10.1016/j.ijantimicag.2014.02.016. PubMed PMID: 24794735. 
25. Towner KJ. Acinetobacter: an old friend, but a new enemy. J Hosp Infect. 
2009;73(4):355-63. doi: 10.1016/j.jhin.2009.03.032. PubMed PMID: 19700220. 
26. Antunes LC, Visca P, Towner KJ. Acinetobacter baumannii: evolution of a global 
pathogen. Pathog Dis. 2014;71(3):292-301. doi: 10.1111/2049-632X.12125. PubMed PMID: 
24376225. 
27. Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant 
Acinetobacter baumannii. Nat Rev Microbiol. 2007;5(12):939-51. doi: 10.1038/nrmicro1789. 
PubMed PMID: 18007677. 
28. Poirel L, Bonnin RA, Nordmann P. Genetic basis of antibiotic resistance in pathogenic 
Acinetobacter species. IUBMB Life. 2011;63(12):1061-7. doi: 10.1002/iub.532. PubMed PMID: 
21990280. 
29. Lederberg J. Encyclopedia of microbiology. 2nd ed. San Diego: Academic Press; 2000. 
30. Chatterjee M, Anju CP, Biswas L, Anil Kumar V, Gopi Mohan C, Biswas R. Antibiotic 
resistance in Pseudomonas aeruginosa and alternative therapeutic options. Int J Med Microbiol. 
2016;306(1):48-58. doi: 10.1016/j.ijmm.2015.11.004. PubMed PMID: 26687205. 
  95 
31. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas 
aeruginosa: our worst nightmare? Clin Infect Dis. 2002;34(5):634-40. doi: 10.1086/338782. 
PubMed PMID: 11823954. 
32. Keller R, Pedroso MZ, Ritchmann R, Silva RM. Occurrence of virulence-associated 
properties in Enterobacter cloacae. Infect Immun. 1998;66(2):645-9. PubMed PMID: 9453621; 
PMCID: PMC113501. 
33. Flynn DM, Weinstein RA, Nathan C, Gaston MA, Kabins SA. Patients' endogenous flora 
as the source of "nosocomial" Enterobacter in cardiac surgery. J Infect Dis. 1987;156(2):363-8. 
PubMed PMID: 3598234. 
34. Herold BC, Immergluck LC, Maranan MC, Lauderdale DS, Gaskin RE, Boyle-Vavra S, 
Leitch CD, Daum RS. Community-acquired methicillin-resistant Staphylococcus aureus in 
children with no identified predisposing risk. JAMA. 1998;279(8):593-8. PubMed PMID: 
9486753. 
35. Kuehnert MJ, Hill HA, Kupronis BA, Tokars JI, Solomon SL, Jernigan DB. Methicillin-
resistant-Staphylococcus aureus hospitalizations, United States. Emerg Infect Dis. 
2005;11(6):868-72. doi: 10.3201/eid1106.040831. PubMed PMID: 15963281; PMCID: 
PMC3367609. 
36. Webb GF, Horn MA, D'Agata EM, Moellering RC, Jr., Ruan S. Competition of hospital-
acquired and community-acquired methicillin-resistant Staphylococcus aureus strains in 
hospitals. J Biol Dyn. 2010;4(1):115-29. doi: 10.1080/17513750903026411. PubMed PMID: 
19587839; PMCID: PMC2706519. 
37. Giske CG, Monnet DL, Cars O, Carmeli Y, ReAct-Action on Antibiotic R. Clinical and 
economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents 
Chemother. 2008;52(3):813-21. doi: 10.1128/AAC.01169-07. PubMed PMID: 18070961; 
PMCID: PMC2258516. 
38. Spellberg B, Guidos R, Gilbert D, Bradley J, Boucher HW, Scheld WM, Bartlett JG, 
Edwards J, Jr., Infectious Diseases Society of A. The epidemic of antibiotic-resistant infections: 
a call to action for the medical community from the Infectious Diseases Society of America. Clin 
Infect Dis. 2008;46(2):155-64. doi: 10.1086/524891. PubMed PMID: 18171244. 
39. Sutton JP, Steiner CA. Hospital-, Health Care-, and Community-Acquired MRSA: 
Estimates From California Hospitals, 2013: Statistical Brief #212.  Healthcare Cost and 
Utilization Project (HCUP) Statistical Briefs. Rockville (MD)2006. 
40. Aminov R. History of antimicrobial drug discovery - Major classes and health impact. 
Biochem Pharmacol. 2016. doi: 10.1016/j.bcp.2016.10.001. PubMed PMID: 27720719. 
  96 
41. Livermore DM. Defining an extended-spectrum beta-lactamase. Clin Microbiol Infect. 
2008;14 Suppl 1:3-10. doi: 10.1111/j.1469-0691.2007.01857.x. PubMed PMID: 18154524. 
42. Nordmann P, Guibert M. Extended-spectrum beta-lactamases in Pseudomonas 
aeruginosa. J Antimicrob Chemother. 1998;42(2):128-31. PubMed PMID: 9738828. 
43. Tamber S, Hancock RE. On the mechanism of solute uptake in Pseudomonas. Front 
Biosci. 2003;8:s472-83. PubMed PMID: 12700103. 
44. Wozniak A, Villagra NA, Undabarrena A, Gallardo N, Keller N, Moraga M, Roman JC, 
Mora GC, Garcia P. Porin alterations present in non-carbapenemase-producing 
Enterobacteriaceae with high and intermediate levels of carbapenem resistance in Chile. J Med 
Microbiol. 2012;61(Pt 9):1270-9. doi: 10.1099/jmm.0.045799-0. PubMed PMID: 22700549. 
45. Lavigne JP, Sotto A, Nicolas-Chanoine MH, Bouziges N, Pages JM, Davin-Regli A. An 
adaptive response of Enterobacter aerogenes to imipenem: regulation of porin balance in 
clinical isolates. Int J Antimicrob Agents. 2013;41(2):130-6. doi: 
10.1016/j.ijantimicag.2012.10.010. PubMed PMID: 23280442. 
46. Tangden T, Adler M, Cars O, Sandegren L, Lowdin E. Frequent emergence of porin-
deficient subpopulations with reduced carbapenem susceptibility in ESBL-producing Escherichia 
coli during exposure to ertapenem in an in vitro pharmacokinetic model. J Antimicrob 
Chemother. 2013;68(6):1319-26. doi: 10.1093/jac/dkt044. PubMed PMID: 23478794. 
47. Meka VG, Gold HS. Antimicrobial resistance to linezolid. Clin Infect Dis. 
2004;39(7):1010-5. doi: 10.1086/423841. PubMed PMID: 15472854. 
48. Wolter N, Smith AM, Farrell DJ, Schaffner W, Moore M, Whitney CG, Jorgensen JH, 
Klugman KP. Novel mechanism of resistance to oxazolidinones, macrolides, and 
chloramphenicol in ribosomal protein L4 of the pneumococcus. Antimicrob Agents Chemother. 
2005;49(8):3554-7. doi: 10.1128/AAC.49.8.3554-3557.2005. PubMed PMID: 16048983; PMCID: 
PMC1196237. 
49. Hakenbeck R, Bruckner R, Denapaite D, Maurer P. Molecular mechanisms of beta-
lactam resistance in Streptococcus pneumoniae. Future Microbiol. 2012;7(3):395-410. doi: 
10.2217/fmb.12.2. PubMed PMID: 22393892. 
50. Katayama Y, Ito T, Hiramatsu K. A new class of genetic element, staphylococcus 
cassette chromosome mec, encodes methicillin resistance in Staphylococcus aureus. 
Antimicrob Agents Chemother. 2000;44(6):1549-55. PubMed PMID: 10817707; PMCID: 
PMC89911. 
  97 
51. Poirel L, Ros A, Carricajo A, Berthelot P, Pozzetto B, Bernabeu S, Nordmann P. 
Extremely drug-resistant Citrobacter freundii isolate producing NDM-1 and other 
carbapenemases identified in a patient returning from India. Antimicrob Agents Chemother. 
2011;55(1):447-8. doi: 10.1128/AAC.01305-10. PubMed PMID: 20974865; PMCID: 
PMC3019622. 
52. Dolejska M, Villa L, Poirel L, Nordmann P, Carattoli A. Complete sequencing of an 
IncHI1 plasmid encoding the carbapenemase NDM-1, the ArmA 16S RNA methylase and a 
resistance-nodulation-cell division/multidrug efflux pump. J Antimicrob Chemother. 
2013;68(1):34-9. doi: 10.1093/jac/dks357. PubMed PMID: 22969080. 
53. Long KS, Porse BT. A conserved chloramphenicol binding site at the entrance to the 
ribosomal peptide exit tunnel. Nucleic Acids Res. 2003;31(24):7208-15. PubMed PMID: 
14654696; PMCID: PMC291879. 
54. Shen J, Xia X, Jiang H, Li C, Li J, Li X, Ding S. Determination of chloramphenicol, 
thiamphenicol, florfenicol, and florfenicol amine in poultry and porcine muscle and liver by gas 
chromatography-negative chemical ionization mass spectrometry. J Chromatogr B Analyt 
Technol Biomed Life Sci. 2009;877(14-15):1523-9. doi: 10.1016/j.jchromb.2009.03.040. 
PubMed PMID: 19395324. 
55. Zhang WJ, Xu XR, Schwarz S, Wang XM, Dai L, Zheng HJ, Liu S. Characterization of 
the IncA/C plasmid pSCEC2 from Escherichia coli of swine origin that harbours the 
multiresistance gene cfr. J Antimicrob Chemother. 2014;69(2):385-9. doi: 10.1093/jac/dkt355. 
PubMed PMID: 24013193; PMCID: PMC3937595. 
56. Vetting MW, Hegde SS, Zhang Y, Blanchard JS. Pentapeptide-repeat proteins that act 
as topoisomerase poison resistance factors have a common dimer interface. Acta Crystallogr 
Sect F Struct Biol Cryst Commun. 2011;67(Pt 3):296-302. doi: 10.1107/S1744309110053315. 
PubMed PMID: 21393830; PMCID: PMC3053150. 
57. Llano-Sotelo B, Chow CS. RNA-aminoglycoside antibiotic interactions: fluorescence 
detection of binding and conformational change. Bioorg Med Chem Lett. 1999;9(2):213-6. 
PubMed PMID: 10021931. 
58. Nakamura A, Miyakozawa I, Nakazawa K, K OH, Sawai T. Detection and 
characterization of a macrolide 2'-phosphotransferase from a Pseudomonas aeruginosa clinical 
isolate. Antimicrob Agents Chemother. 2000;44(11):3241-2. PubMed PMID: 11184231; PMCID: 
PMC101646. 
59. Nakamura A, Naito Y, Nakazawa K, Ohara K, Sawai T. [Selective suppression of 
aminoglycoside 3'-phosphorylating enzyme activities by macrolides--a study by using macrolide-
resistant bacteria]. Jpn J Antibiot. 2000;53 Suppl A:28-31. PubMed PMID: 10756446. 
  98 
60. Nakamura A, Nakazawa K, Miyakozawa I, Mizukoshi S, Tsurubuchi K, Nakagawa M, 
O'Hara K, Sawai T. Macrolide esterase-producing Escherichia coli clinically isolated in Japan. J 
Antibiot (Tokyo). 2000;53(5):516-24. PubMed PMID: 10908116. 
61. Llaneza J, Villar CJ, Salas JA, Suarez JE, Mendoza MC, Hardisson C. Plasmid-
mediated fosfomycin resistance is due to enzymatic modification of the antibiotic. Antimicrob 
Agents Chemother. 1985;28(1):163-4. PubMed PMID: 3899003; PMCID: PMC176334. 
62. Flensburg J, Skold O. Massive overproduction of dihydrofolate reductase in bacteria as 
a response to the use of trimethoprim. Eur J Biochem. 1987;162(3):473-6. PubMed PMID: 
3549289. 
63. Yuan M, Hall LM, Hoogkamp-Korstanje J, Livermore DM. SHV-14, a novel beta-
lactamase variant in Klebsiella pneumoniae isolates from Nijmegen, The Netherlands. 
Antimicrob Agents Chemother. 2001;45(1):309-11. doi: 10.1128/AAC.45.1.309-311.2001. 
PubMed PMID: 11120985; PMCID: PMC90280. 
64. Blair JM, Webber MA, Baylay AJ, Ogbolu DO, Piddock LJ. Molecular mechanisms of 
antibiotic resistance. Nat Rev Microbiol. 2015;13(1):42-51. doi: 10.1038/nrmicro3380. PubMed 
PMID: 25435309. 
65. Buchanan RE. Studies in the Nomenclature and Classification of Bacteria: The Problem 
of Bacterial Nomenclature. J Bacteriol. 1916;1(6):591-6. PubMed PMID: 16558720; PMCID: 
PMC378679. 
66. Ludwig W, Euzéby J, Schumann P, Busse H-J, Trujillo ME, Kämpfer P, Whitman WB. 
Road map of the phylum Actinobacteria. In: Goodfellow M, Kämpfer P, Busse H-J, Trujillo ME, 
Suzuki K-i, Ludwig W, Whitman WB, editors. Bergey’s Manual® of Systematic Bacteriology: 
Volume Five The Actinobacteria, Part A and B. New York, NY: Springer New York; 2012. p. 1-
28. 
67. Adnani N, Vazquez-Rivera E, Adibhatla SN, Ellis GA, Braun DR, Bugni TS. Investigation 
of Interspecies Interactions within Marine Micromonosporaceae Using an Improved Co-Culture 
Approach. Mar Drugs. 2015;13(10):6082-98. doi: 10.3390/md13106082. PubMed PMID: 
26404321; PMCID: PMC4626680. 
68. Goodfellow M, Williams ST. Ecology of actinomycetes. Annu Rev Microbiol. 
1983;37:189-216. doi: 10.1146/annurev.mi.37.100183.001201. PubMed PMID: 6357051. 
69. Cross T, Goodfellow M. Taxonomy and classification of the actinomycetes. Soc Appl 
Bacteriol Symp Ser. 1973;2:11-112. PubMed PMID: 4584092. 
  99 
70. Flardh K. Essential role of DivIVA in polar growth and morphogenesis in Streptomyces 
coelicolor A3(2). Mol Microbiol. 2003;49(6):1523-36. PubMed PMID: 12950918. 
71. Flardh K. Growth polarity and cell division in Streptomyces. Curr Opin Microbiol. 
2003;6(6):564-71. PubMed PMID: 14662351. 
72. Flardh K, Buttner MJ. Streptomyces morphogenetics: dissecting differentiation in a 
filamentous bacterium. Nat Rev Microbiol. 2009;7(1):36-49. doi: 10.1038/nrmicro1968. PubMed 
PMID: 19079351. 
73. Sigle S, Ladwig N, Wohlleben W, Muth G. Synthesis of the spore envelope in the 
developmental life cycle of Streptomyces coelicolor. Int J Med Microbiol. 2015;305(2):183-9. doi: 
10.1016/j.ijmm.2014.12.014. PubMed PMID: 25595023. 
74. Raoult D, Ogata H, Audic S, Robert C, Suhre K, Drancourt M, Claverie JM. Tropheryma 
whipplei Twist: a human pathogenic Actinobacteria with a reduced genome. Genome Res. 
2003;13(8):1800-9. doi: 10.1101/gr.1474603. PubMed PMID: 12902375; PMCID: PMC403771. 
75. Baranasic D, Gacesa R, Starcevic A, Zucko J, Blazic M, Horvat M, Gjuracic K, Fujs S, 
Hranueli D, Kosec G, Cullum J, Petkovic H. Draft Genome Sequence of Streptomyces 
rapamycinicus Strain NRRL 5491, the Producer of the Immunosuppressant Rapamycin. 
Genome Announc. 2013;1(4). doi: 10.1128/genomeA.00581-13. PubMed PMID: 23929477; 
PMCID: PMC3738893. 
76. Berdy J. Thoughts and facts about antibiotics: Where we are now and where we are 
heading. J Antibiot (Tokyo). 2012;65(8):441. doi: 10.1038/ja.2012.54. PubMed PMID: 
22922479. 
77. Challis GL, Hopwood DA. Synergy and contingency as driving forces for the evolution of 
multiple secondary metabolite production by Streptomyces species. Proc Natl Acad Sci U S A. 
2003;100 Suppl 2:14555-61. doi: 10.1073/pnas.1934677100. PubMed PMID: 12970466; 
PMCID: PMC304118. 
78. Bentley SD, Chater KF, Cerdeno-Tarraga AM, Challis GL, Thomson NR, James KD, 
Harris DE, Quail MA, Kieser H, Harper D, Bateman A, Brown S, Chandra G, Chen CW, Collins 
M, Cronin A, Fraser A, Goble A, Hidalgo J, Hornsby T, Howarth S, Huang CH, Kieser T, Larke 
L, Murphy L, Oliver K, O'Neil S, Rabbinowitsch E, Rajandream MA, Rutherford K, Rutter S, 
Seeger K, Saunders D, Sharp S, Squares R, Squares S, Taylor K, Warren T, Wietzorrek A, 
Woodward J, Barrell BG, Parkhill J, Hopwood DA. Complete genome sequence of the model 
actinomycete Streptomyces coelicolor A3(2). Nature. 2002;417(6885):141-7. doi: 
10.1038/417141a. PubMed PMID: 12000953. 
  100 
79. Nett M, Ikeda H, Moore BS. Genomic basis for natural product biosynthetic diversity in 
the actinomycetes. Nat Prod Rep. 2009;26(11):1362-84. doi: 10.1039/b817069j. PubMed PMID: 
19844637; PMCID: PMC3063060. 
80. Challis GL. Exploitation of the Streptomyces coelicolor A3(2) genome sequence for 
discovery of new natural products and biosynthetic pathways. J Ind Microbiol Biotechnol. 
2014;41(2):219-32. doi: 10.1007/s10295-013-1383-2. PubMed PMID: 24322202. 
81. Abdelmohsen UR, Grkovic T, Balasubramanian S, Kamel MS, Quinn RJ, Hentschel U. 
Elicitation of secondary metabolism in actinomycetes. Biotechnol Adv. 2015;33(6 Pt 1):798-811. 
doi: 10.1016/j.biotechadv.2015.06.003. PubMed PMID: 26087412. 
82. Rigali S, Titgemeyer F, Barends S, Mulder S, Thomae AW, Hopwood DA, van Wezel 
GP. Feast or famine: the global regulator DasR links nutrient stress to antibiotic production by 
Streptomyces. EMBO Rep. 2008;9(7):670-5. doi: 10.1038/embor.2008.83. PubMed PMID: 
18511939; PMCID: PMC2475330. 
83. Chen G, Wang GY, Li X, Waters B, Davies J. Enhanced production of microbial 
metabolites in the presence of dimethyl sulfoxide. J Antibiot (Tokyo). 2000;53(10):1145-53. 
PubMed PMID: 11132960. 
84. Norn S, Permin H, Kruse PR, Kruse E. [From willow bark to acetylsalicylic acid]. Dan 
Medicinhist Arbog. 2009;37:79-98. PubMed PMID: 20509453. 
85. Gonzalez J. Medicinal plants in Colombia. J Ethnopharmacol. 1980;2(1):43-7. PubMed 
PMID: 7464182. 
86. Fleming A. On the antibacterial action of cultures of a penicillium, with special reference 
to their use in the isolation of B. influenzae. 1929. Bull World Health Organ. 2001;79(8):780-90. 
PubMed PMID: 11545337; PMCID: PMC2566493. 
87. Jones D, Metzger HJ, Schatz A, Waksman SA. Control of Gram-Negative Bacteria in 
Experimental Animals by Streptomycin. Science. 1944;100(2588):103-5. doi: 
10.1126/science.100.2588.103. PubMed PMID: 17788929. 
88. Waksman SA, Woodruff HB. The Soil as a Source of Microorganisms Antagonistic to 
Disease-Producing Bacteria. J Bacteriol. 1940;40(4):581-600. PubMed PMID: 16560371; 
PMCID: PMC374661. 
89. Waksman SA. Do Fungi Live and Produce Mycelium in the Soil? Science. 
1916;44(1131):320-2. doi: 10.1126/science.44.1131.320. PubMed PMID: 17840079. 
  101 
90. Butler MS. The role of natural product chemistry in drug discovery. J Nat Prod. 
2004;67(12):2141-53. doi: 10.1021/np040106y. PubMed PMID: 15620274. 
91. Berdy J. Bioactive microbial metabolites. J Antibiot (Tokyo). 2005;58(1):1-26. doi: 
10.1038/ja.2005.1. PubMed PMID: 15813176. 
92. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: New 
estimates of R&D costs. J Health Econ. 2016;47:20-33. doi: 10.1016/j.jhealeco.2016.01.012. 
PubMed PMID: 26928437. 
93. Bindseil KU, Jakupovic J, Wolf D, Lavayre J, Leboul J, van der Pyl D. Pure compound 
libraries; a new perspective for natural product based drug discovery. Drug Discov Today. 
2001;6(16):840-7. PubMed PMID: 11495757. 
94. Wilson DN. Ribosome-targeting antibiotics and mechanisms of bacterial resistance. Nat 
Rev Microbiol. 2014;12(1):35-48. doi: 10.1038/nrmicro3155. PubMed PMID: 24336183. 
95. Marinus MG. DNA methylation in Escherichia coli. Annu Rev Genet. 1987;21:113-31. 
doi: 10.1146/annurev.ge.21.120187.000553. PubMed PMID: 3327459. 
96. Heitman J, Model P. Site-specific methylases induce the SOS DNA repair response in 
Escherichia coli. J Bacteriol. 1987;169(7):3243-50. PubMed PMID: 3036779; PMCID: 
PMC212376. 
97. Cheng X. DNA modification by methyltransferases. Curr Opin Struct Biol. 1995;5(1):4-
10. PubMed PMID: 7773746. 
98. Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors 
azacytidine and decitabine. Int J Cancer. 2008;123(1):8-13. doi: 10.1002/ijc.23607. PubMed 
PMID: 18425818. 
99. Wang X, Sena Filho JG, Hoover AR, King JB, Ellis TK, Powell DR, Cichewicz RH. 
Chemical epigenetics alters the secondary metabolite composition of guttate excreted by an 
atlantic-forest-soil-derived Penicillium citreonigrum. J Nat Prod. 2010;73(5):942-8. doi: 
10.1021/np100142h. PubMed PMID: 20450206; PMCID: PMC2878378. 
100. Beau J, Mahid N, Burda WN, Harrington L, Shaw LN, Mutka T, Kyle DE, Barisic B, van 
Olphen A, Baker BJ. Epigenetic tailoring for the production of anti-infective cytosporones from 
the marine fungus Leucostoma persoonii. Mar Drugs. 2012;10(4):762-74. doi: 
10.3390/md10040762. PubMed PMID: 22690142; PMCID: PMC3366674. 
  102 
101. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects 
for epigenetic therapy. Nature. 2004;429(6990):457-63. doi: 10.1038/nature02625. PubMed 
PMID: 15164071. 
102. Suzuki MM, Bird A. DNA methylation landscapes: provocative insights from 
epigenomics. Nat Rev Genet. 2008;9(6):465-76. doi: 10.1038/nrg2341. PubMed PMID: 
18463664. 
103. VanderMolen KM, Darveaux BA, Chen WL, Swanson SM, Pearce CJ, Oberlies NH. 
Epigenetic Manipulation of a Filamentous Fungus by the Proteasome-Inhibitor Bortezomib 
Induces the Production of an Additional Secondary Metabolite. RSC Adv. 2014;4(35):18329-35. 
doi: 10.1039/C4RA00274A. PubMed PMID: 24955237; PMCID: PMC4061710. 
104. Yang XL, Huang L, Ruan XL. Epigenetic modifiers alter the secondary metabolite 
composition of a plant endophytic fungus, Pestalotiopsis crassiuscula obtained from the leaves 
of Fragaria chiloensis. J Asian Nat Prod Res. 2014;16(4):412-7. doi: 
10.1080/10286020.2014.881356. PubMed PMID: 24498889. 
105. Zutz C, Bandian D, Neumayer B, Speringer F, Gorfer M, Wagner M, Strauss J, Rychli K. 
Fungi treated with small chemicals exhibit increased antimicrobial activity against facultative 
bacterial and yeast pathogens. Biomed Res Int. 2014;2014:540292. doi: 10.1155/2014/540292. 
PubMed PMID: 25121102; PMCID: PMC4119895. 
106. Henrikson JC, Hoover AR, Joyner PM, Cichewicz RH. A chemical epigenetics approach 
for engineering the in situ biosynthesis of a cryptic natural product from Aspergillus niger. Org 
Biomol Chem. 2009;7(3):435-8. doi: 10.1039/b819208a. PubMed PMID: 19156306. 
107. Moore JM, Bradshaw E, Seipke RF, Hutchings MI, McArthur M. Use and discovery of 
chemical elicitors that stimulate biosynthetic gene clusters in Streptomyces bacteria. Methods 
Enzymol. 2012;517:367-85. doi: 10.1016/B978-0-12-404634-4.00018-8. PubMed PMID: 
23084948. 
108. Kumar J, Sharma VK, Singh DK, Mishra A, Gond SK, Verma SK, Kumar A, Kharwar RN. 
Epigenetic Activation of Antibacterial Property of an Endophytic Streptomyces coelicolor Strain 
AZRA 37 and Identification of the Induced Protein Using MALDI TOF MS/MS. PLoS One. 
2016;11(2):e0147876. doi: 10.1371/journal.pone.0147876. PubMed PMID: 26844762; PMCID: 
PMC4742224. 
109. Wang B, Waters AL, Sims JW, Fullmer A, Ellison S, Hamann MT. Complex marine 
natural products as potential epigenetic and production regulators of antibiotics from a marine 
Pseudomonas aeruginosa. Microb Ecol. 2013;65(4):1068-75. doi: 10.1007/s00248-013-0213-4. 
PubMed PMID: 23563743; PMCID: PMC3650628. 
  103 
110. Tan C, Tasaka H, Yu KP, Murphy ML, Karnofsky DA. Daunomycin, an antitumor 
antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to 
childhood leukemia. Cancer. 1967;20(3):333-53. PubMed PMID: 4290058. 
111. Weiss RB, Bruno S. Daunorubicin treatment of adult solid tumors. Cancer Treat Rep. 
1981;65 Suppl 4:25-8. PubMed PMID: 7049378. 
112. Di Marco A, Silvestrini R, Di Marco S, Dasdia T. Inhibiting effect of the new cytotoxic 
antibiotic daunomycin on nucleic acids and mitotic activity of HeLa cells. J Cell Biol. 
1965;27(3):545-50. PubMed PMID: 5885429; PMCID: PMC2106764. 
113. Weiss RB, Sarosy G, Clagett-Carr K, Russo M, Leyland-Jones B. Anthracycline analogs: 
the past, present, and future. Cancer Chemother Pharmacol. 1986;18(3):185-97. PubMed 
PMID: 2948729. 
114. Pommier Y, Leo E, Zhang H, Marchand C. DNA topoisomerases and their poisoning by 
anticancer and antibacterial drugs. Chem Biol. 2010;17(5):421-33. doi: 
10.1016/j.chembiol.2010.04.012. PubMed PMID: 20534341. 
115. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular 
advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol 
Rev. 2004;56(2):185-229. doi: 10.1124/pr.56.2.6. PubMed PMID: 15169927. 
116. Westman EL, Canova MJ, Radhi IJ, Koteva K, Kireeva I, Waglechner N, Wright GD. 
Bacterial inactivation of the anticancer drug doxorubicin. Chem Biol. 2012;19(10):1255-64. doi: 
10.1016/j.chembiol.2012.08.011. PubMed PMID: 23102220. 
117. Kaur P. Expression and characterization of DrrA and DrrB proteins of Streptomyces 
peucetius in Escherichia coli: DrrA is an ATP binding protein. J Bacteriol. 1997;179(3):569-75. 
PubMed PMID: 9006006; PMCID: PMC178733. 
118. El-Nakeeb MA, Lechevalier HA. Selective isolation of aerobic Actinomycetes. Appl 
Microbiol. 1963;11:75-7. PubMed PMID: 13937509; PMCID: PMC1057945. 
119. Kuester E, Williams ST. Selection of Media for Isolation of Streptomycetes. Nature. 
1964;202:928-9. PubMed PMID: 14190108. 
120. Pridham TG, Anderson P, Foley C, Lindenfelser LA, Hesseltine CW, Benedict RG. A 
selection of media for maintenance and taxonomic study of Streptomyces. Antibiot Annu. 
1956:947-53. PubMed PMID: 13425486. 
  104 
121. Jensen PR, Gontang E, Mafnas C, Mincer TJ, Fenical W. Culturable marine 
actinomycete diversity from tropical Pacific Ocean sediments. Environ Microbiol. 
2005;7(7):1039-48. doi: 10.1111/j.1462-2920.2005.00785.x. PubMed PMID: 15946301. 
122. Nadkarni MA, Martin FE, Jacques NA, Hunter N. Determination of bacterial load by real-
time PCR using a broad-range (universal) probe and primers set. Microbiology. 2002;148(Pt 
1):257-66. doi: 10.1099/00221287-148-1-257. PubMed PMID: 11782518. 
123. Claus H, Decker H. Bacterial tyrosinases. Syst Appl Microbiol. 2006;29(1):3-14. doi: 
10.1016/j.syapm.2005.07.012. PubMed PMID: 16423650. 
124. Plonka PM, Grabacka M. Melanin synthesis in microorganisms--biotechnological and 
medical aspects. Acta Biochim Pol. 2006;53(3):429-43. PubMed PMID: 16951740. 
125. Linos A, Berekaa MM, Reichelt R, Keller U, Schmitt J, Flemming HC, Kroppenstedt RM, 
Steinbuchel A. Biodegradation of cis-1,4-polyisoprene rubbers by distinct actinomycetes: 
microbial strategies and detailed surface analysis. Appl Environ Microbiol. 2000;66(4):1639-45. 
PubMed PMID: 10742254; PMCID: PMC92035. 
126. Linos A, Steinbuchel A, Sproer C, Kroppenstedt RM. Gordonia polyisoprenivorans sp. 
nov., a rubber-degrading actinomycete isolated from an automobile tyre. Int J Syst Bacteriol. 
1999;49 Pt 4:1785-91. doi: 10.1099/00207713-49-4-1785. PubMed PMID: 10555361. 
127. Arenskotter M, Broker D, Steinbuchel A. Biology of the metabolically diverse genus 
Gordonia. Appl Environ Microbiol. 2004;70(6):3195-204. doi: 10.1128/AEM.70.6.3195-
3204.2004. PubMed PMID: 15184112; PMCID: PMC427784. 
128. Feng H, Sun Y, Zhi Y, Mao L, Luo Y, Wei X, Zhou P. Lignocellulose degradation by the 
isolate of Streptomyces griseorubens JSD-1. Funct Integr Genomics. 2015;15(2):163-73. doi: 
10.1007/s10142-014-0425-9. PubMed PMID: 25452226. 
129. Waksman SA, Lechevalier HA. Neomycin, a New Antibiotic Active against Streptomycin-
Resistant Bacteria, including Tuberculosis Organisms. Science. 1949;109(2830):305-7. doi: 
10.1126/science.109.2830.305. PubMed PMID: 17782716. 
130. Drautz H, Zahner H, Rohr J, Zeeck A. Metabolic products of microorganisms. 234. 
Urdamycins, new angucycline antibiotics from Streptomyces fradiae. I. Isolation, 
characterization and biological properties. J Antibiot (Tokyo). 1986;39(12):1657-69. PubMed 
PMID: 3818439. 
131. Stark WM, Daily WA, Mc GJ. A fermentation study of the biosynthesis of tylosin in 
synthetic media. Sci Rep Ist Super Sanita. 1961;1:340-54. PubMed PMID: 13916323. 
  105 
132. Domingue G, Costerton JW, Brown MR. Bacterial doubling time modulates the effects of 
opsonisation and available iron upon interactions between Staphylococcus aureus and human 
neutrophils. FEMS Immunol Med Microbiol. 1996;16(3-4):223-8. PubMed PMID: 9116639. 
133. Cortes J, Liras P, Castro JM, Martin JF. Glucose regulation of cephamycin biosynthesis 
in Streptomyces lactamdurans is exerted on the formation of alpha-aminoadipyl-cysteinyl-valine 
and deacetoxycephalosporin C synthase. J Gen Microbiol. 1986;132(7):1805-14. doi: 
10.1099/00221287-132-7-1805. PubMed PMID: 3794640. 
134. Chi WJ, Lee SY, Lee J. Functional analysis of SGR4635-induced enhancement of 
pigmented antibiotic production in Streptomyces lividans. J Microbiol. 2011;49(5):828-33. doi: 
10.1007/s12275-011-1100-7. PubMed PMID: 22068502. 
135. Barona-Gomez F, Lautru S, Francou FX, Leblond P, Pernodet JL, Challis GL. Multiple 
biosynthetic and uptake systems mediate siderophore-dependent iron acquisition in 
Streptomyces coelicolor A3(2) and Streptomyces ambofaciens ATCC 23877. Microbiology. 
2006;152(Pt 11):3355-66. doi: 10.1099/mic.0.29161-0. PubMed PMID: 17074905. 
136. Funa N, Funabashi M, Ohnishi Y, Horinouchi S. Biosynthesis of 
hexahydroxyperylenequinone melanin via oxidative aryl coupling by cytochrome P-450 in 
Streptomyces griseus. J Bacteriol. 2005;187(23):8149-55. doi: 10.1128/JB.187.23.8149-
8155.2005. PubMed PMID: 16291687; PMCID: PMC1291289. 
137. Schnellmann J, Zeltins A, Blaak H, Schrempf H. The novel lectin-like protein CHB1 is 
encoded by a chitin-inducible Streptomyces olivaceoviridis gene and binds specifically to 
crystalline alpha-chitin of fungi and other organisms. Mol Microbiol. 1994;13(5):807-19. PubMed 
PMID: 7815940. 
138. Sen A, Daubin V, Abrouk D, Gifford I, Berry AM, Normand P. Phylogeny of the class 
Actinobacteria revisited in the light of complete genomes. The orders 'Frankiales' and 
Micrococcales should be split into coherent entities: proposal of Frankiales ord. nov., 
Geodermatophilales ord. nov., Acidothermales ord. nov. and Nakamurellales ord. nov. Int J Syst 
Evol Microbiol. 2014;64(Pt 11):3821-32. doi: 10.1099/ijs.0.063966-0. PubMed PMID: 25168610. 
139. Wu D, Hugenholtz P, Mavromatis K, Pukall R, Dalin E, Ivanova NN, Kunin V, Goodwin L, 
Wu M, Tindall BJ, Hooper SD, Pati A, Lykidis A, Spring S, Anderson IJ, D'Haeseleer P, Zemla 
A, Singer M, Lapidus A, Nolan M, Copeland A, Han C, Chen F, Cheng JF, Lucas S, Kerfeld C, 
Lang E, Gronow S, Chain P, Bruce D, Rubin EM, Kyrpides NC, Klenk HP, Eisen JA. A 
phylogeny-driven genomic encyclopaedia of Bacteria and Archaea. Nature. 
2009;462(7276):1056-60. doi: 10.1038/nature08656. PubMed PMID: 20033048; PMCID: 
PMC3073058. 
140. Coico R. Gram staining. Curr Protoc Microbiol. 2005;Appendix 3:Appendix 3C. doi: 
10.1002/9780471729259.mca03cs00. PubMed PMID: 18770544. 
  106 
141. Beveridge TJ. Mechanism of gram variability in select bacteria. J Bacteriol. 
1990;172(3):1609-20. PubMed PMID: 1689718; PMCID: PMC208639. 
142. Tsukamura M, Mizuno S, Tsukamura S. Numerical classification of slowly growing 
mycobacteria. Am Rev Respir Dis. 1969;99(2):299-303. doi: 10.1164/arrd.1969.99.2.299. 
PubMed PMID: 4975013. 
143. Woese CR, Fox GE. Phylogenetic structure of the prokaryotic domain: the primary 
kingdoms. Proc Natl Acad Sci U S A. 1977;74(11):5088-90. PubMed PMID: 270744; PMCID: 
PMC432104. 
144. Yap WH, Zhang Z, Wang Y. Distinct types of rRNA operons exist in the genome of the 
actinomycete Thermomonospora chromogena and evidence for horizontal transfer of an entire 
rRNA operon. J Bacteriol. 1999;181(17):5201-9. PubMed PMID: 10464188; PMCID: 
PMC94023. 
145. Roesch LF, Fulthorpe RR, Riva A, Casella G, Hadwin AK, Kent AD, Daroub SH, 
Camargo FA, Farmerie WG, Triplett EW. Pyrosequencing enumerates and contrasts soil 
microbial diversity. ISME J. 2007;1(4):283-90. doi: 10.1038/ismej.2007.53. PubMed PMID: 
18043639; PMCID: PMC2970868. 
146. Torsvik V, Goksoyr J, Daae FL. High diversity in DNA of soil bacteria. Appl Environ 
Microbiol. 1990;56(3):782-7. PubMed PMID: 2317046; PMCID: PMC183421. 
147. Maldonado LA, Fragoso-Yanez D, Perez-Garcia A, Rosellon-Druker J, Quintana ET. 
Actinobacterial diversity from marine sediments collected in Mexico. Antonie Van Leeuwenhoek. 
2009;95(2):111-20. doi: 10.1007/s10482-008-9294-3. PubMed PMID: 19023674. 
148. Ikeda H. Natural products discovery from micro-organisms in the post-genome era. 
Biosci Biotechnol Biochem. 2017;81(1):13-22. doi: 10.1080/09168451.2016.1248366. PubMed 
PMID: 27885932. 
149. Gerea AL, Branscum KM, King JB, You J, Powell DR, Miller AN, Spear JR, Cichewicz 
RH. Secondary metabolites produced by fungi derived from a microbial mat encountered in an 
iron-rich natural spring. Tetrahedron Lett. 2012;53(32):4202-5. doi: 10.1016/j.tetlet.2012.05.156. 
PubMed PMID: 22844162; PMCID: PMC3404852. 
150. Schmidt EW, Donia MS, McIntosh JA, Fricke WF, Ravel J. Origin and variation of 
tunicate secondary metabolites. J Nat Prod. 2012;75(2):295-304. doi: 10.1021/np200665k. 
PubMed PMID: 22233390; PMCID: PMC3288725. 
  107 
151. Piel J. Biosynthesis of polyketides by trans-AT polyketide synthases. Nat Prod Rep. 
2010;27(7):996-1047. doi: 10.1039/b816430b. PubMed PMID: 20464003. 
152. Sarkar A, Funk AN, Scherlach K, Horn F, Schroeckh V, Chankhamjon P, Westermann 
M, Roth M, Brakhage AA, Hertweck C, Horn U. Differential expression of silent polyketide 
biosynthesis gene clusters in chemostat cultures of Aspergillus nidulans. J Biotechnol. 
2012;160(1-2):64-71. doi: 10.1016/j.jbiotec.2012.01.015. PubMed PMID: 22306112. 
153. Nichols D, Cahoon N, Trakhtenberg EM, Pham L, Mehta A, Belanger A, Kanigan T, 
Lewis K, Epstein SS. Use of ichip for high-throughput in situ cultivation of "uncultivable" 
microbial species. Appl Environ Microbiol. 2010;76(8):2445-50. doi: 10.1128/AEM.01754-09. 
PubMed PMID: 20173072; PMCID: PMC2849220. 
154. Ling LL, Schneider T, Peoples AJ, Spoering AL, Engels I, Conlon BP, Mueller A, 
Schaberle TF, Hughes DE, Epstein S, Jones M, Lazarides L, Steadman VA, Cohen DR, Felix 
CR, Fetterman KA, Millett WP, Nitti AG, Zullo AM, Chen C, Lewis K. A new antibiotic kills 
pathogens without detectable resistance. Nature. 2015;517(7535):455-9. doi: 
10.1038/nature14098. PubMed PMID: 25561178. 
155. Hou Y, Tianero MD, Kwan JC, Wyche TP, Michel CR, Ellis GA, Vazquez-Rivera E, 
Braun DR, Rose WE, Schmidt EW, Bugni TS. Structure and biosynthesis of the antibiotic 
bottromycin D. Org Lett. 2012;14(19):5050-3. doi: 10.1021/ol3022758. PubMed PMID: 
22984777; PMCID: PMC3466018. 
156. Dai Z, Zhang X, Tang C, Muhammad N, Wu J, Brookes PC, Xu J. Potential role of 
biochars in decreasing soil acidification - A critical review. Sci Total Environ. 2017;581-582:601-
11. doi: 10.1016/j.scitotenv.2016.12.169. PubMed PMID: 28063658. 
157. Weaver RW, Soil Science Society of America. Methods of soil analysis. Part 2, 
Microbiological and biochemical properties. Madison, Wis., USA: Soil Science Society of 
America; 1994. xxvii, 1121 p. p. 
158. Silver LL. Challenges of antibacterial discovery. Clin Microbiol Rev. 2011;24(1):71-109. 
doi: 10.1128/CMR.00030-10. PubMed PMID: 21233508; PMCID: PMC3021209. 
159. Kieser T, Hopwood DA. Genetic manipulation of Streptomyces: integrating vectors and 
gene replacement. Methods Enzymol. 1991;204:430-58. PubMed PMID: 1943784. 
160. Konig CC, Scherlach K, Schroeckh V, Horn F, Nietzsche S, Brakhage AA, Hertweck C. 
Bacterium induces cryptic meroterpenoid pathway in the pathogenic fungus Aspergillus 
fumigatus. Chembiochem. 2013;14(8):938-42. doi: 10.1002/cbic.201300070. PubMed PMID: 
23649940. 
  108 
161. Fernandez M, Soliveri J, Novella IS, Yebra MJ, Barbes C, Sanchez J. Effect of 5-
azacytidine and sinefungin on Streptomyces development. Gene. 1995;157(1-2):221-3. PubMed 
PMID: 7541762. 
162. Novella IS, Sanchez J. Effects of 5-azacytidine on physiological differentiation of 
Streptomyces antibioticus. Res Microbiol. 1995;146(9):721-8. PubMed PMID: 8584794. 
 
10
9 
A
pp
en
di
x 
Ta
bl
e 
A
 - 
1.
 Id
en
tif
ie
d 
Is
ol
at
es
 in
 A
ct
in
ob
ac
te
ria
 S
tr
ai
n 
C
ol
le
ct
io
n 
St
ra
in
 C
ol
le
ct
io
n 
ID
 
G
en
us
 
Sp
ec
ie
s 
M
ed
ia
 
M
et
ho
d 
Sa
m
pl
e 
1 
R
ho
do
co
cc
us
 
R
ho
do
ch
ro
us
 
S
C
A
 
M
et
ho
d 
3 
S
oi
l 2
 
5 
R
ho
do
co
cc
us
 
R
ho
do
ch
ro
us
 
S
C
A
 
M
et
ho
d 
1 
S
oi
l 2
 
6 
S
tre
pt
om
yc
es
 
V
io
la
ru
s 
S
C
A
 
M
et
ho
d 
3 
S
oi
l 1
 
8 
S
tre
pt
om
yc
es
 
B
ei
jia
ng
en
si
s 
A
G
S
 
M
et
ho
d 
1 
S
oi
l 2
 
10
 
S
tre
pt
om
yc
es
 
C
oe
lic
of
la
vu
s 
S
C
A
 
M
et
ho
d 
1 
S
oi
l 2
 
11
 
G
or
do
ni
a 
N
am
ib
ie
ns
is
 
S
C
A
 
M
et
ho
d 
1 
S
oi
l 2
 
12
 
R
ho
do
co
cc
us
 
R
ho
do
ch
ro
us
 
S
C
A
 
M
et
ho
d 
1 
S
oi
l 2
 
13
 
N
oc
ar
di
a 
V
er
m
ic
ul
at
a 
S
C
A
 
M
et
ho
d 
1 
S
oi
l 2
 
14
 
S
tre
pt
om
yc
es
 
P
la
te
ns
is
 
S
C
A
 
M
et
ho
d 
1 
S
oi
l 1
 
15
 
S
tre
pt
om
yc
es
 
V
io
la
ru
s 
S
C
A
 
M
et
ho
d 
1 
S
oi
l 1
 
16
 
S
tre
pt
om
yc
es
 
A
lb
ifl
av
es
ce
ns
 
S
C
A
 
M
et
ho
d 
1 
S
oi
l 2
 
17
 
S
tre
pt
om
yc
es
 
C
or
ch
or
us
ii 
S
C
A
 
M
et
ho
d 
1 
S
oi
l 2
 
18
 
A
rth
ro
ba
ct
er
 
P
ro
to
ph
or
m
ia
e 
S
Y
E
 
M
et
ho
d 
1 
S
oi
l 2
 
19
 
G
or
do
ni
a 
N
am
ib
ie
ns
is
 
S
C
A
 
M
et
ho
d 
3 
S
oi
l 1
 
20
 
A
er
om
ic
ro
bi
um
 
Ta
m
le
ns
e 
S
C
A
 
M
et
ho
d 
2 
S
oi
l 2
 
21
 
R
ho
do
co
cc
us
 
P
he
no
lic
us
 
S
C
A
 
M
et
ho
d 
2 
S
oi
l 2
 
22
 
G
or
do
ni
a 
Te
rr
ae
 
S
C
A
 
M
et
ho
d 
3 
S
oi
l 1
 
25
 
R
ho
do
co
cc
us
 
R
ho
do
ch
ro
us
 
S
C
A
 
M
et
ho
d 
2 
S
oi
l 2
 
26
 
S
tre
pt
om
yc
es
 
C
hr
om
of
us
cu
s 
S
C
A
 
M
et
ho
d 
1 
S
oi
l 2
 
27
 
S
tre
pt
om
yc
es
 
A
cr
im
yc
in
i 
S
C
A
 
M
et
ho
d 
1 
S
oi
l 2
 
29
 
M
yc
ob
ac
te
riu
m
 
P
ar
af
or
tu
itu
m
 
S
C
A
 
M
et
ho
d 
3 
S
oi
l 2
 
30
 
S
tre
pt
om
yc
es
 
M
ac
ro
sp
or
eu
s 
S
C
A
 
M
et
ho
d 
3 
S
oi
l 2
 
 
11
0 
  
 
31
 
S
tre
pt
om
yc
es
 
A
nt
ib
io
tic
us
 
S
Y
E
 
M
et
ho
d 
3 
S
oi
l 1
 
32
 
S
tre
pt
om
yc
es
 
G
ar
dn
er
i 
S
C
A
 
M
et
ho
d 
3 
S
oi
l 1
 
33
 
S
tre
pt
om
yc
es
 
Tu
m
es
ce
ns
 
A
G
S
 
M
et
ho
d 
1 
S
oi
l 1
 
34
 
N
oc
ar
di
a 
A
st
er
oi
de
s 
A
G
S
 
M
et
ho
d 
1 
S
oi
l 1
 
35
 
S
tre
pt
om
yc
es
 
M
in
oe
ns
is
 
S
Y
E
 
M
et
ho
d 
1 
S
oi
l 1
 
36
 
S
tre
pt
om
yc
es
 
au
ra
nt
io
gr
is
eu
s 
S
Y
E
 
M
et
ho
d 
1 
S
oi
l 2
 
37
 
S
tre
pt
om
yc
es
 
M
at
en
si
s 
S
C
A
 
M
et
ho
d 
3 
S
oi
l 2
 
39
 
S
tre
pt
om
yc
es
 
gr
is
eo
ru
be
ns
 
S
C
A
 
M
et
ho
d 
1 
S
oi
l 2
 
40
 
S
tre
pt
om
yc
es
 
Fr
ad
ia
e 
S
C
A
 
M
et
ho
d 
1 
S
oi
l 2
 
41
 
S
tre
pt
om
yc
es
 
V
io
la
sc
en
s 
S
Y
E
 
M
et
ho
d 
3 
S
oi
l 2
 
42
 
S
tre
pt
om
yc
es
 
za
om
yc
et
ic
us
 
A
G
S
 
M
et
ho
d 
3 
S
oi
l 2
 
43
 
S
tre
pt
om
yc
es
 
vi
rid
oc
hr
om
og
en
es
 
S
C
A
 
M
et
ho
d 
3 
S
oi
l 2
 
44
 
S
tre
pt
om
yc
es
 
be
iji
an
ge
ns
is
 
A
G
S
 
M
et
ho
d 
1 
S
oi
l 2
 
45
 
S
tre
pt
om
yc
es
 
in
te
rm
ed
iu
s 
S
Y
E
 
M
et
ho
d 
1 
S
oi
l 2
 
46
 
S
tre
pt
om
yc
es
 
in
te
rm
ed
iu
s 
S
Y
E
 
M
et
ho
d 
1 
S
oi
l 2
 
47
 
S
tre
pt
om
yc
es
 
al
bi
do
fla
vu
s 
S
Y
E
 
M
et
ho
d 
1 
S
oi
l 2
 
48
 
S
tre
pt
om
yc
es
 
M
at
en
si
s 
S
C
A
 
M
et
ho
d 
3 
S
oi
l 2
 
49
 
S
tre
pt
om
yc
es
 
gr
is
eo
pl
an
us
 
S
Y
E
 
M
et
ho
d 
3 
S
oi
l 2
 
50
 
S
tre
pt
om
yc
es
 
dr
oz
do
w
ic
zi
i 
S
Y
E
 
M
et
ho
d 
1 
S
oi
l 2
 
51
 
S
tre
pt
om
yc
es
 
dr
oz
do
w
ic
zi
i 
A
G
S
 
M
et
ho
d 
1 
S
oi
l 2
 
52
 
S
tre
pt
om
yc
es
 
co
el
ic
of
la
vu
s 
A
G
S
 
M
et
ho
d 
2 
S
oi
l 2
 
54
 
S
tre
pt
om
yc
es
 
in
te
rm
ed
iu
s 
S
Y
E
 
M
et
ho
d 
2 
S
oi
l 2
 
56
 
S
tre
pt
om
yc
es
 
in
te
rm
ed
iu
s 
S
C
A
 
M
et
ho
d 
1 
S
oi
l 2
 
57
 
S
tre
pt
om
yc
es
 
S
am
ps
on
ii 
S
C
A
 
M
et
ho
d 
1 
S
oi
l 2
 
58
 
N
oc
ar
di
a 
A
st
er
oi
de
s 
A
G
S
 
M
et
ho
d 
1 
S
oi
l 1
 
59
 
N
oc
ar
di
a 
A
st
er
oi
de
s 
S
Y
E
 
M
et
ho
d 
1 
S
oi
l 1
 
60
 
S
tre
pt
om
yc
es
 
G
le
bo
su
s 
A
G
S
 
M
et
ho
d 
1 
S
oi
l 1
 
Ta
bl
e 
A
 - 
1.
 (C
on
tin
ue
d)
 
 
11
1 
  
 
61
 
S
tre
pt
om
yc
es
 
ha
w
ai
ie
ns
is
 
S
Y
E
 
M
et
ho
d 
1 
S
oi
l 1
 
62
 
S
tre
pt
om
yc
es
 
V
ar
ia
bi
lis
 
S
C
A
 
M
et
ho
d 
1 
S
oi
l 1
 
63
 
S
tre
pt
om
yc
es
 
dr
oz
do
w
ic
zi
i 
A
G
S
 
M
et
ho
d 
1 
S
oi
l 2
 
64
 
S
tre
pt
om
yc
es
 
dr
oz
do
w
ic
zi
i 
A
G
S
 
M
et
ho
d 
1 
S
oi
l 2
 
65
 
S
tre
pt
om
yc
es
 
dr
oz
do
w
ic
zi
i 
A
G
S
 
M
et
ho
d 
1 
S
oi
l 2
 
66
 
S
tre
pt
om
yc
es
 
gr
is
eo
au
ra
nt
ia
cu
s 
A
G
S
 
M
et
ho
d 
1 
S
oi
l 2
 
67
 
S
tre
pt
om
yc
es
 
in
te
rm
ed
iu
s 
A
G
S
 
M
et
ho
d 
1 
S
oi
l 2
 
68
 
S
tre
pt
om
yc
es
 
th
er
m
oc
ar
bo
xy
du
s 
A
G
S
 
M
et
ho
d 
1 
S
oi
l 2
 
69
 
S
tre
pt
om
yc
es
 
vi
rid
ob
ru
nn
eu
s 
A
G
S
 
M
et
ho
d 
1 
S
oi
l 2
 
70
 
S
tre
pt
om
yc
es
 
in
te
rm
ed
iu
s 
A
G
S
 
M
et
ho
d 
1 
S
oi
l 2
 
71
 
B
re
vi
ba
ct
er
iu
m
 
ep
id
er
m
id
is
 
A
G
S
 
M
et
ho
d 
1 
S
oi
l 2
 
72
 
S
tre
pt
om
yc
es
 
in
te
rm
ed
iu
s 
A
G
S
 
M
et
ho
d 
1 
S
oi
l 2
 
73
 
M
ic
ro
ba
ct
er
iu
m
 
gi
ns
en
gi
te
rr
ae
 
A
G
S
 
M
et
ho
d 
1 
S
oi
l 2
 
74
 
S
tre
pt
om
yc
es
 
co
el
ic
of
la
vu
s 
S
C
A
 
M
et
ho
d 
1 
S
oi
l 2
 
75
 
S
tre
pt
om
yc
es
 
G
ar
dn
er
i 
A
G
S
 
M
et
ho
d 
3 
S
oi
l 1
 
76
 
S
tre
pt
om
yc
es
 
in
te
rm
ed
iu
s 
S
C
A
 
M
et
ho
d 
4 
S
oi
l 2
 
77
 
S
tre
pt
om
yc
es
 
m
al
ac
hi
to
sp
in
us
 
A
G
S
 
M
et
ho
d 
4 
S
oi
l 1
 
78
 
S
tre
pt
om
yc
es
 
in
te
rm
ed
iu
s 
S
C
A
 
M
et
ho
d 
4 
S
oi
l 2
 
79
 
S
tre
pt
om
yc
es
 
au
ra
nt
ia
cu
s 
S
C
A
 
M
et
ho
d 
4 
S
oi
l 2
 
80
 
S
tre
pt
om
yc
es
 
m
al
ac
hi
to
sp
in
us
 
A
G
S
 
M
et
ho
d 
4 
S
oi
l 1
 
81
 
S
tre
pt
om
yc
es
 
Te
nd
ae
 
S
Y
E
 
M
et
ho
d 
1 
S
oi
l 2
 
82
 
S
tre
pt
om
yc
es
 
dr
oz
do
w
ic
zi
i 
S
Y
E
 
M
et
ho
d 
1 
S
oi
l 2
 
84
 
S
tre
pt
om
yc
es
 
Te
nd
ae
 
S
Y
E
 
M
et
ho
d 
1 
S
oi
l 2
 
85
 
S
tre
pt
om
yc
es
 
Te
nd
ae
 
S
Y
E
 
M
et
ho
d 
1 
S
oi
l 2
 
86
 
S
tre
pt
om
yc
es
 
G
ar
dn
er
i 
A
G
S
 
M
et
ho
d 
3 
S
oi
l 1
 
87
 
S
tre
pt
om
yc
es
 
P
ra
ec
ox
 
S
Y
E
 
M
et
ho
d 
3 
S
oi
l 2
 
88
 
S
tre
pt
om
yc
es
 
tu
rg
id
is
ca
bi
es
 
A
G
S
 
M
et
ho
d 
3 
S
oi
l 1
 
Ta
bl
e 
A
 - 
1.
 (C
on
tin
ue
d)
 
 
11
2 
  
 
89
 
S
tre
pt
om
yc
es
 
dr
oz
do
w
ic
zi
i 
A
G
S
 
M
et
ho
d 
3 
S
oi
l 2
 
90
 
S
tre
pt
om
yc
es
 
dr
oz
do
w
ic
zi
i 
A
G
S
 
M
et
ho
d 
3 
S
oi
l 2
 
91
 
S
tre
pt
om
yc
es
 
za
om
yc
et
ic
us
 
A
G
S
 
M
et
ho
d 
3 
S
oi
l 2
 
92
 
G
or
do
ni
a 
na
m
ib
ie
ns
is
 
S
C
A
 
M
et
ho
d 
3 
S
oi
l 1
 
93
 
R
ho
do
co
cc
us
 
O
pa
cu
s 
S
C
A
 
M
et
ho
d 
3 
S
oi
l 1
 
94
 
S
tre
pt
om
yc
es
 
gl
eb
os
us
 
S
Y
E
 
M
et
ho
d 
3 
S
oi
l 1
 
95
 
M
ic
ro
co
cc
us
 
yu
nn
an
en
si
s 
S
C
A
 
M
et
ho
d 
1 
S
oi
l 2
 
96
 
S
tre
pt
om
yc
es
 
gr
is
eo
ru
be
ns
 
S
C
A
 
M
et
ho
d 
1 
S
oi
l 2
 
97
 
S
tre
pt
om
yc
es
 
Li
vi
da
ns
 
S
C
A
 
M
et
ho
d 
1 
S
oi
l 2
 
98
 
N
oc
ar
di
a 
ca
ve
rn
a 
S
C
A
 
M
et
ho
d 
1 
S
oi
l 2
 
99
 
S
tre
pt
om
yc
es
 
vi
ol
as
ce
ns
 
S
C
A
 
M
et
ho
d 
1 
S
oi
l 2
 
10
0 
S
tre
pt
om
yc
es
 
dr
oz
do
w
ic
zi
i 
S
C
A
 
M
et
ho
d 
1 
S
oi
l 2
 
10
1 
S
tre
pt
om
yc
es
 
G
ris
eu
s 
S
C
A
 
M
et
ho
d 
1 
S
oi
l 2
 
10
4 
S
tre
pt
om
yc
es
 
co
el
ic
of
la
vu
s 
S
C
A
 
M
et
ho
d 
1 
S
oi
l 2
 
10
5 
S
tre
pt
om
yc
es
 
m
al
ac
hi
to
sp
in
us
 
S
C
A
 
M
et
ho
d 
1 
S
oi
l 2
 
10
6 
S
tre
pt
om
yc
es
 
Li
ba
ni
 
A
G
S
 
M
et
ho
d 
1 
S
oi
l 1
 
10
7 
N
oc
ar
di
a 
as
te
ro
id
es
 
A
G
S
 
M
et
ho
d 
3 
S
oi
l 1
 
10
8 
S
tre
pt
om
yc
es
 
sp
on
gi
ae
 
A
G
S
 
M
et
ho
d 
1 
S
oi
l 1
 
10
9 
S
tre
pt
om
yc
es
 
pa
rv
ul
us
 
S
C
A
 
M
et
ho
d 
3 
TS
F 
3 
11
0 
S
tre
pt
om
yc
es
 
ol
iv
ov
er
tic
ill
at
us
 
A
G
S
 
M
et
ho
d 
1 
S
oi
l 1
 
11
1 
S
tre
pt
om
yc
es
 
ch
ar
tre
us
is
 
A
G
S
 
M
et
ho
d 
1 
S
oi
l 1
 
11
3 
S
tre
pt
om
yc
es
 
ha
w
ai
ie
ns
is
 
A
G
S
 
M
et
ho
d 
1 
S
oi
l 1
 
11
4 
S
tre
pt
om
yc
es
 
ci
ne
re
os
pi
nu
s 
A
G
S
 
M
et
ho
d 
1 
S
oi
l 1
 
11
5 
S
tre
pt
om
yc
es
 
in
te
rm
ed
iu
s 
A
G
S
 
M
et
ho
d 
1 
S
oi
l 1
 
11
6 
S
tre
pt
om
yc
es
 
ch
ar
tre
us
is
 
S
Y
E
 
M
et
ho
d 
1 
TS
F 
1 
11
7 
S
tre
pt
om
yc
es
 
ch
ar
tre
us
is
 
S
C
A
 
M
et
ho
d 
1 
TS
F 
1 
11
8 
S
tre
pt
om
yc
es
 
gr
is
eo
ca
rn
eu
s 
S
Y
E
 
M
et
ho
d 
3 
TS
F 
1 
Ta
bl
e 
A
 - 
1.
 (C
on
tin
ue
d)
 
 
11
3 
  
 
12
1 
S
tre
pt
om
yc
es
 
cy
an
oa
lb
us
 
S
Y
E
 
M
et
ho
d 
1 
TS
F 
1 
12
2 
R
ho
do
co
cc
us
 
er
yt
hr
op
ol
is
 
S
C
A
 
M
et
ho
d 
1 
TS
F 
1 
12
3 
S
tre
pt
om
yc
es
 
A
tra
tu
s 
S
Y
E
 
M
et
ho
d 
3 
TS
F 
1 
12
4 
S
tre
pt
om
yc
es
 
ch
ar
tre
us
is
 
S
Y
E
 
M
et
ho
d 
3 
TS
F 
1 
12
5 
S
tre
pt
om
yc
es
 
ci
ne
re
or
ec
tu
s 
S
C
A
 
M
et
ho
d 
1 
TS
F 
1 
12
6 
S
tre
pt
om
yc
es
 
di
as
ta
to
ch
ro
m
og
en
es
 
S
C
A
 
M
et
ho
d 
3 
TS
F 
1 
12
7 
S
tre
pt
om
yc
es
 
ch
ar
tre
us
is
 
S
C
A
 
M
et
ho
d 
3 
TS
F 
1 
12
8 
S
tre
pt
om
yc
es
 
dr
oz
do
w
ic
zi
i 
S
Y
E
 
M
et
ho
d 
1 
TS
F 
1 
12
9 
S
tre
pt
om
yc
es
 
pl
at
en
si
s 
S
Y
E
 
M
et
ho
d 
1 
TS
F 
1 
13
0 
R
ho
do
co
cc
us
 
op
ac
us
 
S
C
A
 
M
et
ho
d 
3 
TS
F 
1 
13
1 
R
ho
do
co
cc
us
 
op
ac
us
 
S
Y
E
 
M
et
ho
d 
3 
TS
F 
1 
13
2 
S
tre
pt
om
yc
es
 
ris
hi
rie
ns
is
 
S
C
A
 
M
et
ho
d 
1 
TS
F 
1 
13
3 
S
tre
pt
om
yc
es
 
dr
oz
do
w
ic
zi
i 
S
C
A
 
M
et
ho
d 
1 
TS
F 
1 
13
4 
R
ho
do
co
cc
us
 
op
ac
us
 
S
C
A
 
M
et
ho
d 
1 
TS
F 
1 
13
5 
S
tre
pt
om
yc
es
 
an
gu
st
m
yc
et
ic
us
 
S
C
A
 
M
et
ho
d 
1 
TS
F 
1 
13
6 
S
tre
pt
om
yc
es
 
dr
oz
do
w
ic
zi
i 
S
C
A
 
M
et
ho
d 
3 
TS
F 
1 
13
7 
S
tre
pt
om
yc
es
 
pu
rp
ur
es
ce
ns
 
S
C
A
 
M
et
ho
d 
1 
TS
F 
1 
13
8 
S
tre
pt
om
yc
es
 
ex
fo
lia
tu
s 
S
C
A
 
M
et
ho
d 
1 
TS
F 
1 
13
9 
S
tre
pt
om
yc
es
 
se
pt
at
us
 
S
Y
E
 
M
et
ho
d 
3 
TS
F 
1 
14
0 
S
tre
pt
om
yc
es
 
R
oc
he
i 
S
C
A
 
M
et
ho
d 
1 
TS
F 
1 
14
1 
S
tre
pt
om
yc
es
 
an
gu
st
m
yc
et
ic
us
 
S
C
A
 
M
et
ho
d 
3 
TS
F 
1 
14
2 
S
tre
pt
om
yc
es
 
ol
iv
ov
er
tic
ill
at
us
 
S
C
A
 
M
et
ho
d 
3 
TS
F 
1 
14
3 
S
tre
pt
om
yc
es
 
hi
rs
ut
us
 
S
C
A
 
M
et
ho
d 
1 
TS
F 
1 
14
4 
S
tre
pt
om
yc
es
 
an
gu
st
m
yc
et
ic
us
 
S
C
A
 
M
et
ho
d 
3 
TS
F 
1 
14
5 
S
tre
pt
om
yc
es
 
ol
iv
oc
hr
om
og
en
es
 
S
C
A
 
M
et
ho
d 
3 
TS
F 
1 
14
6 
A
gr
om
yc
es
 
La
pi
di
s 
S
C
A
 
M
et
ho
d 
1 
TS
F 
1 
14
7 
R
ho
do
co
cc
us
 
op
ac
us
 
S
C
A
 
M
et
ho
d 
3 
TS
F 
1 
Ta
bl
e 
A
 - 
1.
 (C
on
tin
ue
d)
 
 
11
4 
  
 
14
9 
A
rth
ro
ba
ct
er
 
ke
rg
ue
le
ns
is
 
S
Y
E
 
M
et
ho
d 
3 
TS
F 
1 
15
0 
S
tre
pt
om
yc
es
 
ex
fo
lia
tu
s 
S
C
A
 
M
et
ho
d 
3 
TS
F 
1 
15
2 
S
tre
pt
om
yc
es
 
Te
nd
ae
 
S
Y
E
 
M
et
ho
d 
1 
TS
F 
1 
15
3 
S
tre
pt
om
yc
es
 
la
ve
nd
ul
ae
 
S
C
A
 
M
et
ho
d 
1 
TS
F 
3 
15
4 
M
yc
ob
ac
te
riu
m
 
pa
ra
fo
rtu
itu
m
 
S
C
A
 
M
et
ho
d 
1 
TS
F 
3 
15
5 
S
tre
pt
om
yc
es
 
m
al
ac
hi
to
sp
in
us
 
S
C
A
 
M
et
ho
d 
1 
TS
F 
3 
15
6 
S
tre
pt
om
yc
es
 
pa
ct
um
 
S
C
A
 
M
et
ho
d 
1 
TS
F 
3 
15
7 
S
tre
pt
om
yc
es
 
ol
iv
ac
eu
s 
S
C
A
 
M
et
ho
d 
1 
TS
F 
3 
15
8 
S
tre
pt
om
yc
es
 
m
al
ac
hi
to
sp
in
us
 
S
C
A
 
M
et
ho
d 
1 
TS
F 
3 
15
9 
S
tre
pt
om
yc
es
 
ol
iv
ac
eu
s 
S
C
A
 
M
et
ho
d 
1 
TS
F 
3 
16
0 
S
tre
pt
om
yc
es
 
pr
ae
co
x 
S
C
A
 
M
et
ho
d 
1 
TS
F 
3 
16
1 
S
tre
pt
om
yc
es
 
m
al
ac
hi
to
sp
in
us
 
S
C
A
 
M
et
ho
d 
1 
TS
F 
3 
16
2 
S
tre
pt
om
yc
es
 
gr
is
eo
au
ra
nt
ia
cu
s 
S
C
A
 
M
et
ho
d 
1 
TS
F 
3 
16
3 
S
tre
pt
om
yc
es
 
gr
is
eo
pl
an
us
 
S
C
A
 
M
et
ho
d 
1 
TS
F 
3 
16
4 
S
tre
pt
om
yc
es
 
m
al
ac
hi
to
sp
in
us
 
S
C
A
 
M
et
ho
d 
1 
TS
F 
3 
16
5 
S
tre
pt
om
yc
es
 
m
al
ac
hi
to
sp
in
us
 
S
C
A
 
M
et
ho
d 
1 
TS
F 
3 
16
6 
S
tre
pt
om
yc
es
 
m
al
ac
hi
to
sp
in
us
 
S
C
A
 
M
et
ho
d 
1 
TS
F 
3 
16
7 
S
tre
pt
om
yc
es
 
gr
is
eo
pl
an
us
 
S
C
A
 
M
et
ho
d 
1 
TS
F 
3 
16
8 
S
tre
pt
om
yc
es
 
vi
rid
oc
hr
om
og
en
es
 
S
C
A
 
M
et
ho
d 
1 
TS
F 
3 
16
9 
S
tre
pt
om
yc
es
 
m
al
ac
hi
to
sp
in
us
 
S
C
A
 
M
et
ho
d 
1 
TS
F 
3 
17
0 
S
tre
pt
om
yc
es
 
m
al
ac
hi
to
sp
in
us
 
S
C
A
 
M
et
ho
d 
3 
TS
F 
3 
17
1 
S
tre
pt
om
yc
es
 
bu
ng
oe
ns
is
 
S
C
A
 
M
et
ho
d 
1 
TS
F 
3 
17
2 
S
tre
pt
om
yc
es
 
ps
am
m
ot
ic
us
 
S
C
A
 
M
et
ho
d 
1 
TS
F 
2 
17
3 
S
tre
pt
om
yc
es
 
m
al
ac
hi
to
sp
in
us
 
S
C
A
 
M
et
ho
d 
1 
TS
F 
3 
17
4 
S
tre
pt
om
yc
es
 
ra
m
eu
s 
S
Y
E
 
M
et
ho
d 
1 
TS
F 
2 
17
5 
M
yc
ob
ac
te
riu
m
 
ob
ue
ns
e 
S
Y
E
 
M
et
ho
d 
1 
TS
F 
2 
17
7 
G
or
do
ni
a 
Te
rr
ae
 
S
C
A
 
M
et
ho
d 
1 
TS
F 
2 
Ta
bl
e 
A
 - 
1.
 (C
on
tin
ue
d)
 
 
11
5 
  
 
17
8 
S
tre
pt
om
yc
es
 
ra
m
eu
s 
S
C
A
 
M
et
ho
d 
1 
TS
F 
2 
18
0 
S
tre
pt
om
yc
es
 
ch
am
pa
va
tii
 
S
Y
E
 
M
et
ho
d 
1 
TS
F 
3 
18
1 
S
tre
pt
om
yc
es
 
gr
is
eo
pl
an
us
 
S
Y
E
 
M
et
ho
d 
1 
TS
F 
3 
18
2 
S
tre
pt
om
yc
es
 
fla
vo
gr
is
eu
s 
S
Y
E
 
M
et
ho
d 
1 
TS
F 
3 
18
3 
S
tre
pt
om
yc
es
 
pa
rv
us
 
S
Y
E
 
M
et
ho
d 
1 
TS
F 
3 
18
5 
S
tre
pt
om
yc
es
 
vi
rid
oc
hr
om
og
en
es
 
S
C
A
 
M
et
ho
d 
1 
TS
F 
3 
18
6 
S
tre
pt
om
yc
es
 
m
ic
ro
fla
vu
s 
S
C
A
 
M
et
ho
d 
1 
TS
F 
3 
18
7 
S
tre
pt
om
yc
es
 
ol
iv
ac
eu
s 
S
C
A
 
M
et
ho
d 
1 
TS
F 
3 
18
8 
N
oc
ar
di
oi
de
s 
al
pi
nu
s 
S
Y
E
 
M
et
ho
d 
3 
TS
F 
3 
18
9 
S
tre
pt
om
yc
es
 
ga
lb
us
 
S
C
A
 
M
et
ho
d 
1 
TS
F 
2 
31
7 
S
tre
pt
om
yc
es
 
pr
ae
co
x 
S
Y
E
 
M
et
ho
d 
3 
S
IS
 1
9 
31
8 
S
tre
pt
om
yc
es
 
en
do
ph
yt
ic
us
 
S
C
A
 
M
et
ho
d 
3 
S
IS
 1
9 
31
9 
S
tre
pt
om
yc
es
 
en
do
ph
yt
ic
us
 
S
C
A
 
M
et
ho
d 
3 
S
IS
 1
9 
32
0 
S
tre
pt
om
yc
es
 
na
rb
on
en
si
s 
S
Y
E
 
M
et
ho
d 
3 
S
IS
 1
9 
32
1 
Is
op
te
ric
ol
a 
va
ria
bi
lis
 
S
Y
E
 
M
et
ho
d 
1 
S
IS
 1
9 
32
2 
S
tre
pt
om
yc
es
 
ph
ila
nt
hi
 
S
C
A
 
M
et
ho
d 
3 
S
IS
 1
9 
32
3 
S
tre
pt
om
yc
es
 
ph
ila
nt
hi
 
S
Y
E
 
M
et
ho
d 
3 
S
IS
 1
9 
33
4 
S
tre
pt
om
yc
es
 
ps
am
m
ot
ic
us
 
S
C
A
 
M
et
ho
d 
3 
TS
F 
7 
33
5 
S
tre
pt
om
yc
es
 
ly
di
cu
s 
S
C
A
 
M
et
ho
d 
3 
TS
F 
7 
33
6 
S
tre
pt
om
yc
es
 
co
st
ar
ic
an
us
 
S
Y
E
 
M
et
ho
d 
3 
TS
F 
7 
33
7 
S
tre
pt
om
yc
es
 
sh
en
zh
en
si
s 
S
Y
E
 
M
et
ho
d 
3 
TS
F 
7 
33
8 
S
tre
pt
om
yc
es
 
ga
rd
ne
ri 
S
Y
E
 
M
et
ho
d 
3 
S
IS
 1
9 
33
9 
S
tre
pt
om
yc
es
 
ka
na
m
yc
et
ic
us
 
S
Y
E
 
M
et
ho
d 
1 
S
IS
 1
9 
34
0 
S
tre
pt
om
yc
es
 
dr
oz
do
w
ic
zi
i 
S
C
A
 
M
et
ho
d 
3 
S
IS
 1
9 
34
1 
S
tre
pt
om
yc
es
 
dr
oz
do
w
ic
zi
i 
S
C
A
 
M
et
ho
d 
3 
S
IS
 1
9 
34
2 
S
tre
pt
om
yc
es
 
en
do
ph
yt
ic
us
 
S
Y
E
 
M
et
ho
d 
1 
S
IS
 1
9 
34
3 
S
tre
pt
om
yc
es
 
sh
en
zh
en
si
s 
S
Y
E
 
M
et
ho
d 
1 
TS
F 
7 
Ta
bl
e 
A
 - 
1.
 (C
on
tin
ue
d)
 
 
11
6 
  
 
34
4 
S
tre
pt
om
yc
es
 
ly
di
cu
s 
S
Y
E
 
M
et
ho
d 
1 
TS
F 
7 
34
5 
S
tre
pt
om
yc
es
 
ly
di
cu
s 
S
Y
E
 
M
et
ho
d 
1 
TS
F 
7 
34
6 
S
tre
pt
om
yc
es
 
gi
ns
en
gi
so
li 
S
Y
E
 
M
et
ho
d 
1 
TS
F 
7 
34
7 
S
tre
pt
om
yc
es
 
pr
as
in
op
ilo
su
s 
S
Y
E
 
M
et
ho
d 
1 
TS
F 
7 
34
8 
S
tre
pt
om
yc
es
 
in
di
ae
ns
is
 
S
Y
E
 
M
et
ho
d 
1 
TS
F 
7 
35
6 
S
tre
pt
om
yc
es
 
m
al
ac
hi
to
sp
in
us
 
S
C
A
 
M
et
ho
d 
1 
C
W
R
 2
3 
35
7 
S
tre
pt
om
yc
es
 
vi
ol
as
ce
ns
 
S
C
A
 
M
et
ho
d 
1 
C
W
R
 3
1 
35
8 
S
tre
pt
om
yc
es
 
ja
ve
ns
is
 
S
C
A
 
M
et
ho
d 
1 
C
W
R
 2
7 
40
8 
M
yc
ob
ac
te
riu
m
 
ne
oa
ur
um
 
S
C
A
 
M
et
ho
d 
3 
TS
F 
2 
40
9 
N
oc
ar
di
oi
de
s 
sp
. 
S
C
A
 
M
et
ho
d 
3 
TS
F 
7 
41
0 
M
yc
ob
ac
te
riu
m
 
ob
ue
ns
e 
S
C
A
 
M
et
ho
d 
3 
TS
F 
7 
41
1 
R
ho
do
co
cc
us
 
eq
ui
 
S
C
A
 
M
et
ho
d 
1 
TS
F 
7 
41
2 
S
tre
pt
om
yc
es
 
ph
ila
nt
hi
 
S
C
A
 
M
et
ho
d 
3 
S
IS
 1
9 
43
5 
S
tre
pt
om
yc
es
 
za
om
yc
et
ic
us
 
S
Y
E
 
M
et
ho
d 
3 
S
IS
 1
9 
43
6 
M
yc
ob
ac
te
riu
m
 
ob
ue
ns
e 
S
Y
E
 
M
et
ho
d 
3 
TS
F 
2 
43
7 
M
yc
ob
ac
te
riu
m
 
ob
ue
ns
e 
S
Y
E
 
M
et
ho
d 
3 
TS
F 
2 
44
5 
M
ic
ro
ba
ct
er
iu
m
 
fo
lio
ru
m
 
S
Y
E
 
M
et
ho
d 
3 
S
H
H
 1
8 
44
6 
S
tre
pt
om
yc
es
 
sp
. 
S
Y
E
 
M
et
ho
d 
3 
S
H
H
 1
8 
44
7 
A
gr
om
yc
es
 
sp
. 
S
C
A
 
M
et
ho
d 
1 
S
H
H
 1
8 
44
8 
Le
ifs
on
ia
 
sp
. 
S
Y
E
 
M
et
ho
d 
1 
TS
F 
7 
44
9 
S
tre
pt
om
yc
es
 
pi
om
og
en
us
 
S
Y
E
 
M
et
ho
d 
1 
TS
F 
7 
45
0 
R
ho
do
co
cc
us
 
sp
. 
S
C
A
 
M
et
ho
d 
1 
S
H
H
 1
8 
45
1 
R
ho
do
co
cc
us
 
eq
ui
 
S
Y
E
 
M
et
ho
d 
1 
TS
F 
4 
45
2 
S
tre
pt
om
yc
es
 
sp
. 
S
Y
E
 
M
et
ho
d 
3 
S
H
H
 1
8 
45
3 
M
yc
ob
ac
te
riu
m
 
rh
od
es
ia
e 
S
C
A
 
M
et
ho
d 
3 
TS
F 
4 
45
4 
R
ho
do
co
cc
us
 
eq
ui
 
S
Y
E
 
M
et
ho
d 
1 
TS
F 
4 
45
5 
W
ill
ia
m
si
a 
sp
. 
S
Y
E
 
M
et
ho
d 
3 
S
H
H
 1
8 
Ta
bl
e 
A
 - 
1.
 (C
on
tin
ue
d)
 
 
11
7 
  
 
47
5 
Le
ifs
on
ia
 
sp
. 
S
C
A
 
M
et
ho
d 
1 
TS
F 
5 
47
6 
M
ic
ro
ba
ct
er
iu
m
 
az
ad
ira
ch
ta
e 
S
C
A
 
M
et
ho
d 
3 
TS
F 
5 
47
8 
M
yc
ob
ac
te
riu
m
 
ne
gl
ec
tu
m
 
S
C
A
 
M
et
ho
d 
3 
TS
F 
5 
57
1 
M
yc
ob
ac
te
riu
m
 
po
rif
er
ae
 
S
Y
E
 
M
et
ho
d 
1 
TS
F 
9 
57
2 
R
ho
do
co
cc
us
 
eq
ui
 
S
C
A
 
M
et
ho
d 
1 
TS
F 
9 
57
3 
M
yc
ob
ac
te
riu
m
 
po
rif
er
ae
 
S
Y
E
 
M
et
ho
d 
3 
TS
F 
9 
57
4 
M
yc
ob
ac
te
riu
m
 
ps
yc
hr
ot
ol
er
an
s 
S
Y
E
 
M
et
ho
d 
1 
TS
F 
9 
57
5 
M
yc
ob
ac
te
riu
m
 
ai
ch
ie
ns
e 
S
C
A
 
M
et
ho
d 
1 
TS
F 
9 
58
6 
M
ic
ro
m
on
os
po
ra
 
tu
lb
ag
hi
ae
 
S
C
A
 
M
et
ho
d 
1 
TS
F 
4 
58
7 
M
yc
ob
ac
te
riu
m
 
ch
lo
ro
ph
en
ol
ic
um
 
S
C
A
 
M
et
ho
d 
1 
TS
F 
5 
58
8 
M
yc
ob
ac
te
riu
m
 
m
ad
ag
as
ca
rie
ns
e 
S
C
A
 
M
et
ho
d 
3 
TS
F 
7 
58
9 
Le
ifs
on
ia
 
sh
in
sh
ue
ns
is
 
S
Y
E
 
M
et
ho
d 
3 
TS
F 
4 
59
0 
N
oc
ar
di
a 
no
va
 
S
C
A
 
M
et
ho
d 
1 
TS
F 
2 
59
1 
M
yc
ob
ac
te
riu
m
 
sp
. 
S
C
A
 
M
et
ho
d 
1 
TS
F 
4 
65
7 
M
yc
ob
ac
te
riu
m
 
rh
od
es
ia
e 
S
C
A
 
M
et
ho
d 
3 
TS
F 
4 
65
8 
M
yc
ob
ac
te
riu
m
 
sp
. 
S
Y
E
 
M
et
ho
d 
1 
TS
F 
9 
68
2 
G
or
do
ni
a 
te
rr
ae
 
S
C
A
 
M
et
ho
d 
3 
H
R
T 
79
 
68
3 
R
ho
do
co
cc
us
 
rh
od
oc
hr
ou
s 
S
Y
E
 
M
et
ho
d 
1 
H
R
T 
79
 
68
4 
P
se
ud
on
oc
ar
di
a 
ku
je
ns
is
 
S
Y
E
 
M
et
ho
d 
1 
H
R
T 
79
 
70
7 
M
yc
ob
ac
te
riu
m
 
sp
. 
S
C
A
 
M
et
ho
d 
1 
S
IS
 2
0 
70
8 
P
ro
m
ic
ro
m
on
os
po
ra
 
sp
. 
S
Y
E
 
M
et
ho
d 
3 
TS
F 
12
 
70
9 
M
yc
ob
ac
te
riu
m
 
sp
. 
S
C
A
 
M
et
ho
d 
1 
TS
F 
12
 
71
0 
R
ho
do
co
cc
us
 
sp
. 
S
Y
E
 
M
et
ho
d 
3 
TS
F 
13
 
71
1 
N
oc
ar
di
a 
ol
ei
vo
ra
ns
 
S
Y
E
 
M
et
ho
d 
1 
TS
F 
10
 
71
2 
N
oc
ar
di
a 
rh
am
no
si
ph
ila
 
S
Y
E
 
M
et
ho
d 
1 
TS
F 
10
 
71
3 
M
ic
ro
co
cc
us
 
sp
. 
D
is
ha
w
 
N
/A
 
S
ea
sq
ui
rt 
71
4 
R
ho
do
co
cc
us
 
sp
. 
S
C
A
 
M
et
ho
d 
3 
TS
F 
13
 
Ta
bl
e 
A
 - 
1.
 (C
on
tin
ue
d)
 
 
11
8 
Ta
bl
e 
A
 - 
2.
 B
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C
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xt
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m
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iu
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m
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	c
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	m
L	-
1 		
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μg
	m
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1 		
0	
μg
	m
L	-
1 		
0	
μg
	m
L	-
1 		
0	
μg
	m
L	-
1 		
0	
μg
	m
L	-
1 		
1	
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N
M
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)	
0	
μg
	m
L	-
1 		
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μg
	m
L	-
1 		
0	
μg
	m
L	-
1 		
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μg
	m
L	-
1 		
0	
μg
	m
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0	
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	m
L	-
1 		
5	
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tr
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)	
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μg
	m
L	-
1 		
0	
μg
	m
L	-
1 		
0	
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1 		
0	
μg
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L	-
1 		
0	
μg
	m
L	-
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0	
μg
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L	-
1 		
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N
M
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)	
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μg
	m
L	-
1 		
0	
μg
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L	-
1 		
0	
μg
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L	-
1 		
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μg
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L	-
1 		
0	
μg
	m
L	-
1 		
0	
μg
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L	-
1 		
6	
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tr
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)	
0	
μg
	m
L	-
1 		
4	
μg
	m
L	-
1 		
0	
μg
	m
L	-
1 		
50
	μ
g	
m
L	-
1 		
0	
μg
	m
L	-
1 		
0	
μg
	m
L	-
1 		
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N
M
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m
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M
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	m
L	-
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M
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0	
μg
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tr
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	m
L	-
1 		
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	m
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0	
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L	-
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	(D
N
M
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)	
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1 		
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L	-
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L	-
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L	-
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tr
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)	
0	
μg
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L	-
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L	-
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0	
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1 		
0	
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N
M
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)	
0	
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	m
L	-
1 		
0	
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	m
L	-
1 		
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0	
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L	-
1 		
0	
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	m
L	-
1 		
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1 		
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